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CHAPTER 1 PARKINSON DISEASE OVERVIEW
Neurodegenerative diseases represent a highly variable group of age-associated
disorders that are characterized by their clinical presentations, with cognitive and
movement disorders being the most popular. Parkinson disease (PD) is recognized as
the second most common neurodegenerative disorder after Alzheimer’s disease (AD),
affecting up to 1% of population above 65 years old (De Lau and Bretler, 2006). Many
advances have been achieved regarding pathophysiology and symptomatic therapy, but
little is known about the etiology of PD. Currently, there are no disease modifying
treatments that can slow PD progression, and only symptomatic therapy exists for the
management of motor impairments. There is an unmet need to understand the
pathological changes associated with disease progression occurring in the brain in order
to develop innovative treatments that can target these potential mechanisms.
In section 1.1.1, we will describe the epidemiology and etiology of PD highlighting its
growing prevalence, sporadic nature and the lack of disease-modifying therapies. Then,
we will describe the clinical picture of PD in sections 1.1.2 and 1.1.3, by defining the
classical motor symptoms and debilitating non-motor features, and importantly
highlighting the role of cortical Lewy pathology in mediating the cognitive decline. Chapter
2 wil be dedicated to understating the neuropathology of PD (section 1.2.1), Braak’s
staging system supported with clinical evidence (sections 1.2.2 and 1.2.3), and the
potential role of abnormal α-syn spread in cognitive decline and impaired neurite
morphology (sections 1.2.3 and 1.2.4).
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1.1 Epidemiology and Etiology
In the following section, we will introduce the potential role of aging, genetic
susceptibility and environmental factors in PD etiology. The multifactorial nature of
PD etiology has important implications on understanding the pathological
mechanisms involved in the initiation and progression of PD.
Globally, the number of PD patients has doubled from 2.5 million in 1990 to 6.1
million individuals in 2016, and the future projection estimates that more than 12
million individuals will be suffering from PD by 2050 (GBD, 2016). As the size of the
elderly population is growing, the prevalence of PD in the United States among those
aged ≥45 years, is estimated to be 572 per 100,000 (Marras et al., 2018). This will
also be matched with an increase in the number of PD patients from 680,000 in 2010
to 1,238,000 in 2030 (Marras et al., 2018). PD is 1.4 times more frequent in men than
women (GBD, 2016) and gender differences in the clinical characteristics also exists.
Men are more likely to develop rigidity and rapid eye movement (REM) disorder,
compared to women who exhibit dyskinesias and depression (Miller et al., 2010).
Although the exact cause of PD remains unknown, current theories suggest an
elaborate interplay among aging, genetic susceptibility and environmental exposures
(Kouli et al., 2018). Increasing age is the most important risk factor for the
development of PD (Tanner et al., 1996). The prevalence of PD increases from 41
per 100,000 in individuals 40–49 years of age, to 1903 per 100,000 in those older
than age 80 (Pringsheim et al., 2014). A meta-analysis including 27 epidemiological
studies of PD, showed an increase in incidence of PD for both males and females
with age which peaked at 70–79 years old. In females, the incidence of PD increased
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steadily from 3.26 per 100,000 subjects aged 40-49 years to 103.48 at age 80+. Males
had a significantly higher incidence rate of PD, with 162.58 per 100,000 subjects
compared to 93.32 per 100,000 in females (Hirsch et al., 2016). Cognitive changes in
in processing speed observed during aging has been shown to associate with the loss
of dendritic surface, where dendritic regression in the pyramidal neurons of high-order
association areas is a major histological finding (Scheibel et al., 1975). Whether more
a prominent regression of cortical neuropil occurs in PD compared to healthy ageing,
is not a well characterized pathological process and will be highly insightful to study
in PD patients in-vivo.
Although PD is mainly sporadic, monogenic forms of PD caused by a single gene
mutation account for 3-5% of sporadic cases and 30% of familial occurrences.
Mutations in six genes has been linked unequivocally to monogenic forms of PD and
include mutations in SNCA and LRRK2 responsible for autosomal-dominant mode of
inheritance, and mutations in Parkin, PINK1, DJ-1, and ATP13A2 responsible for
autosomal-recessive PD forms (Klein et al., 2012). Genetic forms of the disease
highlight a prominent role for impaired mitochondrial function in PD pathogenesis.
Several products of PD-associated genes, including α-synuclein (SNCA), Parkin,
PINK1, DJ-1, LRRK2, have protein products linked to mitochondrial function. DJ-1 is
a putative mitochondrial protein localized in to the mitochondrial matrix and intermembrane space (Zhang et al., 2005), while LRRK2 is associated with the outer
membrane of mitochondria (West et al., 2005). Phosphatase and Tensin homolog
(PTEN)-induced kinase 1 (PINK1) is a serine–threonine mitochondrial kinase
(Valente et al., 2004), that is responsible for detecting mitochondrial dysfunction.
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PINK1 can activate Parkin to ubiquitinate the damaged mitochondria and signal it for
removal (Narendra, 2010). Three autosomal-dominant forms of PD have been linked
to mutations in the SNCA gene (A53T, A30P and E46K) and Lewy body formation.
SNCA is found primarily in the mitochondrial outer membrane and can gain access to
the inner membrane causing changes in the mitochondrial morphology. Increased
expression of α-synuclein was found to induce mitochondrial fragmentation (Hsu et
al., 2000) and A53T mutant mice models develop dysmorphic mitochondria with
inclusions involving mitochondrial DNA damage (Martin et al., 2006).
Despite the identification of a number of genes causing PD, elucidating the genetic
contribution to PD susceptibility is likely incomplete. Understanding the role of genes
associated with monogenic PD in regulating mitochondrial physiology can have
important implications for clarifying the pathogenic process in PD and represents a
target for therapeutic intervention.
Table 1. List of Candidate Genes Involved in Parkinson Disease
Gene symbol
Protein
Protein
Mode of
product
function
inheritance
SNCA
Alpha
Neurotransmitter Dominant
synuclein
and Synaptic
recycling and
LRRK2
Leucine-rich
Phosphorylation Dominant
repeat kinase
and scaffolding
2
protein
DJ-1
Protein DJ-1
Protection from
Recessive
oxidative stress
ATP13A2
ATPase 13A2 Lysosomal
Recessive
transporter
ATPase
PINK1
PTEN-induced Mitochondrial
Recessive
putative kinase serinethreonine kinase
PARKIN
PARKIN
E3 ubiquitin
Recessive
protein ligase

Pathology
Rapid
progressive
course
Consistent with
idiopathic PD
Unknown
Unknown
Unknown
Nigrostriatal
degeneration,
no inclusions
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Environmental factors. Various environmental agents have been shown to increase
the risk of PD. Exposure to a toxin called 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine
(MPTP), can damage the substantia nigra dopaminergic neurons and induce
Parkinsonism (Langston et al., 1983). MPTP is oxidized to 1-methyl-4-phenylpyridinium
(MPP+) and upon its uptake into the dopaminergic neurons, MPP+ inhibits mitochondrial
complex I activity which impairs ATP formation and subsequent energy-dependent
processes and generate reactive oxygen radicals including nitric oxide (Sian et al., 1999).
Pesticides and herbicides like Rotenone and paraquat, are associated with PD
development in humans (Tanner et al., 2011). Like MPTP, Rotenone selectively inhibit
complex I and is associated with SNCA aggregates. PD is 2.5 times more present in
Rotenone user compared with non-users (Tanner et al., 2011). Exposure of mice to
Paraquat has also been shown to cause selective death of dopaminergic neurons
accompanied by the formation of α-synuclein inclusion bodies and microglial and
astrocytic activation (McCormack et al., 2002). Impaired mitochondrial function has been
proposed as a common pathway mediating the pathogenic effects of environmental toxins
and genetic forms of PD.
1.2 Motor and Non-Motor Clinical Symptoms
Clinically, PD patients show a range of motor symptoms such as bradykinesia, rigidity,
and resting tremor and a host of nonmotor symptoms, including autonomic disturbances,
cognitive deficits and mood disorders.
Motor symptoms. PD is a debilitating disorder characterized by cardinal motor
symptoms including, resting tremor, progressive bradykinesia (slowed movement) and
muscle rigidity (increased muscular tone). PD is also associated with postural instability
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and gait dysfunction that frequently leads to falls. A dimorphic pattern of clinical
presentation is also evident, where rigidity and REM is more often in males, compared to
more dyskinesias and depression in females. At disease onset, patients predominantly
present symptoms on one side of the body, prominently in the upper extremities.
Typically, degeneration of the nigral dopaminergic neurons begins asymmetrically and is
greater on the side contralateral to the initially affected body side (Kempster et al., 1989).
As a result, motor symptoms begin unilaterally early in the course of PD. As the disease
progresses, neurodegeneration spreads to the other SN and both sides of the body
become equally affected. Possible explanations for the early asymmetric involvement of
the SN include innate variations in the number of DA neurons in each hemisphere.
Consequently, the degenerative process will be more pronounced in the side with lower
number of DA neurons and thus will be vulnerable earlier (Djaldetti et al., 2006). A human
postmortem study of healthy subjects by McRitchie et al., 1995 showed that there is a
considerable variability of up to 30% in the number of neurons between sides of the SN.
Non-motor symptoms. PD Patients can also suffer from a spectrum of non-motor
features involving autonomic dysfunction, sleep disorders with high prevalence of REM
disorder, cognitive decline, mood disorders and can ultimately develop dementia. With
disease progression, the severity of symptoms increases and impairs the ability of
patients to work and live independently, which translates into elevated costs of medical
treatment, caregivers, hospitalization, nursing home care and loss of productivity. In 2010,
approximately 630,000 individuals had PD in the US and the estimated economic burden
was $14.4 billion, with $22,800 per patient (Kowal et al., 2013). The cognitive deficits in
PD range from mild executive dysfunction in the early stages of the disease to mild
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cognitive impairment (MCI) and ultimately dementia in the advanced stages. Executive
dysfunction occurs early in the disease and affects nearly 30% of PD patients (WilliamsGray et al., 2009). The deficits in executive function include several cognitive processes
required to enable goal-oriented behavior and apply novel adjustments, namely, working
memory, planning strategies, inhibition, attention and processing speed (Friedman and
Miyake, 2017).
By time of diagnosis, up to 36% of PD patients present evidence of cognitive decline
(Foltynie et al., 2004). The cognitive domains affected extend beyond executive
dysfunction and include deficits in language, memory and visuospatial function (Litvan et
al., 2012). The presence of mild cognitive impairment (MCI) in PD patients has been
shown to be a strong predictor of dementia, which can develop in 83% of the patients
after 20 years from disease onset (Hely et al., 2008). From disease onset, the mean time
of progression to dementia is nearly 10 years (Aarsland and Kurz et al., 2010). In a 16year longitudinal study of the Denbighshire PD cohort (Hobson and Meara, 2015), 21%
of patients at baseline presented with MCI, and after 4 years, the prevalence of MCI
increased to 33%, and reached 38% by six years of follow up. After16 years, 91% of the
PD-MCI group had progressed to PD-dementia (PDD). Declines in the domains of the
semantic fluency, visuospatial function and explicit memory were found to be strong
predictive of developing PD dementia (Hobson and Meara, 2015). PD dementia (PDD) is
considered a subcortical dementia, characterized by cognitive slowing (bradyphrenia),
deficits in executive and visuospatial function more than language and recent memory.
PDD severely impairs activities of daily life, independent of the motor deficits contribution,
and add a substantial burden for the patient and caregiver.
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1.3 Pathophysiology of PD
Pathologically, PD is characterized by the selective loss of dopaminergic neurons in
the Substantia Nigra compacta (SNc), with intracellular inclusions containing α-synuclein
(α-syn) protein in the cell bodies and processes of surviving neurons known as Lewy
bodies (LB) and Lewy neurites (LN), respectively. PD motor manifestations are
attributable to the dopaminergic cell loss and resultant dopamine (DA) denervation to the
striatum (Figure 1). The striatum is the primary input division of the basal ganglia and
receives information from cortical, thalamic and nigral sources. The striatum consists
mainly of medium spiny neurons (MSNs), that express either stimulatory dopamine D1
receptors or inhibitory dopamine D2 receptor. Dopaminergic input from the SNc causes
the activation of D1 receptors on MSNs, which in turn inhibits the globus pallidus internal
(GPi) and leads to a net disinhibition of the thalamus and initiation of movement (direct
pathway). On the other hand, dopaminergic innervation inhibits D2 receptors, which in
turn project to the globus pallidus external and inhibits the subthalamic nucleus (STN).
The inhibition of the STN leads to disinhibition of the GPi which in turn send inhibitory
GABAergic projections to thalamus and inhibits movement (indirect pathway). In the case
of PD, the reduced striatal dopamine innervation leads to a net increase in the inhibitory
activity of the GPi to the subthalamic nucleus which project to motor cortex, thereby
suppressing the initiation of movement and leading to bradykinesia and rigidity
(Rodriguez et al., 2009).
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Figure 1. Simplified Schematic of Neuronal Circuits Involved in PD

Healthy: Dopaminergic neurons in the SNc project primarily to the striatum, which is excitatory to
the direct pathway. The putamen (Pu) inhibits (red) the globus pallidus interna (GPi), which
subsequently disinhibits the thalamus (Th). The thalamus projects excitatory input (green) to the
motor cortex and facilitates movement. The indirect pathway (not shown), includes the globus
pallidus externa (GPe) and subthalamic nucleus and is inhibited by SNc dopaminergic input and
normally functions to repress movements.
PD: Degeneration within the SNc leads to depletion of striatal dopamine and a net increased
inhibitory output from the GP to Th and indirectly to the cortex. The inhibition of the thalamocortical
projection repress the initiation of movement. The activity of the indirect pathway is further
enhanced leading to the characteristic motor manifestations (Adapted from Shulman et al., 2011).

The extent of lost dopaminergic neurons at the time of symptom onset is estimated
to be 31%, most profound in the lateral ventral tier of the SNc, followed by the medial
ventral tier and lastly the dorsal tier with the least loss in neurons (Fearnley and Lees,
1991). The latero-ventral nigral tier of the SNc projects mainly to the dorsal putamen to
provide dopaminergic innervation. In a postmortem study by Kish et al. (1988), complete
DA depletion was found in all subdivisions of the putamen (DA levels were reduced to
2.2% of control values), being greatest in the dorsal and intermediate portions, followed
by the ventral zone. The caudate nucleus was less affected (18.5% of control level), with
severe DA reduction occurring in the dorsal-rostral part (Kish et al., 1988).
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The heterogeneity of striatal DA loss, results in specific patterns of functional deficits.
The putamen is predominantly involved in motor programming, receiving connections
from the supplementary motor area, primary motor and primary sensory areas to the
posterior and ventral parts (sensorimotor striatum). The dorsal-rostral caudate and rostral
putamen receives cortical input mainly from the frontal-lateral association areas
(dorsolateral prefrontal cortex) and is involved in working memory (associative striatum).
The clinical relevance of dopaminergic innervation to the sensorimotor striatum explains
the motor impairments of the disease. The loss of DA input to the associative striatum is
known to disturb the frontal-striatal cognitive loop (dorsolateral prefrontal cortex and
dorsal caudate nucleus) and affect the executive function.
In summary, PD is characterized by dysfunction of the dopaminergic nigrostriatal
pathway with a resultant motor dysfunction. Nigrostriatal denervation is region-specific,
with more severe changes occurring in the putamen compared to the caudate.
Histological studies have identified dendritic regression in the striatal medium spiny
projection neurons as a pathological hallmark of PD (Zaja-Milatovic et al., 2005). In-vivo
assessment of the striatal neuropil is currently lacking and studies are limited by the use
of conventional MRI measures of atrophy. Evaluating the striatal neuropil in-vivo will be
clinically useful to assess pathological changes associated with motor impairments and
to predict the trajectory of disease progression. In this study, we will address the
microstructural changes at the level of the dendritic tree that might be preceding the
detectable volumetric loss in the striatal structures.
Beside the well documented motor symptoms of PD, patients also experience
debilitating non-motor symptoms characterized by the loss of cognitive function and
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development of dementia at the late stages of the disease. Mild cognitive impairment is
present in 34% of early stage PD patients, increasing their risk to convert to PD dementia
(Pfeiffer et al., 2014). In fact, 50% of PD patients with MCI can convert to dementia within
5 years of follow up (Domellöf et al., 2015).
Cognitive deficits in PD vary in severity and clinical features and can take several
forms, starting with executive dysfunction, progressing to visual hallucinations and
behavioral disorders and eventually reaching dementia. In this regard, the dual syndrome
hypothesis was proposed (Kehagia et al., 2013), suggesting two categories of cognitive
decline in PD. In the early phases of the disease, a fronto-straital loop dysfunction leading
to deficits in planning, working memory, attention and planning and in the late stages,
impairment in visuospatial and semantic functions, related to posterior cortical Lewy
pathology spread and possible cholinergic loss, and culminating in dementia. The
development of PD dementia is likely due to several underlying mechanisms.
The causes of cognitive decline in PD are multifactorial and include Lewy pathology
spread into limbic and neocortical brain areas, neurotransmitters deficits, especially
acetylcholine and dopamine, concomitant Alzheimer’s disease (AD) pathology and
cerebrovascular diseases. In early stages of PD, the loss of dopaminergic innervation in
the striatum is greatest in the posterior putamen and dorsal caudate, while the ventral
striatum is relatively spared. The drastic reduction in dopamine levels in the posterior
putamen early on in the disease, are particularly relevant for the impairment of automatic
habit behaviors (Redgrave et al. 2010). In the caudate, dopamine loss occurs mostly in
the rostrodorsal area, which connects heavily with the dorsolateral prefrontal cortex
(DLPFC) (Yeterian and Pandya, 1991). Dopamine impairment in the caudate has been
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shown to associate with metabolic dysfunction in the DLPFC and anterior cingulate
cortex, and to correlated with verbal fluency, a cognitive domain that relies heavily on
executive control (Polito et al., 2012). A research study using positron emission
tomography (PET) imaging aimed at investigating cortical and striatal dopamine receptors
availability in PD patients with MCI (PD-MCI) or intact cognition (PD-NC) versus healthy
control (Christopher et al., 2014). They showed that PD-MCI patients had severe
dopamine depletion in the associative striatum (anterior putamen and caudate) combined
with dopamine receptor (D2) loss in the insula bilaterally, after controlling for
dopaminergic medication intake. Interestingly, the levels of D2 receptors in the insula
were positively correlated with executive performance in PD-MCI patients, the most
impaired cognitive domain. The loss of D2 receptors might affect the ability of the insula
to effectively recruit the central executive network during cognitive tasks, which includes
the dorsolateral prefrontal cortex and posterior parietal cortex.
Another study with functional magnetic resonance imaging (fMRI) of PD-MCI and PDNC patients practicing a working-memory paradigm (Tower of London planning task)
showed less brain activation during the information manipulation phase, in the bilateral
caudate, right putamen and the dorsolateral and ventrolateral prefrontal cortices of PDMCI group (Lewis et al., 2003). The caudate nucleus is connected with the dorsolateral
prefrontal cortex (DLPFC) and the lateral orbitofrontal cortex and dopamine levels in the
prefrontal cortices is known to play important role in modulating executive function (Logue
et al., 2014).

18

F- 6-fluorodopa (F-DOPA) PET studies assessing presynaptic dopamine

storage capacity in early PD patients revealed decrease F-DOPA uptake in the striatum,
more pronounced in the putamen than in the caudate nucleus and increased F-DOPA
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uptake in parieto-frontal areas, including the anterior cingulate (Bruck et al., 2005). The
increased F-DOPA uptake might be a compensatory mechanism in response to the
striatal dopaminergic hypofunction early in the course of the disease.
18

F-fluorodeoxyglucose PET studies have shown metabolic reduction in areas beyond

frontal-straital regions such as parietal association areas and temporal lobe of cognitively
impaired PD patients. Nonetheless, changes in dopaminergic innervation to frontal areas
cannot fully explain the cognitive decline and progression to dementia, which show little
or no response to dopamine replacement. In this regard, neurochemical and
neuropathological studies are highlighting a role for cholinergic disturbances and spread
of cortical Lewy pathology in mediating decline and dementia over the course of the
disease.
In PD, neurodegeneration of the cholinergic projections in the pedunculopontine
complex (PPN) and basal forebrain is confirmed both by post-mortem and neuroimaging
studies. Neuropathological studies have reported the loss of about 50% of the large
cholinergic neurons of the PPN in PD patients, with Lewy bodies affecting 6 to 39% of the
remaining cells (Jellinger et al., 1988). The loss of PPN cholinergic neurons plays a critical
role in PD-related postural and gait instabilities (Karachi et al., 2010). In parallel,
significant cholinergic loss has also been reported in the nucleus basalis of Meynert
(Nbm) with a mean loss of 45.8% and presence of Lewy inclusions in surviving cells. This
loss of cholinergic neurons was present in the absence of any volumetric changes in Nbm
and especially in the presence of dementia (Tagliavini et al., 1984).
Cholinergic PET studies as assessed by acetylcholinesterase (AChE) [11C]PMP
showed that cholinergic deficits in the cortex was significantly associated with cognitive
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deterioration and longer gait speed (Muller et al., 2015). Despite these findings, the
degree of cholinergic deficits appears to be heterogenous in PD. In a group of nondemented PD patients (n=101) subject to [11C]PMP radioligand, only 36% of the subjects
had low AChE levels in the neocortex and thalamus, which was significantly associated
with lower global cognition compared with the PD group with normal AChE activity
(Bohenn et al., 2012). In the case of PD dementia (Bohnen et al., 2003), cortical AChE
activity is even more pronounced (−20.0%) in frontal, parietal and temporal neocortex
compared to PD subjects with no dementia (-12.9%). These results reflect the
heterogenic etiology behind PD cognitive decline which also includes cortical Lewy
pathology.
Cognitive dysfunction represents highly debilitating non-motor manifestations of PD
that cause additional burden to both patients and caregivers. Pathophysiologic substrates
of cognitive decline and ultimately dementia, developed in the late stages of the disease,
is not yet established in detail. Postmortem (Hurtig et al., 2000) and neuroimaging studies
(Uribe et al., 2016) highlight a relationship between pathological processes in the cerebral
cortex and cognitive decline. In this regards, in-vivo assessment of cortical microstructure
in regions susceptible to PD pathology is warranted to identify non-invasive pathological
correlates of cognitive decline and to detect patients at risk of developing cogntive
decline.
1.4 Treatment of Parkinson Disease
Currently, PD is an incurable condition and symptomatic therapy is available to
manage the motor symptoms of the disease. The choice of pharmacological interventions
for the initial treatment of PD motor symptoms take into consideration a number of factors
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like the level of disability experienced by the patient, need for relief from motor symptoms,
tolerability of medication side effects and the necessity to delay the development of longterm motor complications.
In early PD, both Levodopa (precursor of dopamine) and dopamine agonists
significantly ameliorate motor symptoms, with a greater effect size for Levodopa on the
motor features. However, it is recommended to initiate the PD therapy with dopamine
agonists drugs like Pramipexole and Ropinirole, especially in patients with disease onset
at a young age to avoid the development of drug-induced motor complications. This is
particularly relevant in the case of Levodopa (L-DOPA), where chronic treatment is
associated with involuntary movements or dyskinesias (Hauser et al., 2007).
As PD progresses, the concerns of motor fluctuations and levodopa-induced
dyskinesia (LID) become prominent, affecting more than 40% of patients on L-DOPA for
more than 6 years (CALM, 2009) and typically require medication changes without
worsening dyskinesia. Amantadine, an antagonist for the glutamate-N-Methyl-Daspartate (NMDA) receptor, is currently the most effective medication in reducing
dyskinesias without worsening motor symptoms with sustained use (Sawada et al., 2010).
Postural instability and gait difficulties also worsen as PD progresses, degrading the
patient’s quality of life and raising the likelihood of falls. They are targeted with
cholinesterase inhibitors such as Donepezil (Chun et al., 2010) and Rivastigmine
(Henderson et al., 2016) because falls are partly due to cholinergic brainstem dysfunction,
particularly in the pedunculopontine nucleus, that contributes to gait instability in PD
patients.
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Table 2. Pharmacological Therapy in Parkinson Disease
Substance
Mechanism
Dosage/day
Levodopa
Precursor to dopamine
Up to 1000–1500 mg
Pramipexole
Dopamine receptor
3 × 0.35–0.7 mg
agonist
Ropinirole
Dopamine receptor
6–24 mg
agonist
Amantadine
NMDA-receptor
2–3 × 100–200 mg
antagonist
Donepezil
Acetylcholinesterase
5–10 mg
inhibitor
Rivastigmine
Acetylcholinesterase
4.6–9.2 mg
inhibitor
Nonpharmacological interventions to alleviate a range of motor symptoms are also
expanding and include deep brain stimulation to the subthalamic nucleus and the Globus
pallidum internal to improve tremors and physical therapy exercises for falls prevention.
Despite the remarkable achievements in the management of motor decline in PD,
neuroprotective interventions that are able to modify the disease progression are still
unavailable and treatment of cognitive impairments is still under-developed. To data,
Rivastigmine, an acetylcholinesterase and butyrylcholinesterase inhibitor, is the only
approved agent by the Food and Drug Administration for the management of PD
dementia, producing significant moderate improvements in cognition (Emre et al., 2004).
The lack of treatment options to slow disease progression, in combination with
increasing elderly population, poses a rising economic burden and an unmet need for
disease-modifying interventions. In order to test the efficacy of candidate treatments, it is
essential to establish non-invasive brain biomarkers that can objectively and reliably
assess pathological changes and thus, be able to evaluate the response to treatments
over time.
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1.5 Neuropathology of Parkinson disease
1.5.1 Alpha-Synuclein and Lewy pathology
In PD, there is progressive formation and accumulation of intraneuronal proteinaceous
inclusions known as LB and LN, in neuronal cell bodies and processes, respectively.
Lewy pathology forms principally from the accumulation of fibrillary forms of the
phosphorylated alpha-synuclein (α-syn) protein and are commonly observed in the
surviving neurons of the SNc and multiple regions of the central and peripheral nervous
system.
Function. α-syn is a natively soluble protein (14 kDa) and exists in equilibrium
between unfolded state localized within the presynaptic terminals and the membranebound state near synaptic vesicles in a folded helical form, where it binds to the vesicular
membranes. Due to its presynaptic location and association with synaptic vesicular
membranes, it has been proposed that α-syn has a role in synaptic recycling (docking
and fusion) as well as the release of neurotransmitter (Murphy et al., 2000), partly through
the interaction between α-syn and synaptic SNARE complexes (Burre et al., 2014). In
particular, α-syn regulates trafficking and recycling of synaptic vesicle through binding to
the synaptobrevin2/vesicle-associated membrane protein 2 (VAMP2) and promoting
SNARE’s assembly (Burre et al., 2010).
In addition, α-syn is capable of modulating the size and release properties of
neurotransmitters, where it regulates the trafficking of synaptic vesicles from the resting
pool into the active zone by interacting with Rab3A protein, an important regulator in
vesicular trafficking (Dalfo et al., 2005). Consistently, it was shown that α-syn knock-out
mice display an increased release of dopamine in response to paired pulse stimulation,
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supporting the hypothesis that α-syn is a negative regulator of dopamine
neurotransmission (Abeliovich et al., 2005).
Although α-syn is thought to exist only as an intracellular protein, monomeric α-syn
was found in the cerebrospinal fluid (Borghi et al., 2000) and blood (El-Agnaf et al., 2003)
in both normal and PD subjects and in similar concentrations. These findings suggest that
extracellular forms of α-syn might be released as part of a normal neuronal process with
a possible physiological function throughout life, and may contribute to the pathogenic
process of PD.
Pathology. Under pathological conditions, α-syn monomers abnormally misfold and
aggregate into oligomeric intermediates and protofibrils, a process that is mediated by the
non-amyloid-β component region of α-syn. The pathway ends with the formation of
insoluble amyloid-like fibrils and deposition into Lewy bodies. A growing body of evidence
suggests that abnormal α-syn can behave like a prion and mediate the spread of
pathogenic α-syn aggregates between neurons (Brundin and Melki, 2017). Desplats et
al. (2009) demonstrated direct cell-to-cell propagation of α-syn aggregates in both tissue
culture and transgenic mice. Overexpressed α-syn spread to engrafted healthy embryonic
stem cells and was associated with the appearance of α-syn inclusion bodies and
neuronal degeneration. Monomeric and aggregate forms of α-syn can be released from
the neurons into extracellular space, in part, by exosomes in a calcium-dependent
manner (Emmanouilidou et al., 2010) and the uptake of the secreted α-syn is mediated
by endocytosis of recipient cells (Desplats et al., 2009).
Spread of pathology. Clinical evidence for prion-like mechanisms spread of Lewy
pathology comes from histological analysis of embryonic dopaminergic grafts in the
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putamen of PD patients. Transplanted neurons were positive for α-syn inclusions 12–22
y after transplantation, indicating potential spread of Lewy pathology from host to grafted
neurons (Li et al., 2008 and Li et al., 2016). A possible explanation for this observation is
the spread of misfolded α-syn from affected neurons to the healthy embryonic grafts and
the consequent recruitment of endogenous α-syn to misfold.
Patterns of α-syn pathology spread has been described well in non-transgenic (NTG)
and Parkinson mouse models. In a seminal paper by Luk et al (2012), the injection of αsyn fibrils into the dorsal striatum of NTG mice led to cell-cell transmission of misfolded
α-syn into the SNc of the injected side and loss of dopaminergic neurons, resulting in
motor deficits. Intraneuronal α-Syn aggregates were also present in cortical areas IV-V,
amygdala and the olfactory bulb, areas known to be directly interconnected to the
striatum. These results indicate that the cell-cell transmission of Lewy pathology requires
the recruitment of endogenous α-syn as templates for aggregation and suggests that the
pathology spreads between anatomical connectivity regions throughout the brain.
Factors regulation the spread of Lewy pathology remains a matter of debate in terms
of neuronal vulnerability to α-syn aggregation and mechanisms of α-syn aggregates
transport of between neurons. In an experimental study to explore the factors contributing
to the rate and severity of pathological α-syn spread, selective vulnerability of brain
regions to develop Lewy pathology was found to be correlated with endogenous α-syn
expression and at a rate that is proportional to the density of axonal projections from the
seed brain area to the targeted region (Henderson et al., 2019). That is to say, regions
with less Lewy pathology had a very low α-syn expression compared to regions more
vulnerable to Lewy inclusion with higher α-syn expression. These finding are consistent
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with data from human brains also showing that regions with low α-syn expression are
resistant to LB pathology (Erskine et al., 2018).To summarize, the propagation of PD
Lewy pathology is highly stereotypical following anatomically interconnected brain
regions and requires endogenous α-syn as templates for pathogenic conversion,
suggesting that the transmission and conversion of the endogenous protein play central
roles in PD progression. The stereotypical path of PD pathology is highly important
because it will enable us to select a priori regions of interest that are known to be
susceptible to PD pathology and evaluate the cortical microstructure in vivo.
1.5.2 Braak’s Pathological Staging System
It has been recognized that α-syn pathology extends beyond the SN. Autopsy studies
of human PD brains showed that Lewy pathology is present in the enteric nervous system,
autonomic nervous system, brain stem (dorsal motor nucleus of the vagus), limbic
structures (amygdala and hippocampus) and in the neocortex. Following pioneering
postmortem analysis, Braak and colleagues proposed a staging system in PD based on
the assessment of the anatomical distribution of Lewy pathology (Braak et al., 2003).
According to the neuropathological staging system, α-syn pathology occurs first in the
dorsal motor nucleus of the glossopharyngeal and vagal nerves in the medulla oblongata,
as well as in the anterior olfactory nucleus, which worsens in stage 2 and includes
additionally, the intermediate reticular zone and the caudal raphe nucleus in the pontine
tegmentum (Stages 1-2). From the lower brainstem, the pathology spread rostrally
reaching the midbrain SN pars compacta (SNpc), magnocellular nuclei of the basal
forebrain and pedunculopontine tegmental nucleus in stage 3. During stage 4, Lewy
pathology progresses to the anteromedial temporal mesocortex (including the
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transentorhinal region) and appears mainly in projection neurons of the deep cortical
layers V– VI. Cortical and central nuclei sub-nuclei of the amygdala also develop Lewy
pathology and severe involvement of the magnocellular nuclei of the basal forebrain,
hypothalamic tuberomamillary nucleus and oral raphe nuclei is recorded. Typical of stage
4 is the marked loss of melanized dopaminergic neurons, especially in the posterior
regions of the SNpc, in PD cases compared to control cases. During stages 3-4, it is
highly likely that the clinical motor manifestations of PD emerge. At stage 5, Lewy
pathology in the transentorhinal region worsens and extends to the limbic temporal areas,
insular and cingulate cortices (subgenual and anterior), higher order association areas
and prefrontal neocortical areas. In stage 6, nearly the entire neocortex is involved with
Lewy pathology and can reach the sensory association areas, premotor area, primary
sensory and motor areas.
Figure 2. Schematic representation of Braak staging system for PD (Adapted
from Halliday et al., 2011)

The staging system of PD was followed by the “Dual Hit” theory, also known as Braak’s
hypothesis (Hawkes et al., 2007), which states that sporadic PD is caused by an
exogenous pathogen that enters the body through two portals, the olfactory bulb and
enteric plexus of the stomach, initiating the Lewy pathology in the olfactory tract and
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digestive system, respectively. The exogenous pathogen can progress from the enteric
plexuses to the CNS retrogradely through the preganglionic parasympathetic vagal motor
neurons. Once in the CNS, the pathogen can ascend from spinal cord into the medulla,
pons and midbrain. From the nasal pathway, the pathogen progresses anterogradely into
the temporal lobe, amygdala as well as piriform cortex.
1.5.3 Postmortem and Clinical Evidence Supporting Braak’s Staging
The relevance of α-syn pathology in the pathogenesis of PD is supported by the onset
of premotor clinical symptoms which coincide with α-syn accumulation in both central and
peripheral brain regions. The early involvement of the enteric and autonomic nervous
systems is given by the prominent gastrointestinal (GI) problems, urinary incontinence
and orthostatic hypotension in PD, present early in the disease. GI symptoms include
constipation, excessive drooling, dysphagia and defactory dysfunction and are a
significant cause of disability. Among GI problems, chronic constipation is the most
frequent, affecting about 60% of PD patients and may precede the development of motor
symptoms in by several years (Kaye et al., 2006).
Neuropathological studies have identified the accumulation of LN in the colonic
submucosal plexus, derived from colonoscopy biopsies of PD patients at early stages of
the disease (Lebouvier el., 2010). Lewy inclusions are also found in the dorsal motor
nucleus of the vagus (DMV), leading to vagal dysfunction and subsequent constipation
(Hawkes et al., 2009). These findings provided the basis for the hypothesis that α-syn
pathology starts in the ENS and spreads to the central nervous system through the DMV
in a caudo-rostral fashion, affecting the midbrain first and reaching the neocortex (Braak
et al., 2006). Similarly, the involvement of the olfactory structures is congruent with clinical
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evidence of olfactory deficits in early stage PD patients with a prevalence of about 8090% (Tissingh et al., 2001), sometimes even preceding motor manifestations (Ross et
al., 2008).
The involvement of Lewy pathology in the SN and loss of dopaminergic neurons in
mid stages of the disease is universally acknowledged and correlates with motor
symptoms defining PD (Dickson et al., 2010). In the last stages, α-syn aggregates are
found in the neocortex and trans-entorhinal region. In these late stages, many PD patients
experience cognitive decline and a number of human postmortem studies identified a
positive correlation between the presence of cortical LB and dementia in PD (Van den
Berge et al., 2012 and Aarsland et al., 2005).
1.5.4 Link Between Alpha-Synuclein Pathology and Neuronal Loss
Post-mortem analysis of neuronal density in the SN of PD subjects, revealed a
linear relationship with motor symptoms, evaluated using the motor section of the Unified
Parkinson Disease Rating Scale (Greffard et al., 2006). A postmortem study of PD
patients found no support for a pathogenic role of Lewy bodies in the SNpc, as there was
no relationship between the severity of SNpc neuronal loss and the regional distribution
and density of α-syn aggregates (Parkkinen et al., 2011). Other postmortem studies have
identified significant neuronal loss (-30%, p=0.007) and total volume reduction (-20%,
p=0.02) in the amygdala of PD group, which was associated with high concentrations of
LB aggregates (Harding et al., 2002). Similarly, volumetric imaging studies have found
volume reduction (-16.5%, p<0.001) in the centromedial amygdala of PD patients
compared to healthy controls (Blair et al., 2019). The contribution of α-syn aggregates to
the neurodegenerative process has not been established yet, but neurite pathology might
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be one of the earliest events without profound cell loss (Prots et al., 2013). α-Syn
oligomers induce depolymerization of microtubules (MT), essential for neurite structure
and intracellular transport. Impaired MT stability is accompanied with reduction in the and
kinesin-dependent cargoes within neurites (Prots et al., 2013).
Dysfunctions of α-syn can cause presynaptic dysfunction and consequent axonal
damage, likely preceding neurodegeneration (Calo et al., 2016). Experimental data from
a transgenic mice model of aggregation-prone human α-syn, showed that α-syn
aggregates are found at the striatal dopaminergic terminals accompanied with profound
striatal DA deficiency, in the absence of dopaminergic neuron loss in the SN (Garcia et
al., 2010). Garcia et al., showed that the expression of α-syn aggregates lead to a
redistribution of the SNARE complex at the synaptic terminals and a subsequent
reduction of exocytosis and dopamine release. Further immunohistochemical analysis of
human PD postmortem tissue revealed reductions in the anterograde axonal motor
protein, kinesin, in early PD stages which was significantly greater in dopaminergic
neurons containing α-syn aggregates (Chu et al., 2012). In late PD stages, the levels of
the retrograde axonal motor protein, dynein, are severely reduced suggesting functional
alterations in dynein in PD. These studies suggest that axonal transport dysfunction and
synaptic impairments are key feature preceding neuronal death in PD, however, their
contribution neurodegeneration and the exact role of α-syn aggregation in these
processes remain to be clarified.
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1.5.5 Role of Cortical Lewy Pathology in Cognitive Decline
Lewy pathology spread and the associated pathological changes have been proposed
as a significant contributor to the progress of cognitive decline in PD. In a post-mortem
study assessing the neuropathologic abnormalities of 22 demented and 20 nondemented
PD patients by Hurtig et al. (2000), Lewy pathological changes were widely found in the
cerebral cortex, mainly in the frontal lobe and cingulate cortex, and were found to be the
most significant pathologic correlates of dementia (sensitivity of 91% and specificity of
90%). In another group of 8 PD patients with mild cognitive impairment (PD-MCI), Limbic
Lewy bodies and coexisting AD pathology were major contributors to the cognitive decline
(Adler et al., 2010).
However, not all PD dementia patients have concurrent cortical AD pathology. In fact,
Arsland et al. (2005) showed in a post-mortem brain analysis of 22 PD patients, that the
rate of cognitive decline was significantly associated with Lewy bodies score (Spearman's
ρ, −0.45; p < 0.05) and less closely associated with AD pathology, highlighting the role of
Lewy pathology in driving dementia and the progression of cognitive decline in PD. A
more detailed post-mortem study by Mattila et al. (2000), aimed at studying the relative
contribution of cortical LB pathology and AD pathology to cognitive impairment in 45 PD
patients. Despite the fact that 40% of the patients had histological evidence of AD
pathology (Senile Plaques), the number of LB in the frontal and cingulate gyri were the
most significant predictor of cognitive decline independent of the AD pathology (Mattila et
al., 2000). LBs were most numerous in the amygdala, cingulate and entorhinal cortex,
followed by the temporal, frontal, precentral and angular regions where cortical LB were
located predominantly in layers V and VI and in the deep a-layer of the entorhinal cortex.
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A more recent post-mortem study examining the neuropathological substrates of PDMCI in 25 PD-MCI patients revealed a similar increase in Lewy pathology in Limbic and
neocortical brain regions, which was associated with Braak stages 3 and 4, respectively
(Knox et al., 2020). Notably, specific patterns of LB distribution in Limbic areas, namely
the entorhinal and anterior cingulate cortices, were significantly associated with the
clinical dementia rating (CDR) score in post-mortem study of 22 PD patients (Kovari et
al., 2003), accounting for 40% of the variability in the CDR score. These studies suggest
that while LB formation in limbic and neocortical structures is essential for development
of PD dementia, other neuropathological markers might also play role in the pathogenesis
of PD dementia such as neuronal and synaptic loss. The limited availability of a
neuroimaging techniques to study the distribution of cortical α-syn aggregates in vivo
hinders our understanding of the exact contribution of Lewy pathology in PD
pathogenesis. Nonetheless, plasma and CSF α-syn levels have been studied in PD
patients.
Visual hallucinations (VH) are the most common hallucination modality in PD and can
vary across the disease course. In the early stages, PD patients can experience passage
hallucinations of an object or a person passing briefly in the peripheral visual field,
illusions or misperception of actual stimuli and presence hallucination which is a
perceptual experience without a visual stimulus. As PD progresses, patients experience
formed visual hallucinations of animals or people while recognizing it as hallucinations.
This insight is lost later in PD, with the onset of delusions or false beliefs and
hallucinations in other sensory modalities such as auditory. When present, VH can last
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for seconds to minutes and their severity depends on their frequency and whether the
insight of the patients is preserved or lost.
The primary visual nature of PD psychotic symptoms reflects a dysfunction in the
visual system, although other systems can be involved. Neuropathological studies in nondemented PD patients with visual hallucinations (PD-VH) point to role for a higher Lewy
pathology load in the amygdala and parahippocampal gryus, and inferior temporal lobe,
where the proportion of LB inclusion nearly doubled in the basolateral nucleus of the
amygdala of the hallucinating group (PD-VH: 5.7 ± 0.9 versus PD non-VH
3.1 ± 0.4; p = 0.01) and was accompanied by cell loss. These results suggest that
pathologic changes in temporal areas due to high Lewy pathology is associated with the
emergence of visual hallucinations in PD (Harding et al., 2002). Subsequent postmortem
studies in PD-VH (n=10) and PD non-VH (n=10) subjects have replicated the involvement
of the amygdala and showed increased burden of LB pathology in frontal (Brodmann area
9), parietal (Brodmann area 39) and limbic areas (Brodmann area 20) more pronounced
in the PD-VH group (Papapetropoulos et al., 2006). The amygdala is involved in the
ventral visual stream functioning in visual identification and discrimination. Dopamine
receptor activation in the basolateral nucleus of the amygdala removes the suppression
of neuronal output from the prefrontal cortex and plays a role in neural integration. In the
case of PD, the increased LB pathology in the basolateral amygdala will likely disrupt its
ability to integrate coordinated responses between the visual systems.
VH in the absence of dementia have also been linked to volumetric loss in the DLPFC,
cingulate cortex, primary and secondary visual cortices, lingual and supramarginal gyri
and the fusiform using in vivo structural imaging and voxel-based morphometry
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(Watanabe et al., 2013). A whole-brain resting-state functional connectivity analysis
further revealed a significantly lower functional connectivity of the superior frontal gyrus
and superior temporal gyrus in PD-VH patients (ρ = −0.601, p = .018; and ρ = −0.539, p
= .038, respectively) (Hepp et al., 2017). The superior frontal lobe has an important role
in the maintenance of visuospatial attention and inhibitory control to reflect upon sensory
experience. The superior temporal lobe is involved in visual attention and the ventral and
visual streams. Based on their functional roles, findings from this study support the
hypothesis of dysfunctional attention, a top-down process, in the generation of VH
(Collerton et al., 2005). In particular, the functional disconnectivity between the frontal
and temporal areas impairs the ability to discriminate external perceptions from internally
generated information, so PD-VH patients will be more likely to report internally generated
stimuli as external visual input (Barnes et al., 2003).
Glucose hypometabolism in PD-VH patients with normal cognition have also been
reported in area of the ventral visual stream, the inferior and middle temporal cortices,
fusiform gyri and frontal lobe (Park et al., 2013). The ventral visual stream is responsible
for object representation and recognition, by capturing feature information like the shape,
color, size and brightness. More evidence on the contribution of the ventral visual stream
in the genesis of VH in PD, stems from reduced levels of γ-aminobutyric acid (GABA) in
the primary visual cortex and gray matter atrophy in the anterior temporal lobe, amygdala
and area V4 of the visual cortex (Firbank et al., 2018). Areas V4 projects to the
parahippocampal gyrus to aid in object recognition and coordination between primary and
associative visual areas. However, no associated was found between the GABA levels
and severity of visual hallucinations, which implies that GABA levels may increase
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likelihood of VH, but their occurrence and severity might be controlled by other factors
including attention, visual environment, and distribution of Lewy pathology.
1.6 Study Aims and Hypotheses
Parkinson disease pathophysiology extends beyond nigrostriatal dopamine loss, and
can include the cerebral cortex and major white matter tracts. Microstructural changes in
gray matter regions susceptible to Lewy pathology remain an unexplored area and their
contribution to the cognitive decline is less understood. For this purpose, our study will
address the microstructural changes in the cerebral cortex associated with PD pathology
and its relationship with cognitive decline by acquiring diffusion MRI metrics specific to
tissue microstructure, namely fractional anisotropy, intracellular volume fraction and
orientation dispersion index. Furthermore, the established histological evidence of
dendritic regression in the striatum enables us to test the sensitivity of the tissue diffusion
indices to the underlying pathological changes compared to conventional volumetric
measures. Finally, white matter involvement in PD has been limited in the past to whole
brain analysis and little has been achieved in characterizing the extent and distribution of
white matter changes. Thus, our study will aim to reconstruct the nigrostriatal tract which
is heavily involved in PD pathology and analyze the diffusion metrics of tissue
microstructure in the NST. In addition, we will also explore PD-related pathological
changes in the corpus callosum subregions, which have not been studied in detail before.
Postmortem studies support a role for Lewy pathology distribution in cortical regions
in cognitive decline. In vivo assessment of the distribution of LB and LN in the human
cerebral cortex is currently inaccessible due to the lack of a non-invasive imaging marker
of α-syn. With the histological evidence of axonal and dendritic damage in the presence
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of abnormal α-syn aggregates, it is essential to explore the possible microstructural
abnormalities in cortical areas known to be associated with Lewy pathology and in white
matter tracts affected by dopaminergic denervation. In this vein, diffusion MRI studies
might help characterize the tissue microstructural changes associated with PD pathology.
Diffusion MRI utilizes water molecular displacement as an endogenous probe of tissue
microstructure. It is possible then to relate the diffusion-weighted signal to meaningful and
specific features of tissue microstructure by using biophysical models. The bedrock of
biophysical modeling is the assumption of water compartmentalization, which assumes
that the sum of water signal from different tissue compartments contribute to the overall
measured diffusion signal. The diffusion signal from each compartment can be used to
estimate the relative size and geometry of the underlying tissue compartments. Neurite
density and dispersion imaging (NODDI) is one such biophysical model that produces
three main metrics representing tissue characteristics, including the intracellular volume
fraction (ICVF), orientation dispersion index (ODI) and isotropic volume fraction. ICVF
represents the fraction of axons and dendrites (neurite) and is an index for neurite density.
The ODI describing the complexity of neurites architecture and is usually lower in highly
aligned structures like white matter tracts.
The central aim of this dissertation was to test the hypothesis that PD pathology
includes alteration in tissue microstructure, as reflected by MRI diffusion measures,
intracellular volume fraction and orientation dispersion index. We were specifically
interested in assessing the intracellular volume fraction, reflecting the fraction of axons
and dendrites (neurite), and the orientation dispersion index, describing the complexity of
neurites architecture, in cortical regions known to be susceptible for Lewy pathology. This
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study will allow us to test the utility of NODDI in assessing the potential tissue
microstructural abnormalities related to PD pathology. Findings from this study can be
clinical useful to monitor disease progression and evaluate the extent of pathological
changes in PD.
To test this hypothesis, it was necessary to study three aims plus an exploratory aim:
•

Aim 1: Show that diffusion MR measures such as the intracellular volume fraction
(ICVF) and orientation dispersion index (ODI), are altered in cerebral cortex in PD
patients compared to HC. This will allow us to characterize the topographical
distribution of cortical microstructural changes associated with PD pathology and
identify patients at risk of developing dementia. Relating changes in the cortical
neuropil to cognitive decline will be instrumental in improving our understanding of
the underlying mechanisms contributing to dementia.

•

Aim 2: Show that ICVF and ODI are altered in the dorsal striatum, a subcortical
region known to be affected in PD. This will allow us to test whether ICVF and ODI
are sensitive to well-established dendritic regression in these regions. Results from
this aim will enable us to identify non-invasive biomarkers of striatal microstructure
that can be used to assess disease severity and predict the clinical progression of
the patient.

•

Aim 3: Show that ICVF and ODI is altered in the reconstructed nigrostriatal tract in
PD patients compared to HC, and explore possible changes in the corpus
callosum. This will allow us to test whether ICVF and ODI are sensitive to the loss
of dopaminergic projection in nigrostriatal tract. PD-related changes in the
nigrostriatal tract microstructure can help us identify patients who are at risk of
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developing motor impairments, given that it is one of the first tracts to be
compromised in PD. The secondary aim helps us understand if the corpus
callosum, as a major white matter tract, is involved in PD pathology. Little has been
known on how PD pathology can affect axonal integrity, in terms of axonal loss or
re-organization. Results from this aim will help us disentangle the possible
pathological processes affecting the corpus callosum in PD.
•

Aim 4: Explore the significance of ICVF and ODI using a sub-region analysis of the
corpus callosum in HC group. Using the corpus callosum as a white matter model
of known fiber composition, will help us interpret the changes observed in ICVF
and ODI.

In order to answer the question of whether PD pathology alters tissue microstructure
as a result of underlying α-syn accumulation, NODDI measures of neuropil
microstructure, intracellular volume fraction (ICVF) and orientation dispersion index
(ODI), are warranted. ICVF is an index of neurite density and measures the fraction of
water diffusion signal restricted within the axons and dendrites (Zhang et al., 2012). ODI
describes the extent of neurite dispersion, which can be highly dispersed dendrites in
gray matter or coherently aligned axons in white matter.
The first aim tests the ability to detect in vivo microstructural changes in cortical areas
known to be involved with PD pathology according to Braak staging. By estimating the
ICVF and ODI from the NODDI model, we can test the hypothesis that PD pathology
alters cortical microstructure. Elucidating such a relationship in vivo is critical because it
provides us with microstructural biomarkers to track disease progression and potentially
assess the efficacy of future treatments.
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The second aim addresses the ability of ICVF and ODI to detect microstructural
abnormalities in the dorsal striatum. Striatal morphological pathology in PD, in terms of
reduced dendritic length and spine density have been validated using postmortem
studies, which make this region ideal to investigate the sensitivity of ICVF and ODI.
Similarly, in the third aim we expect a pattern of microstructural abnormalities in the
nigrostriatal tract, also known to be involved early in the disease.
Additionally, aim three addresses the potential microstructural abnormalities in the
corpus callosum (CC) subregions associated with PD, where we are the first to use
subregional CC analysis in the context of PD. The CC has been extensively studied and
characterized histologically in terms of fiber composition using human postmortem data
which makes it a suitable white matter model to interpret the ICVF and ODI, which is our
exploratory aim in this dissertation. Indeed, if ICVF was able to capture the regional
variation in fiber composition as established histologically, then we will be able to better
interpret the changes observed in the PD subjects.
Chapter 3 describes study design, demographics of PD and HC groups, and MRI preand post-processing methods. Chapters 4 and 5 provides results of cortical and
subcortical microstructural abnormalities in brain regions associated with PD pathology.
Chapter 6 provides details of white matter involvement in PD, in which we studied both
the microstructure of both nigrostriatal tract and the corpus callosum. Chapter 8
addresses the significance of ICVF and ODI in the corpus callosum subregions in
comparison to established histological fiber composition. Finally, chapter 8 provides a
summary of the results, discussion, limitations, and future directions.
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CHAPTER 2 DIFFUSION MAGNETIC RESONANCE IMAGING
Diffusion MRI (dMRI) is a non-invasive imaging technique that exploits the
displacement of water molecules, in vivo, for probing tissue microstructure. Water
molecules are subject to Brownian motion due to thermal energy carried by these
molecules. In a free medium, water molecules diffuse randomly with equal probability
along any direction. However, in biological tissue water diffusion is influenced by a
number of factors such as cell membranes, macromolecules and organelles, which acts
as barriers to water movement. Based on the non-invasive observation of water motion
in the brain, dMRI may provide valuable information about the neuronal tissue
microstructure and geometric organization. The challenge in dMRI is to relate the
obtained water diffusion signal to physical quantities characterizing the underlying tissue
composition, such as axon diameter, density and spatial organization. This issue has
been addressed using biophysical modelling of the diffusion weighted signal, which can
help gain specificity to the microstructural changes observed in development, aging or
pathology.
The human brain is classically composed of two major tissue types, gray matter (GM)
and white matter (WM). GM consists of neuronal cell bodies and their dendritic
arborization, glial cells, including astrocytes, oligodendrocytes, and microglia, as well as
efferent and afferent axons. Dendrites are highly branched and dispersed extensions that
form tree-like arrangement around the cell soma and intermingle strongly with
neighboring dendrites to form a complex dendritic network. As such, water diffusion in the
GM has no preferred orientation and is hindered equally in all directions. The morphology
of the dendritic tree is not stable but can undergo significant remodeling with increasing
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age (Scheibel et al., 1975) and under many pathological conditions such as Alzheimer
disease (Elburg and Ooyen, 2010 and Cochran et al., 2014). The water diffusion profile
in the gray matter can thus help us study the architecture and complexity of dendritic
arborizations.
WM contains bundles of myelinated and unmyelinated axons, connecting various GM
regions to each other. The myelin sheath encapsulates axons along its length, with
periodic gaps where no myelin is present (nodes of Ranvier). The diameter of the axons
can vary between 0.1 μm to 25 μm and is a key feature related to neuronal function, as
axonal diameter is related to the neurotransmission speed (Beaulieu, 2002 and Ritchie,
1995). In general, axons in WM are densely packed and highly organized, running in
parallel arrangements that favor water diffusion along the fiber axis and hinders
movement perpendicular to the fiber by barriers such as the myelin sheath (Beaulieu,
2002). Since water diffuses preferentially along the length of the axon, if we can determine
the dominant diffusion orientation, then it is possible to infer the dominant fiber orientation.
Neurite is a collective term used for both axons and dendrites.
2.1 Basic Principles of Diffusion
Brownian motion governs the random walk of molecules in a medium due to thermal
agitation that is dependent on multiple factors such as mass of the molecules,
temperature and the medium viscosity. This physical process was first described by the
botanist Robert Brown (1827) who observed random displacement of pollen grains
suspended in water. Independently, Adolf Fick (1855) explained the macroscopic
phenomenon of diffusion, which refers to the flux of particles arising from a concentration
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gradient (Fick’s first law). Einstein recognized that Brownian motion is associated with
diffusion without the need for a macroscopic concentration gradient.
Einstein explained that molecules undergo a process of self-diffusion, arising from
the imbalance of exterior collisions of surrounding water molecules (Einstein, 1905).
Using the concept of Brownian motion and Fick’s Law of diffusion, Einstein introduced the
“displacement distribution”, which is the likelihood that a given particle will undergo
displacement. In a free medium, the conditional probability P(r|r’, t) that a particle starting
at position r at time zero will move to r’ in a given interval of time t:
-.

𝑃(𝑟|𝑟 % , 𝑡) = (4𝜋𝐷𝑡) / exp (

−(𝑟 % − 𝑟)/
4𝐷𝑡

(𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 1.1)

where D is the diffusion coefficient, a constant that depends on the temperature and
viscosity of the medium. For example, D = 3 × 10-3 mm2/s in the case of “free” water
molecules diffusing at 37°C which translates to a diffusion distance of 25 μm during 30
ms timeframe. Einstein also introduced the equation of diffusion (m2/s) represented by:
< 𝑟 / >= 2𝐷𝑡

(𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 1.2)

where <r2> is the average mean-squared diffusion distance along one dimension
during a timeframe t.
Tissue microstructure affects the properties of water diffusion. In the absence of
barriers to diffusion or if the barriers are randomly orientated, water molecules diffuse
equally in all directions, known as isotropic diffusion. In the presence of barriers that limit
water movement in particular directions while favoring diffusion along other, water can
diffuse preferentially along a particular direction, known as anisotropic diffusion. And thus,
by measuring the degree and direction of water diffusion non-invasively, which is possible
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with diffusion weighted imaging (DWI), can provide a unique opportunity to infer tissue
microstructure and its architectural organization.
2.2 Basic principles of Nuclear Magnetic Resonance Imaging
Nuclear magnetic resonance (NMR) was first described by Felix Purcell and Edward
Bloch in 1946, and in 1952 they both received Nobel Prize in Physics for their discovery.
The term “magnetic” refers to the use of magnetic fields and “resonance” refers to the
generated magnetic field in the coil that is oscillating at the Larmor frequency of the atomic
nucleus and hence “nuclear”. Thus, NMR is based on the interaction between a nuclear
spin with a magnetic moment and a magnetic field (B0), which produces a torque or
turning force, causing the nucleus to precess about the direction of B0 and the
precesseional frequency is proportional to the strength of the B0 field.
The dominant nucleus usually probed in MRI is the Hydrogen in the water (1H or
proton), which is a single positively charged proton. 1H continuously spin on their axis and
have an associated magnetic moment (µ) which interacts with the main field (B0) of the
scanner. This interaction results in a circular motion of the nucleus about the main axis of
B0, with a precessional frequency that is proportional to the applied magnetic field, given
by the Larmor equation:
𝜔B = 𝛾𝐵B

(𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 1.3)

𝛾 is the gyromagnetic ratio and equals 42.58 MHz/Tesla for the hydrogen nuclei. So,
in the presence of an external magnetic fields, all protons precess at the same Larmor
frequency 𝜔B and this is the “resonance” condition. Two possible energy states exist for
protons exposed to an external magnetic field, either spin-up (low energy state) or spindown (high energy state). In the presence of B0 and at body temperature, there are more
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nuclei spinning in the low energy state than high energy state with a ratio of approximately
1.000004 (for every 1 million protons in the anti-parallel direction, there are 1 million and
4 protons aligning with the field). The source of the MRI signal is the net magnetization
M0, which is the vector sum of all spins up and spin down (measured in µT) in alignment
with the direction of B0 (longitudinal- or z-magnetization). In order to measure M0, it is
tipped away from the equilibrium plane (z-axis) into to the x-y plane (transverse plane) by
applying radiofrequency (RF) pulse. The RF pulse is sent to the coil to generate an
magnetic field (B1) oscillating at or near the Larmor frequency. If a 90o RF pulse is used,
then M0 is exactly in the transverse plane. The strength or the duration of the RF pulse
can be modulated to produce a different flip angle.
Gradient. In order to correlate the measured signal with a spatial location it originates
from, we introduce the concept of magnetic field gradients. Gradients are spatial linear
variations in the magnetic field along a certain direction and are measured in milli
Tesla/meter. The purpose of applying a gradient is the accurate encoding of spatial
position. For example, a gradient in the x-direction (Gx) will increase or decrease the main
magnetic field linearly along the x-direction. Spins at different locations will thus
experience a linear change in the magnetic field. Because a spin’s precessional
frequency is determined by the local magnetic field (Equation 1.3), adding a gradient will
cause protons to precess faster or slower, depending on their position along the gradient
direction. Spins at different locations along the gradient will acquire different phase shifts.
The combined effect of spins precessing at different frequencies will be dephasing or
fanning out of the protons relative to the initial in phase condition. Once the gradient is
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switched off, all spins will revert back to their original frequency, but their accumulated
phase change is maintained, and thus spins are phase encoded.
Spin Echo. There are two principle types of pulse sequence, called gradient echo and
spin echo (SE), which will be our focus. SE sequence involves two RF pulses, an
excitation pulse and a refocusing pulse. It starts with an excitation pulse (90o) to flip the
net magnetization in the transverse plane (Mxy). Immediately after excitation, all spins are
in phase (all aligned together) and precessing at the same Larmor frequency. In the
transverse plane, spins interact with each other by exchanging energy as they move
within the tissue and there is no net loss of energy. This spin-spin interaction is
characterized by time, T2 in milliseconds.
During this time, spins experience local fields as a combination of the applied
magnetic fields and fields from neighboring spins. This variation in the local fields lead to
small differences in the precessional frequencies. As protons precess at different
frequencies, spins experience a loss of phase coherence or dephasing, resulting in the
decay of Mxy. Additional dephasing of the spins is introduced by inhomogeneities in the
main magnetic field and tissue susceptibility effects (differences in the magnetic
properties between tissue types or at boundaries of tissue-air), which accelerates the loss
of Mxy. The combined effects of T2 and magnetic field inhomogeneity is known as T2 *.
F

After a certain time /, a refocusing pulse is applied (180o), which flips all the spins
within the transverse plane about the y axis. Assuming that the spins did not change their
F

location during time /, their phase change will be reversed. Spins continue to experience
the same magnetic field inhomogeneities and still precess with their original frequencies,

40
so that slower spins will catch up with faster spins. At time, t, the spins regain their phase
coherence and a spin-echo is formed.
Pulsed field gradient spin echo. SE sequence can be made sensitive to molecular
diffusion by applying strong magnetic field gradients, designed to make the magnetic field
vary linearly across space. In this context, the 𝑏-factor or 𝑏-value has been introduced
globally as measure of the degree of diffusion weighting measured in 𝑠/𝑚𝑚/ and is
determined by:
𝛿
𝑏 = 𝛾 / 𝛿 / 𝐺(∆ − )
3

(𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 1.4)

𝑮 being the amplitude of the gradient pulse in mT/m, 𝛿 is the duration of a single lobe
(s), separated by Δ (s), the time between the start of the first and second lobe (s). The
diffusion-weighting gradients can be applied to x, y, or z axes, as well as in a combination
of them. Linear variation in the gradient field enables accurate spatial encoding of spins,
where spins at different positions experience different magnetic fields and thus, they
precess at different Larmor frequencies according to the equation:
𝜔(𝑟) = 𝛾(𝐵B + 𝐺𝑟)

(𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 1.5)

where 𝜔(𝑟) is the Larmor frequency at position (𝑟), 𝛾 is the gyromagnetic ratio of 1H
(42.58 MHzT-1), 𝐵B is the main magnetic field and is complemented by a gradient
magnetic field 𝑮 parallel to 𝐵B . Spins carried by the diffusing molecules become spatially
labelled and act as endogenous tracers whose random motion is being characterized.
Pulsed field gradient spin echo (PGSE) is the most widely used pulse sequence for
the measurement of diffusion and was developed by Stejskal and Tanner (1965). The
PGSE sequence starts with a 90o radio-frequency pulse (RF), which tips the
magnetization vector into the transverse space. After excitation, the first diffusion
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gradient, which is spatially changing, is applied in a specific direction. Spins precessing
in the direction of the gradient, will have different frequencies to match the magnetic field
strength at their spatial location. In this case, the Larmor frequency of a spin isochromat
will vary strongly according to their spatial position in the direction of the applied gradient.
Thus, spins will acquire a phase angle, relative to protons at the isocenter where the effect
of the gradient is zero.
Spins located at position r1 in the direction of the diffusion gradient, will precess at a
certain frequency and thus accumulate phase 𝜙R . Phase is described as the position
within a cyclic variation in terms of an angle (0o-360o) and is given by:
𝜙R = 𝛾𝐺𝑟R 𝛿

(𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 1.6)

where δ and G are the duration and the magnitude of the diffusion gradient,
respectively.
S

During diffusion time Td (∆ − .), protons diffuse through the tissue and acquire a new
spatial position (r2). After a time,

TU
/

with TE being the echo-time, a refocusing RF pulse

(180o) is applied, which flips the magnetization about the axis in the transverse plan. The
purpose of this pulse is to reverse the dephasing due to magnetic field inhomogeneities
and generate an echo of the signal at TE, corresponding to the end of the sequence.
Following the 180o refocusing pulse and after a time ∆ from the start of the first gradient,
a second diffusion gradient of the same polarity and magnitude as the first is applied.
In the case of stationary spins (r1 – r2 = 0), the second gradient will reverse the phase
shift imposed by the first gradient, spins will be completely rephase and no signal
attenuation is observed. If spins move to a position r2 as a result of Brownian motion, then
the spins will acquire a different phase shift depending on their location:
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𝜙/ = 𝛾𝐺𝑟/ 𝛿

(𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 1.7)

In the presence of diffusion, the phase imposed by the second b-factor will not be
equal to the phase accumulated by the first b-factor (𝜙/ ≠ 𝜙R ). The net dephasing will be
proportional to the distance travelled in the direction of the diffusion gradient and the
phase accrual amounts to:
𝜙R − 𝜙/ = 𝛾𝐺(𝑟R − 𝑟/ )𝛿

(𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 1.8)

The induced-phase dispersion will not be fully refocused by the second gradient
resulting in signal attenuation. The net dephasing of the spin system will be more
pronounced when stronger diffusion gradients are applied because the phase difference
when moving from r1 to r2 in the direction of the gradient will be sharper and thus the
diffusion weighting is stronger.
As a result of molecular diffusion, the intensity of the diffusion-weighted signal 𝑆Y is
lower than the signal intensity of the non-diffusion weighted image, 𝑆B . The attenuation of
MR signal due to diffusion is expressed for each voxel as:
𝑆Y = 𝑆B . 𝑒 -Y.[\]

(𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 1.9)

which reflects an exponential attenuation profile. The degree of attenuation depends
on the 𝐴𝐷𝐶 (𝑚𝑚/ /𝑠) and 𝑏-value (𝑠/𝑚𝑚/ ) (Tanner, 1977). For a given diffusion gradient
direction, 𝐴𝐷𝐶 can be derived by collecting two signal measurements, a diffusion
weighted signal Sb in the desired direction and non-diffusion weighted signal S0. At body
temperature 37°C, the diffusivity of free water has been shown to be approximately D =
3.0×10-3 mm2/s.
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While diffusion is a three-dimensional process and might not be the same in all
directions (anisotropy) in biological tissue, 𝐴𝐷𝐶 is not suitable to represent diffusion in
anisotropic media. To infer tissue microstructural properties from the diffusion-weighted
data, several techniques have been developed such including diffusion tensor imaging
(Basser et al., 1994).
2.3 Models of Diffusion Weighted MRI
2.3.1 Diffusion Tensor Imaging
As discussed in sections 2.2.3 and 2.2.4, water diffusion is influenced and shaped by
the presence of tissue structures and barriers. In highly aligned biological tissue, such
white matter, water diffusion is significantly larger along nerve fibers, leading to diffusion
anisotropy. Anisotropy is a measure of the degree of water diffusion anisotropy. The more
anisotropic the media is, there is greater dependence of 𝐴𝐷𝐶 on the axis along which
diffusion gradient is applied. Thus, a single scalar 𝐴𝐷𝐶 is no longer sufficient to
characterize the behavior of water mobility at the voxel scale. Instead, a diffusion tensor
is used to map diffusion anisotropy at each voxel.
Diffusion tensor (DT) characterizes anisotropic free diffusion in a 3 × 3 symmetric
matrix

𝑫

containing

multiple

diffusion

𝐷dd
𝑫 = 𝐷ed
𝐷fd

𝐷de
𝐷ee
𝐷fe

coefficients
𝐷df
𝐷ef
𝐷ff

(Basser,

1994):

(𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 2.1)

Each of the six matrix elements represent a unique diffusion coefficient, where
diagonal elements (𝐷dd , 𝐷ee , 𝐷ff ) correspond to diffusivities along that axis in the
laboratory reference frame (𝑥, 𝑦 and 𝑧) and off-diagonal elements (𝐷de , 𝐷fd , 𝐷fe ) describe
correlation between displacements along these axes.
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To estimate the six unknowns the diffusion coefficient,

𝐴𝐷𝐶 in equation 1.8 is

substituted by the tensor 𝑫:

(𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 2.2)

𝑆Y
= exp (− j j
𝑏kl 𝐷kl )
𝑆B
lmd,e,f
kmd,e,f

where 𝑏kl are the elements of the symmetrical 𝑏-matrix. The 𝑏-matrix corresponds to
the degree of diffusion weighting applied in all three directions, 𝑥, 𝑦 𝑎𝑛𝑑 𝑧.
Knowing that the tensor is symmetric (𝐷ed = 𝐷de , 𝐷fd = 𝐷df 𝑎𝑛𝑑 𝐷fe = 𝐷ef ), there are
six-unknown variables to determine. To estimate the diffusion coefficients, two sets of
MRI data are acquired using two b-factors, 𝑏 and 𝑏B , which correspond to diffusion and
non-diffusion weighted data, respectively. DTI schemes are typically acquired with two 𝑏values, 𝑏B = 0 𝑠/𝑚𝑚/ and 𝑏 = 1000 𝑠/𝑚𝑚/ for a minimum of six noncollinear gradient
directions. Thus, at least six diffusion weighted images are required to estimate the
elements of the tensor, in addition to the non-diffusion-weighted image. The elements of
the DT can then be estimated by fitting the log-transformed signal intensity at each pixel
obtained for each 𝑏-factor, using the linear least square algorithm.
Both the diagonal and off-diagonal diffusivities are needed to characterize the size,
shape and orientation of the diffusion ellipsoid. Solving for the eigenvalues 𝜆R , 𝜆/ , 𝜆. of the
3 × 3 tensor provides the three principle diffusivities. The largest eigenvalue is considered
the principal diffusion coefficient and its eigenvector is aligned along the principal diffusion
coefficient. Once the eigenvalues are estimated, a number of diffusion metrics can be
inferred.
The DTI model is based largely on the assumption that the probability distribution
function (PDF) of water displacement in tissue is a 3-dimentional Gaussian distribution of
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diffusivities (Basser, 1995). As result, the diffusion weighted signal is expected to follow
a monoexponential decay profile. While this assumption is valid for b-values ≤1000
s/mm2, it has been shown to deviate from monoexponential decay behavior in neuronal
tissue for high b-values >1000 s/mm2 (Assaf and Cohen, 1998). The reason for this nonmonoexponential decay behavior at high b-values is suggested to be as a result of
increased sensitivity to restricted water diffusion within microstructural barriers like cell
membranes (Jensen et al., 2005). The non-gaussian properties of water diffusion within
tissue can be estimated by a metric called mean kurtosis, which reflects the
microstructural complexity of the tissue.
Parameters derived from DTI. The primary metrics obtained from the tensor are the
mean diffusivity (𝑀𝐷), and fractional anisotropy (𝐹𝐴). 𝑀𝐷 is defined as the mean of the
three diagonal elements of the diffusion tensor (eigenvalues):
𝑀𝐷 =

𝜆R + 𝜆/ + 𝜆.
3

and 𝐹𝐴 is related to the degree of anisotropy of the tensor:

(𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 2.3)

(𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 2.4)

3
𝑣𝑎𝑟 (𝜆)
𝐹𝐴 = t t /
2 𝜆R + 𝜆// + 𝜆/.

As the aim of this thesis is to study neural tissue microstructure, it is appropriate to
start with one of the most commonly used diffusion metrics, fractional anisotropy (Basser,
1995). 𝐹𝐴 is related to the degree of anisotropy of water diffusion, ranging from zero for
isotropic diffusion to one when diffusion is constrained along one axis only. In the light of
the different tissue composition of grey matter (GM) and white matter (WM), GM is
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characterized by a low FA compared to a higher FA in WM. GM is occupied by cell bodies
and dendritic processes of neurons and glial cells and water diffusion around these
structures is nearly isotropic, resulting in a low diffusion anisotropy. In WM, the highly
oriented structure of the axonal architecture is responsible for the high anisotropy but
other factors can contribute to the anisotropy, including myelin, axonal membrane and
the cytoskeleton comprising neurofilaments and microtubules. It is thus difficult to
interpret changes in FA, as there are a multitude of components that can contribute to the
increase or decrease of the degree of diffusion anisotropy such as variations in myelin
content, axonal density, axonal caliber or a combination of these key parameters.
In addition to the multiple DT-derived scalar metrics to quantify diffusivity and
anisotropy, DT also provides useful information on the dominant fiber direction within WM,
which enables fiber tractography. DTI fiber tractography is based on the idea that in highly
organized tissue, the eigenvector associating with the largest eigenvalue within a voxel,
is also parallel to the local fiber orientation. Following the identification of local fiber
direction, it is possible to reconstruct fiber tract trajectories in the WM. Two main
tractography algorithms have been proposed to follow fiber tracts, deterministic and
probabilistic.
DTI Fiber Tractography. Deterministic streamline tractography (Jones, 2008) uses
the major eigenvector of the DT to provide a voxel-wise map of local fiber direction, while
assuming that there is only one main diffusion direction within each voxel. Deterministic
tracts are reconstructed from an initial position known as the seed voxel and follows the
local fiber orientations identified by the major eigenvector. To obtain a continuous
streamline pathway, the local diffusion orientations are integrated using linear step-wise
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algorithm such as Fiber Assignment by Continuous Tracking (FACT). FACT uses the
same major eigenvector over the entire voxel and the diffusion direction can only change
at the interface between voxels. FACT applies forward integration of the major
eigenvector direction from the seed voxel. The local direction of diffusion is followed
linearly from the seed voxel until the fascicle quits the voxel it belongs to. The streamline
propagation then continues until some termination criteria are met:
•

The reconstructed tract reaching an area outside the brain or leave the tissue
region of interest

•

The reconstructed tract entering a region with low anisotropy (FA<0.2). Areas
of low FA tend to be associated with great uncertainty in the principal diffusion
direction and thus poses a potential error for the next streamline step.

•

The reconstructed tract reaching an area of too much bending of its curvature,
usually more than an angular threshold

While deterministic tractography reconstruct tracts by following the directional
information described by the diffusion tensor, a significant limitation of this method is that
errors in a reconstructed tract are unknown. The uncertainty in a tract orientation can
arise from image noise or partial volume effects within voxels containing different fiber
orientations like crossing and diverging fibers, potentially leading to misleading
information regarding white matter connectivity.
Probabilistic tractography framework overcome these limitations and accounts for the
uncertainty of the estimated local orientations. The degree of orientation uncertainty can
be estimated by creating a probability density function (PDF) of the underlying fiber
orientation. The aim of this step is to characterize the expected distribution of possible
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fiber orientations within a given voxel given the diffusion data. Once fiber orientation PDFs
have been generated for each voxel, the degree of uncertainty can be estimated using
multiple algorithms and an appropriate threshold can be selected, below which
connections ae discarded ad tract is reconstructed. Probabilistic tractography yields maps
that are related to the probability that a certain voxel is connected to the starting point
Limitations of DTI. Although diffusion tensor imaging is widely used clinically and in
research settings, it is not without limitations. Complexities of the tissue configuration and
environment, and CSF contamination can cause inaccuracies in DTI metrics estimation.
DTI assumes a single gaussian displacement model of water diffusion within tissue.
In line with this assumption, DTI approximates an average-diffusion tensor that best fits
the overall signal for each voxel, thus belying the complex tissue fiber configurations.
White matter axons have radii in the range of 0.1–5 μm, whereas voxels sizes are typically
around 1–5 mm. Therefore, voxels can encompass hundreds of thousands of axons,
which can adopt a wide range of complex configurations. With DTI, only one single fiber
orientation can be recovered in each voxel. With this limitation, DTI is incapable of
characterizing complex microstructural configurations within a voxel, particularly in areas
with crossing fiber, kissing or fanning fiber configurations (like Centrum Semiovale).
Another limitation of the DT model is that it does not take into account the presence
of multiple tissue components such as neuronal cell bodies, dendrites, glia and
extracellular space that compartmentalize water distribution and may have different
diffusion properties. Eq 1.8 assumes a free and homogenous medium for diffusion, where
the relationship between signal attenuation and the diffusion weighting factor is linear. In
neuronal tissue, it is widely accepted that Gaussian diffusion mode is not valid due to the
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presence of barriers, particularly for high b-values where the diffusion experiment become
sensitive to restricted intracellular compartments. It has been shown that the diffusion
signal deviates from mono-exponential decay described in Eq 1.8.
DTI measures also lack specificity. FA can be affected simultaneously by a number of
microstructural processes such as changes in myelination, inflammation, axon diameter
and or loss. For example, a decrease in FA can be due to a myriad of structural alterations
from demyelination, increased neurite dispersion, decrease in axon diameter or edema
(Bealieu, 2009). Thus, DTI measures are not able to assess specific measures such as
axonal density, dendritic morphology and myelin content. This lack of specificity hampers
the biological interpretation of pathophysiological phenomena.
Many new approaches have been developed to characterize features of the nonGaussian displacement profile such as diffusion kurtosis imaging (DKI), high angular
resolution diffusion imaging (HARDI), composite hindered and restricted model of
diffusion (CHARMED) and neurite density and dispersion imaging (NODDI).
2.3.2 Neurite Orientation Dispersion and Density Imaging
Multi-compartment diffusion models (MCDM) decode the water signal as the
contribution coming from 𝑁 tissue compartments, each occupying a relative fraction 𝑣. A
multi-compartmental model of WM microstructure was first proposed by Stanisz in 1997.
In this model, water pool is assumed to belong three different compartments. The
intracellular compartment is comprised of axons and glial cells and are represented by
prolate ellipsoids and spheres, respectively. Water diffusion in the intracellular
compartment is highly restricted due to barriers such as cell membranes. The
extracellular compartment is assumed to undergo hindered diffusion, where the presence

50
of axons and glial cells in this space obstruct water motion. Finally, exchange of water
between intra- and extracellular compartments is controlled by the permeability of the cell
membranes and can be described by an exchange ratio that depend on the geometry of
the intracellular compartments.
Since 1997, several MCDM have been proposed and include the ball-and-stick model
(Behrens 2003), the Composite Hindered and Restricted Model of Diffusion (Assaf 2004)
and the Neurite Orientation Dispersion and Density Imaging model (NODDI) (Zhang
2012). The NODDI framework utilizes DWI data sensitive to tissue microstructure,
combined with a biophysical model, relating specific tissue features to the diffusion signal.
NODDI Model. NODDI is three-compartment biophysical tissue model. It assumes
that the diffusion signal in each voxel stems from three compartments, intracellular,
extracellular and isotropic water pools, where all compartments are presumed
impermeable. In the intracellular compartment, water diffusion is restricted inside the
axons and dendrites. The extracellular compartment refers to the space occupied by cell
bodies and glia around the neurites. In this compartment, water diffusion is hindered by
the presence of neurites but not restricted. Finally, the isotropic compartment
is occupied
(𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛
3.1)
by cerebrospinal fluid (CSF) and is designed to capture free water diffusion. The
normalized diffusion weighted signal, 𝐴, is modelled as the signal contribution from the
tissue (𝐴Fkwwxy ) and non-tissue (𝐴kwz ) compartments, weighted by their respective volume
fractions 𝑣, and can be written as:
𝐴 = (1 − 𝑣kwz )𝐴Fkwwxy + 𝑣kwz 𝐴kwz
Where 𝐴Fkwwxy is the normalized signal coming from the intra- and extracellular
compartments and 𝐴kwz represents the signal coming from the free diffusing water (CSF).
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The volume fraction of the free water is denoted by, 𝑣kwz making that of the tissue
compartments, as 1 − 𝑣kwz .
The tissue signal, 𝐴Fkwwxy , is further broken down into the signal originating from inside
the axons and dendrites, 𝐴k{ , and that from the extracellular space, 𝐴y{ ,weighted by their
respective volume fractions:
𝐴Fkwwxy = 𝑣k{ 𝐴k{ + (1 − 𝑣k{ )𝐴y|

(𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 3.2)

Where 𝑣k{ is the intracellular volume fraction, and by construction, 1 − 𝑣k{ , is the
extracellular volume fraction. In this context, the volume fraction of the CSF, intracellular
and extracellular compartments sum up to:
𝑣kwz + 𝑣k{ + 𝑣y|

(𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 3.3)

CSF Compartment. The signal contribution of the free diffusing water (CSF) is
modelled as an isotropic Gaussian distribution with diffusion coefficient 𝑑kwz :
𝐴kwz = 𝐴B 𝑒 -Y}~•€

(𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 3.4)

Where 𝑑kwz = 3.0 × 10-3 mm2/ s/
Intracellular Compartment. This compartment refers to the space bound by the
membrane of the axons and dendrites, collectively known as neurites. The NODDI model
depicts neurites as a set of cylinders of zero radius because during the typical DWI time
scale, the neurite membrane restricts the water diffusion to be along their length. NODDI
also accounts for the neurite orientational dispersion, where neurites can be either
orientationally dispersed as in grey atter or coherent like in WM.
Thus, the intracellular signal, 𝐴k{ , coming from a neurite along an orientation 𝑛• and
parallel to the gradient direction (𝑞) is modelled as:
(𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 3.5)
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…

𝐴k{ = 𝐴B ‚ 𝑓(𝑛•)𝑒 -Y}~ („.{•) 𝑑𝑛•
Where 𝐴k{ depicts signal attenuation due to restricted diffusion within the neurites,
characterized by intrinsic diffusivity 𝑑k = 1.7 × 10-. 𝑚𝑚/ /𝑠. To account for the neurite
orientation dispersion, the signal attenuation is summed over all possible orientations,
given a certain density of neurites along each orientation 𝑛•.
𝑓(𝑛•) is the orientation distribution function (ODF) and gives the probability of finding
a neurite along direction 𝑛•. 𝑓(𝑛•) is modelled as a Watson distribution, the spherical
equivalent of the Gaussian. It is a probability density functions that describes the
probability along an orientation 𝑛•, characterized by a concentration 𝜅 𝜖 (0; ∞) and mean
orientation 𝜇:
1 2
…
𝑓(𝑛; 𝜅, 𝜇) = 𝑀( , , 𝜅)-R 𝑒 Œ(•.{)
2 3

(𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 3.6)

Where 𝑀 is a confluent hypergeometric function of the first kind. 𝜇 is the mean
orientation and currently NODDI estimates only one orientation per voxel. 𝜅 is the
concentration parameter that quantifies the coherence of the orientations about 𝜇. For
high dispersion, 𝜅 tends to zero; and for fully coherent neurites, 𝜅 goes to infinity. NODDI
reparametrizes the concentration parameter 𝜅 into the normalized orientation dispersion
index (ODI):
𝑂𝐷𝐼 =

2
1
arctan ( )
𝜋
κ

(𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 3.7)

Where ODI can ranged from 0 to 1. ODI=0 when neurites are all aligned in a voxel
and therefore have a high diffusion anisotropy. ODI=1 when neurites are randomly
oriented (isotropic diffusion). This is essential to represent the full spectrum of orientation
arrangements existing in brain tissue that include: 1) highly coherent white matter axons
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2) cortical and subcortical gray matter structures characterized by dendritic processes
orientated in all directions.
Extracellular compartment. This compartment refers to space surrounding the
neurites, which is occupied by various types of glia and neuronal cell bodies. In this space,
water diffusion is hindered by the presence of neurites but not restricted. As such, the
space around the neurites is prescribed an anisotropic diffusion model:
𝐴y| = 𝐴B 𝑒 -Y„

–\ „
—˜

(𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 3.8)

Where 𝐴y| , is the normalized extracellular signal. 𝐷y| represents the diffusion tensor
modelling water diffusion in the presence of orientationally dispersed neurites. The
presence of neurites hinders water diffusion in the surrounding space, which might be
greater if the neurite density is larger. This indicates that the extracellular and intracellular
spaces are linked by the ODF, 𝑓(𝑛), as follows:

𝐷y| = ‚ 𝑓(𝑛)𝐷(𝑛)𝑑𝑛

(𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 3.9)

This diffusion tensor 𝐷(𝑛), is characterized by a principal diffusion direction, 𝑛, parallel
diffusivity coefficient, 𝑑∥ , and perpendicular diffusivity 𝑑š to 𝑛. The parallel diffusivity of the
extracellular compartment, 𝑑∥ , is assumed to be the same as the intrinsic diffusivity inside
neurites, 𝑑k , i.e. 𝑑∥ = 𝑑k = 1.7 × 10-. 𝑚𝑚/ /𝑠. The perpendicular diffusivity, 𝑑š , is assumed
to be related to the parallel diffusivity and estimated for a given 𝑣k| as:
𝑑š = 𝑑∥ (1 − 𝑣k| )

(𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 3.10)

This relationship is based on the assumption that water diffusing in the extracellular
space have to navigate between the axonal and dendritic barriers.
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Acquisition protocol. Both low and high b-values are needed to fit the NODDI model
(Figure 3). The high b-value is sampled at a higher angular resolution compared to the
lower b-value. This is done to account for the higher signal changes observed at higher
b-values due to its greater sensitivity to restricted diffusion in complex microstructural
configurations. Clinically feasible acquisition parameters have been proposed for the
estimation of the NODDI parameters (Figure 4). The optimized imaging protocol consist
of two b-values, 𝑏 = 711 𝑠/𝑚𝑚/ with 30 diffusion weighted directions and 𝑏 =
2855 𝑠/𝑚𝑚/ with 60 directions (Zhang, 2012). In addition to the 90 diffusion weighted
images, an additional 9 non-diffusion weighted images are acquired (𝑏 = 0 𝑠/𝑚𝑚/ ).

Diffusion
weighting
(s/mm2)

b0

b711

b2000

b2855

Figure 3. Signal Intensity as a Function of Diffusion Weighting. In diffusion weighted images, the
overall signal intensity decreases with the b-value. At low b-values, the signal in areas with fast
diffusion like ventricles decays rapidly and tissues with slow diffusion remain with a higher signal.
At high b-values, the diffusion signal becomes sensitive to slow diffusion in the restricted
intracellular compartments and signal intensity becomes darker.

Model fitting. A hierarchical fitting strategy is used to compute the NODDI model
parameters. The CSF compartment is separated first from the tissue compartment.
Subsequently, the tissue compartment is separated into an intracellular and extracellular
compartment.
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Table 3. Estimated NODDI Parameters
𝒗𝒊𝒏
Intracellular volume fraction
𝒅∥
Intrinsic free diffusivity
𝜿
Concentration parameter of Watson distribution
Dominant orientation of Watson distribution
𝝁
Isotropic volume fraction
𝒗𝒊𝒔𝒐
𝒅𝒊𝒔𝒐
Isotropic diffusivity
The diffusion coefficients are fixed to typical values 𝑖𝑛 𝑣𝑖𝑣𝑜: 𝑑∥ = 1.7 × 10-. 𝑚𝑚/ /𝑠
and 𝑑kwz = 3 × 10-. 𝑚𝑚/ /𝑠. The remaining parameters are estimated using a using a
Rician noise model with the Gauss-Newton nonlinear optimization technique. This
method maximizes the likelihood of the NODDI parameters given the measured diffusion
signal. The NODDI model fitting algorithm is available as open source toolbox using
MATLAB.
NODDI indices of tissue microstructure. The NODDI model produces three main
metrics representing tissue characteristics, including the intracellular volume fraction,
orientation dispersion index and isotropic volume fraction (Figure 4). The intracellular
volume fraction (ICVF) is a proxy for neurite density, including both axons and dendrite.
It is lower in gray matter regions than in white matter. The orientation dispersion (ODI)
index describes the axonal organization, indexing intra-voxel axonal misalignment.
Isotropic volume fraction (VISO) gives the fraction of free-water.
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Figure 4. NODDI Maps

Intracellular Volume
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Orientation Dispersion
Index

Isotropic Volume
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Histological validation of NODDI. Validation of the estimated NODDI parameters
has been examined by comparison with histological tissue measures of neurite density
and orientation. Histological and MRI analysis of fiber orientation dispersion in squirrel
money brains revealed a significant correlation between MRI-ODI and histology ODI
(r=0.66, p<0.001) in highly aligned WM structures (Schilling, 2018). ODI ranged between
0.02-0.03 in voxels containing coherent single fiber populations, corresponding to a fiber
spread of ~7–9° from. ODI increases to 0.08–0.13 in more typical WM voxels,
corresponding to a fiber spread of ~17–19°. In areas with crossing fibers, ODI is greater
than 0.40, with a histological fiber spread greater than 37°. Histologic validation of ODI
has been also reported in mice. ODI was significantly higher in portions of the anterior
commissure with crossing fibers (0.227 ± 0.169) compared to tightly coherence parts
(0.0178 ± 0.0108) of the AC (p = 0.0247). MRI-ODI measures were in good agreement
with histology in terms of the orientation dispersion of neurites (Sato et al., 2017).
ICVF, the NODDI-derived index of fiber density was also validated with histologic
evidence. MRI ICVF values were compared to measures of axonal density extracted from
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electron microscopy of a mouse brain (Sepehrband et al., 2015). ICVF in the corpus
callosum (CC) was in high agreement with the histology neurite density measure from an
ex vivo mouse brain. Sub-regional CC analysis of ICVF in the genu, body and splenium
showed a high-low-high trend, which is agreement with previously reported fiber densities
of large diameter axons in the human CC (Aboitiz et al., 1992). The CC can be further
parcellated into 10 subregions according to Aboitiz et al. (1992). The profile of ICVF
across the ten segments of the CC in sample of children aged 9–12 years also revealed
a high–low–high profile, with a minimum value in the isthmus and maximum in the
splenium (Genc et al., 2017).
Clinical applications of NODDI. The public availability of the NODDI toolbox and the
feasibility of the acquisition parameters, has facilitated the widespread adoption of NODDI
in clinical settings. In the following, we will list the potential applications of NODDI in
human and aging and Parkinson disease.
Human aging is accompanied by both gross and microscopic brain changes. Previous
postmortem histological studies have demonstrated that healthy aging is accompanied
by progressive regression in the horizontal dendritic arbors of pyramidal neurons, mainly
in the prefrontal cortex, superior temporal lobe and precentral gyrus (Scheibel et al.,
1975). The architecture of dendritic arbors is an important determinant for the neuron’s
computational properties and ability to integrate synaptic input, with profound functional
implications for cortical processing. Changes in processing speed with increasing age
might be related to the decline in dendritic neuropil, with subsequent disappearance of
synaptic connections and restrictions in the computational abilities of the brain (Scheibel
et al., 1975). Several studies have also pointed out that the neuron number is relatively
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preserved in healthy aging, while alterations in the neuronal morphology are highly
evident (Dickstein et al., 2013). Contemporary neuroimaging studies of the cerebral
cortex have also confirmed the presence of cortical thinning, with preferential vulnerability
of the prefrontal cortex (Raz et al., 1997).
Recent NODDI studies have explored how the developing brain and healthy aging can
influence the microstructural metrics of gray and white matter. In a sample of 45 healthy
controls (21–84 years), a widespread decrease in ODI was observed in cerebral gray
matter (Nazeri et al., 2015). These results are not surprising, given the decline in the
dendritic neuropil observed in histological studies with advancing aging. These changes
were localized to the frontoparietal cortical areas. A study by Merluzzi et al., 2016 in a
sample 116 middle to older-aged participants (45–72 years), localized decreases in ICVF
was observed in the frontal WM, Including the ventromedial and dorsomedial prefrontal
cortex. These results agree with the anterior-posterior trend observed in aging or the “last
in, first out”, where fibers that myelinate latest tend to be the first to be affected with aging
(Brickman et al., 2012). Finally, Kodiweera, et al., 2016 also found increased ODI in WM
tracts in a young-middle aged cohort of 47 adults (18–55 years). No age-related changes
in ICVF were observed, potentially reflecting the stable axonal density in this middle-aged
cohort (Kodiweera, et al., 2016).
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Table 4. NODDI Studies Investigating Age-Related White Matter Changes
Study
Number of
Mean Age
ICVF
ODI
participants
(±SD) and
Range in
years
Merluzzi, 2017
116; 62%
Linear
No significant
62±6
female
reduction in
changes in
45–72
frontal WM
ODI
Billiet, 2015
59
Mixed ICVF
• Linear
17–70
results
Increase in
ODI in
frontal WM
Chang, 2015

66; 48%
female

25±14
7–63

Logarithmic
growth in ICVF

Exponential
growth in ODI

Kodiweera,
2016

47; 51%
female

36±11
18–55

No changes

Increased ODI

Lower in fornix
in older adults
Linear increase
in major WM
tracts

No significant
changes
No significant
changes

Radhakrishnan,
38; 58%
2020
female
Genc, 2017
72;50% female

young (20–38)
older (59–84)
10±4
7-19

Limitations of NODDI. Similar to all diffusion models, NODDI has several limitations.
In the NODDI framework, axons and dendrites are modeled as rigid sticks with a Watson
distribution (Zhang, et al, 2012). The Watson distribution is a unimodal distribution and
assumes a single fiber orientation within a voxel. As such, NODDI is incapable of
modelling complex axonal configurations such as those arising from fanning and bending
axons. In the case of two non-dispersed crossing fibers, NODDI models the fibers as one
big dispersed bundle and thus can affect the accuracy of the estimated ODI measure. To
overcome this limitation, the latest NODDI model substituted the Watson distribution with
a Bingham distribution. Bingham distribution is the spherical analogue of a 2-dimentional
gaussian PDF. This allows NODDI to model both anisotropic orientation dispersion, as
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well as isotropic dispersion. More details on the new model can found elsewhere (Tariq
et al., 2016).
Furthermore, the intrinsic diffusivity 𝑑k is fixed to 1.7 × 10-. 𝑚𝑚/ /𝑠 throughout the
brain and is assumed to be equal to the parallel diffusivity in the extracellular compartment
𝑑∥ = 𝑑k = 1.7 × 10-. 𝑚𝑚/ /𝑠. Intrinsic diffusivity might be susceptible to age-related
changes and different between white and gray matter. Fixing the diffusivities of both
compartments might bias NODDI parameter estimation where these diffusivities do not
reflect the actual values. This is important for clinical applications as well, where the
correct diffusivity values must be applied to ensure the correct characterization of tissue
microstructural changes (Guerrero et al., 2017)
Another major caveat to the NODDI model, is that there exists little information on
what ICVF and ODI actually mean in terms of cytoarchitecture and myeloarchitecture.
NODDI is a relatively recent technique and has not been validated yet in human tissue.
An increase in ICVF does not necessarily correspond to an actual increase in the density
of axons and dendrites in a voxel. Moreover, the title of the model and the nomenclature
of the metrics can be quite misleading. For example, the intracellular volume
fraction,𝑣kwz , is coined as “neurite density” and the concentration parameter,𝜅, is labelled
“neurite orientation dispersion”. This overextending of the microstructural interpretation of
its estimated parameters has subjected NODDI to criticism.
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CHAPTER 3 MATERIALS AND METHODS
3.1 Study Design
All aspects of this study, including subject recruitment and consent process, were
approved by the Institutional Review Board at Wayne State University and Detroit Medical
Center. A written informed consent was obtained from all participants (IRB no.:
120117M1F).
From January 2019 to February 2020, twenty Parkinson disease (PD) patients were
recruited from the Movement Disorders clinic at the Detroit Medical Center, MI, USA by
their neurologist (Dr. Edwin George, EG). During the same period of time, ten Healthy
controls without any history of neurological or psychiatric disease and matched for age
and gender were recruited from the Detroit Medical Center using an ad placed in the
waiting rooms.
Both PD and HC subjects were first assessed for cognition. Following cognitive
testing, only the PD group was seen by the neurologist (EG) to evaluate the motor
impairments. Lastly, both PD and HC participants were subject to one hour of MRI to
collect structural, diffusion and functional MRI datasets.
Demographic and clinical characteristics of the two groups are reported in Table 6.
The participants of the two groups of PD and HC, were matched for age (p=0.08), race
(p=0.6) and gender (p=0.4). The PD group was characterized by a median H&Y of 2, a
stage that indicates the presence of bilateral motor symptoms without impairment of
balance. The mean disease duration in PD patients was 7.3±4.5 years and their motor
severity score (UPDRS part-III) was 28.4±9.2.
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Six PD patients reported their motor symptoms to begin on the right side initially, while
12 PD patients had their motor symptoms onset on the left side. The mean±SD Unified
Parkinson’s Disease Rating Scale motor score was significantly higher on the initial side
of symptoms onset 11.06±3.57 compared to the contralateral side 6.69±3.66 in the PD
group (p=0.004). Patients were treated by using levodopa, ropinirole, or pramipexole
alone or in combination. The Levodopa Equivalent Dose Calculator was used to calculate
the contribution made by each prescribed drug to the Levodopa intake level. The average
daily levodopa equivalent dose for the 18 PD patient was 792±512 mg.
Since PD patients overwhelmingly (95%) presented asymmetric onsets of motor
symptoms, we replaced the left and right brain hemisphere labels with contralateral and
ipsilateral labels, according to each patient’s clinically predominated side of Parkinsonian
symptoms onset (i.e. contralateral denotes the brain side opposite to the body side of
symptoms; ipsilateral denotes the same brain side as the body side of symptoms).
3.2 Inclusion and Exclusion Criteria
The inclusion criteria at baseline for PD patients were: fulfilment of the UK PD Society
Brain Bank diagnostic criteria for PD and age 18 years and above; Exclusion criteria for
all subjects were: claustrophobia, medical or other contraindications for undergoing MRI
and inability to give written informed consent (Table 5). We made sure that PD subjects
with hallucinations are not on medication that may facilitate the development of
hallucinations in PD (like neuroleptics and anticholinergics) or on medications that treat
hallucinations (like Seroquel and Quetiapine). The Levodopa equivalent daily dose
(LEDD) was calculated for each patient.
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Two PD patients were excluded for the presence of metal implant that is incompatible
with MRIs and for having a MOCA >27 (was later modified to include patients will any
MOCA score), respectively. MRI data for 2 HCs was not collected.
Table 5. Inclusion/Exclusion Criteria
Inclusion Criteria
Diagnosed with idiopathic PD for at least
2 or more years
Age 18 years and above
Have been on stable doses of antiParkinson medication (for at least 6
months)
Able to give informed consent
Able to undergo brain MRI

Exclusion Criteria
History of any surgical intervention for
treating PD (i.e. deep brain stimulation)
Extreme physical disability
History or current diagnosis of unstable
psychiatric condition
Treatment for visual hallucinations
Other brain disease

3.3 Cognitive and Motor Assessment
The severity of motor symptoms and disease stage for the PD group was evaluated
with the Unified Parkinson’s Disease Rating Scale part III (UPDRS-III) and the Hoehn and
Yahr (HY) staging system, which was obtained in the on-medication state by the
neurologist (EG). Disease duration was self-reported based on subjective estimate of the
time since the beginning of the characteristic motor symptoms.
Overall cognitive status for PD and HC groups was evaluated using the Montreal
Cognitive (MOCA) test which allows assessment of seven cognitive domains, visuospatial
function (max score=5), orientation (max score=6), language (max score=3), memory
(max score=5), attention and calculation (max score=6), semantic memory (max score
3), and abstraction (max score 2). A total MOCA score below 26 is considered indicative
of mild cognitive impairment (max total score=30). The symbol digit modality test (SDMT)oral version was used to assess information processing speed. Raw SDMT scores were
converted to z scores based on published age and gender-based normative data.
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Impaired SDMT performance was defined as z-score < -1.5. The patient health
questionnaire (PHQ) was used to assess presence and severity of depressive symptoms
in both groups. In the PD group, the presence of visual hallucination was evaluated using
the Parkinson's Psychosis Rating Scale (PPRS).
Table 6. Demographic and Clinical Characteristics of PD Subjects and Healthy
Controls
Participant
PD
HC
P-value
N
18
8
Gender(F:M)
4 F:14 M
3 F, 5 M
.4
Race (AA:C)
7 AA:11 C
4 AA, 4C
.6
Age (years)
69±9
63±5.8
.08
MOCA
21±4.9
25±3.6
0.048
SMDT raw
34.6±3.6
46.7±4.4
0.02
Disease duration
7.3±4.5
_
years
UPDRS III
28±9
_
UPDRS III Onset
10.6±4.2
Side
UPDRS III
7.4±3.3
Contralateral Side
H & Y Median
2.0
Onset Side (R:L)
6:12
LEDD (mg)
792±512
Hallucination (N)
6 (MOCA range:
0
10-25)
Legend:
N: Number of Subjects; F: Female; M: Male; AA: African American; C: Caucasian; MOCA =
Montreal Cognitive Assessment test; SDMT: Symbol Digit Modality Test; UPDRS -III = Unified
Parkinson’s Disease Rating Scale part III; H&Y = Hoehn and Yahr stage; LEDD = Levodopa
Equivalent Daily Dose. Difference is statistically significant (*p<0.05) (mean ± SD)

PD patients scored significantly lower on the MOCA compared to the HC (p=0.048).
The mean±SD MOCA score of the PD group was 21±4.9 versus 25±3.6 in the HC.
Similarly, the SDMT raw score was significantly lower (p=0.02) in the PD group (34.6±3.6)
compared to the HC (46.7±4.4).
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3.4 Magnetic Resonance Imaging Acquisition and Preprocessing
MRI data was acquired on a 3-Tesla Siemens MAGNETOM VerioTM MRI system
located at the Detroit Receiving Hospital - University Health Center, using a 32-channel
head volume coil. For all subjects, we acquired anatomical T1-weighted, T2-weighted, T2weighted fluid-attenuated inversion recovery (FLAIR), diffusion MRI, resting and
functional MRI.
High-resolution, three-dimensional structural T1-weighted images were acquired in
the axial plane with a magnetization prepared rapid gradient-echo (MPRAGE) sequence
(repetition time (TR)/echo time (TE) 2,150/2.53 ms; inversion time (TI) 1100 ms; flip angle
(FA)=8o; 256 x 256 matrix size, 1 mm isotropic voxel; number of slices = 160; GRAPPA
factor = 2, and acquisition time (TA) = 4:59 minutes.
The multi-shell diffusion weighted data was acquired using a pulsed-gradient spinecho (PGSE) diffusion-weighted imaging (DWI) sequence with axial echo-planar imaging
(EPI) readout. Three different b-values were used, b-values = 0 (9 volumes), 711 s/mm2
(30 directions), 2000 s/mm2 (60 directions) and 2855 s/mm2 (60 directions). The different
b-values were achieved by creating a table file of 160 vectors in the x, y, and z directions.
We multiplied each vector by alpha which is obtained using the following equation:
𝛼=

𝑏ª«¬xy
𝑏-«d

Where bvalue is for example 711 s/mm2 and bmax is 2855 s/mm2. Data were acquired in
an anterior-posterior (AP) phase-encoding direction.
The 9 b=0 s/mm2 volumes were interleaved throughout the acquisition. The EPI
readout uses a matrix size of 128x128 over a field of view (FOV) of 256x256mm 2 and
slice thickness of 2mm, resulting in isotropic voxels of 2x2x2mm3. TE=99 ms, TR=4.0 s
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and bandwidth= 1860 Hz/Px. A total of 66 slices are acquired to cover the whole brain.
The total scanning time for the NODDI protocol was 11 min.
One additional non-diffusion weighted volume (b=0) was acquired in the PA-encoding
direction at the end of the diffusion sequence for subsequent use in TOPUP and EDDY
(66 slices, 2mm slice thickness, TE = 99 ms, TR = 4.0 s, bandwidth= 1860 Hz/Px).
Diffusion weighted images were preprocessed using fMRI Software Library (FSL, v.6.0.1,
Oxford, UK) and MRtrix3 (Tournier, 2019) as follows:
1. Diffusion weighted images were first denoised from the physiological noise arising
from the thermal motion of water molecules in the brain using Mrtrix3 function
dwidenoise (Veraart et al., 2016)
2. Gibbs ringing artifacts were removed using Mrtrix3 function dwidegibbs (Kellner et
al., 2016)
3. With a pair of reverse phase–encoded b0 images (AP and PA), the susceptibility
off-resonance field was estimated using fsl function TOPUP
4. Diffusion weighted images were finally corrected for motion artefacts, eddy current
distortions and Susceptibility-induced distortions using fsl function EDDY
The preprocessed diffusion weighted data were used to compute diffusion metrics of
DTI and NODDI. The DTI metrics FA and MD, were calculated using dtifit diffusion tensor
modeling tool in FSL 6.0.1. This linear DTI model was applied to the first shell b=711
s/mm2 diffusion weighted images.
The diffusion data of the 3 shells (711, 2000 and 2855 s/mm2) were fitted to the NODDI
model using the NODDI MATLAB toolbox (available from the UCL Microstructure Imaging
Group). The default parameters (parallel diffusivity dll=1.7 × 10−3 mm2/s, intrinsic
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diffusivity diso=3 × 10−3 mm2/s) were used. The model generates maps of ODI, ICVF, and
VISO in diffusion space.
Surface-based cortical thickness analyses were performed using the FreeSurfer
software, version 6.0. The implemented processing pipeline included the following:
motion correction, removal of non-brain tissue, transformation to the Talairach reference
space, segmentation of the subcortical WM and deep GM volumetric structures, intensity
normalization, tessellation of the GM-WM boundary, automated topology correction, and
surface deformation following intensity gradients to optimally place the gray/white and
gray/cerebrospinal fluid borders at the location where the greatest shift in intensity defines
the transition to the other tissue class. Cortical thickness was calculated as the shortest
distance between the GM/WM boundary and the corresponding pial surface at each
vertex across the cortical mantle. The maps were smoothed using a surface-based
Gaussian kernel of 10-mm FWHM and averaged across the subjects. In addition,
estimated total intracranial volume (eTIV), total GM volume, and total WM volume were
calculated from the Freesurfer processing stream. These volumes were extracted from
the aseg.stats file, which is an output of the recon-all workflow in Freesurfer.
The preprocessing pipeline is summarized below in Figure 5. Further details on each
imaging modality in terms of analysis will be discussed separately in each chapter.
3.5 Statistical analysis
All statistical analyses were performed with R Studio software version 3.3.3 (2017-0306). The normality assumption was checked by computing Shapiro-Wilk test for each
studied measure. Gender distribution between groups (HC and PD) was compared with
the Fisher exact test.
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Descriptive variables were compared between groups using the Fisher exact test for
categorical data (gender and race). An independent t-test was performed for normally
distributed data (age) to compare group differences. Linear regression was used to look
for differences in clinical scores between patient and control groups, correcting for age
and gender with the SDMT and MOCA scores used as the dependent variable. Statistical
significance was set at 0.05.
We used correlation analysis to investigate associations between diffusion metrics in
the nigrostriatal pathways and duration of illness and UPDRS motor score. We used
Spearman’s R to examine the correlations, because not all measurements were normally
distributed (as shown by Shapiro-Wilk tests).
Figure 5. Summary of Imaging Processing Pipeline
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CHAPTER 4 CORTICAL MICROSTRUCTURAL ABNORMALITIES ASSOCIATED
WITH PD
4.1 Summary
The prevalence of neurodegenerative disorders is increasing in combination with an
increasing elderly population. The fastest growing neurological disorder is Parkinson
disease (PD), whose growth is surpassing that of Alzheimer disease (Pringsheim et al.,
2014). Non-invasive biomarkers that enable the staging and early diagnosis of PD are
highly needed to monitor disease progression and evaluate efficacy of future therapies.
On this basis, changes in microstructure are often the precursors of gross volumetric
changes. Thus, microstructural imaging biomarkers can be more sensitive and detect the
earliest stages of tissue involvement compared to conventional volumetric assessment.
For this purpose, we used two diffusion MRI models, DTI and NODDI, in combination with
cortical thickness assessment using T1-weighted volume to study the structural changes
in the cerebral cortex of a PD cohort (n=18) compared to healthy controls (n=8).
We demonstrate that PD pathology is associated with significant abnormalities in
tissue diffusion metrics in the PD group, in the absence of cortical thinning. Specifically,
we found that the cingulate cortex and temporal lobe are consistently involved in PD
through reductions in ICVF, FA and increased ODI. These observed changes in diffusion
metrics were clinically relevant in the PD group, where cognition correlated negatively
with FA and ICVF and positively with ODI. These findings of altered diffusion metrics
might explain the presence of cognitive dysfunctions in the absence of evident structural
changes. In summary, tissue microstructural changes as reflected by diffusion MRI
indices might detect the earliest pathological changes associated with the presence of
cortical Lewy pathology.
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4.2 Introduction
Parkinson’s disease (PD) pathology goes beyond nigrostriatal degeneration and
extends to affect the cerebral cortex. In addition to dopaminergic neuronal cell loss in the
substantia nigra (SN), another neuropathological hallmark of PD is the widespread
aggregation of α-synuclein (α-syn) protein in the form of Lewy bodies (LB) and Lewy
neurites (LN). A variety of evidence suggests that α-syn pathology initiates in the
gastrointestinal and/or olfactory bulb and spreads into the lower brainstem, and from there
ascends into the limbic system and ultimately to the neocortex (Braak et al., 2003).
Braak’s hypothesis proposes a topographic spread of Lewy pathology that can be
classified into six neuropathological stages based on α-syn deposition.
In stage 1, Lewy pathology is found in the dorsal nucleus of the vagus nerve and the
olfactory bulb. During stage 2, α-syn aggregates are found in the medulla oblongata and
pontine tegmentum. Consistently, Lewy pathology fits remarkably with premotor
symptoms of PD including anosmia, REM sleep disorders and gastrointestinal problems
like constipation. At stage 3, Lewy pathology is found in the SN and the amygdala, which
correlates with the onset of the cardinal motor symptoms. During stage 4, Lewy pathology
progresses to the temporal, limbic and paralimbic cortices. With disease progression,
Lewy pathology extends to the prefrontal cortex, insula, and anterior cingulate areas
(Braak stage 5) which is paralleled by the emergence of cognitive decline. Finally, PD
pathology reaches the primary sensory and motor areas in stage 6.
Evidence supporting the hypothesis of Lewy pathology spread in PD stems from both
human postmortem studies and in-vivo PD models. The findings of LB in grafted nigral
neurons into the striatum of PD patients, 14 years after transplantation, has led to the
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notion that Lewy pathology can propagate from host to graft cells (Kordower et al., 2008).
In a seminal work by Luk et al. (2012), results demonstrated cell-cell transmission of
pathologic α-syn in non-transgenic mice following a single intrastriatal inoculation of
synthetic α-syn fibrils. Lewy pathology aggregation also caused loss of dopaminergic
neurons and reduced dopamine resulting in motor deficits. Nonetheless, in-vivo human
support for the hypothesis of Lewy pathology spread is still lacking, because currently
there is no technique for the detection of α-syn aggregates in living human PD patients.
To circumvent this issue, many studies have utilized various MRI methods to study
neurodegeneration in PD as a proxy for Lewy pathology.
To better understand structural changes associated with PD in the cerebral cortex,
several studies have used morphological MRI methods such as, voxel-based
morphometry (VBM) and surface based cortical thickness analysis. VBM analysis in PD
patients with significant cognitive impairments compared to healthy controls, have shown
prominent cortical atrophy in the inferior and superior parietal lobules, cuneus, posterior
cingulate, and parahippocampal gyrus (Uribe et al., 2016). Longitudinal studies also
support a role for cortical thinning as a precursor for cognitive decline and transitioning
into dementia (Gasca-Salas et al., 2019). PD patients with mild cognitive impairment
(MCI) that transition into dementia after 31-months from follow up, are characterized by
a widespread pattern of cortical thinning, particularly in the frontal and insular cortices
and middle temporal areas. Nevertheless, there exists a subgroup of PD patients with
mild cognitive impairment and no detectable cortical atrophy (Uribe et al., 2016).
Volumetric MRI measures are limited by their sensitivity to severe tissue damage, as
opposed to earlier microstructural changes such as fiber loss, reduced dendritic
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complexity and demyelination (Scheltens et al., 1995). Neuronal death is relatively a late
event in the pathogenic process of PD (Kurowska et al., 2016). The accumulation of
pathogenic α-syn occur in axonal and synaptic compartments occur precede neuronal
loss (Hattori et al., 2013). In this regard, microstructural alterations that may occur prior
to detectable volume loss might be better suited to detect the earliest cortical involvement
in PD.
With increasing age and under non-pathological conditions, human postmortem
studies have shown that the dendritic tree of pyramidal neurons undergo significant
regression in their dendritic arbors, length and spine density (Scheibel et al., 1975 and
Jacobs et al., 2001). Scheibel et al. (1975) have demonstrated that aging is associated
with progressive loss in the horizontal dendritic arbors of pyramidal neurons in high-order
cortical regions, namely prefrontal, superior temporal, and precentral cortices. The extent
of the neuronal dendritic arborization crucially affects the synaptic properties and
integration of input, and hence the computation powers of the neuron (Branco and
Häusser, 2010). The resultant shrinkage of the dendritic arborization with increasing age
and the progressive restriction in computational powers can thus be related to the
cognitive decline in processing speed that develop during increasing age (Scheibel et al.,
1975). In pathological conditions such as Alzheimer’s disease, the shrinkage in the
dendritic tree of the hippocampal CA1 pyramidal cells is profound, with selective loss of
basal dendrites, reductions in size of neuronal cell bodies and loss of spines (Yamada et
al., 1988). Considering that dendritic morphology and complexity can undergo significant
changes with profound functional implications for cortical processing and cognition, it is
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important to characterize possible microstructural changes in the cortical neuropil
associated with PD pathology.
Diffusion MRI is one possible technique to assess tissue microstructure in PD. One
meta-analysis of 39 DTI studies in PD showed a decrease in fractional anisotropy (FA)
and increase in mean diffusivity (MD) in the corpus callosum, the cingulate and the
temporal cortices (Atkinson-Clement et al., 2017). More specifically, DTI abnormalities in
the cingulate and temporal cortices also correlated with cognitive decline and
discriminated PD patients from HC (Kamagata et al., 2012). The microstructural
abnormalities in the cingulate and temporal cortices may be related to the presence of
Lewy pathology. In fact, the anterior cingulate is known to be one of the early and most
affected brain regions with Lewy pathology and, associates with cognitive decline
(Arsland et al., 2005). In Braak stages, the deposition of LB in the cingulate cortex is
classified as Stage 4, which is a relatively early stage for the neocortex. This raises the
question of what actually drives the decrease in FA in cortical gray matter areas.
In this regard, neurite density and dispersion imaging (NODDI), is a diffusion MRI
technique that probes the microstructure of neurites in terms of density and complexity.
While DTI provides structural metrics averaged within an imaging voxel, NODDI diffusion
metrics from distinguishable water compartments. The NODDI model provides three
metrics, the fraction of free water (isotropic volume fraction), intracellular water fraction
(ICVF) as a proxy for axonal density and orientation dispersion index (ODI) that describes
the axonal organization. It would be valuable to investigate the cortical microstructure in
PD using NODDI metrics to probe for microstructural deficits related to dendritic
arborization.
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4.3 Aims
In this study, we aim to show that (i) NODDI markers of tissue microstructure, namely
ICVF and ODI, are significantly lower in the PD group, in cortical areas known to be
involved with PD pathology, (ii) ODI and ICVF will be clinically relevant and will correlate
with cognitive decline, and (iii) NODDI metrics will detect microstructural alterations in
more cortical regions compared to the DTI metric, FA.
4.4 Methods
Cortical thickness estimation. Cortical thickness (measured in millimeters)
estimates were obtained using Freesurfer by calculating the shortest distance between
grey matter/white matter and pial surface at each vertex across the cortical mantle (Fischl
and Dale, 2000). In addition, FreeSurfer parcellates the cortex into 34 ROIs per
hemisphere, according to the Desikan-Killiany atlas. For each ROI, FreeSurfer outputs
the average cortical thickness (mm), surface areas (mm2) and gray matter volume (mm3).
Region of Interest Analysis of Diffusion Metrics in the Cerebral Cortex. Mean
cortical thickness, FA, ICVF and ODI values were extracted for a number of a priori
cortical ROIs from both hemispheres. The FreeSurfer Desikan-Killiany atlas was used to
parcellate the cortex and cortical labels were created using the mri_annotation2label
function in Freesurfer. The steps involved in the surface-based cortical ROI analysis of
diffusion metrics are summarized below (Figure 6):
a) Automated surface-based reconstruction of T1-weighted images using reconall in FreeSurfer
b) Registration of diffusion maps to structural T1-brain extracted image using flirt
and the boundary-based registration cost function
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c) Create surface images from the diffusion maps using mri_vol2surf and assign
for each surface vertex the diffusion values from the volume maps using the
projfrac-avg
d) Extract mean FA, ICVF and ODI values for each ROI.
Figure 6. Processing Pipeline for Extracting Diffusion Metrics from Cortical
ROIs
a) Reconstruction of T1 image

b) NODDI maps registered to T1

c) Mean ODI/ICVF extracted
for each ROI

Pial Surface
WM/GM
Surface

T1 image

ODI

ICVF

Three ROIs were chosen on the basis of being early sites of neuropathological change
in the cerebral cortex in PD. These included cingulate cortex, entorhinal cortex and
parahippocampus (Stage 4). For later stages, the insula, inferior temporal and prefrontal
cortical regions were chosen, all of which have been implicated with Lewy pathology
during stage 5. Thus, cortical regions of interest hypothesized to show significant diffusion
abnormalities were chosen according to Braak’s staging and are summarized in Figure
7.
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Figure 7. Summary of Cortical Regions Identified in Braak Stages 4 and 5

Rostral anterior cingulate
Caudal anterior cingulate
Entorhinal cortex
Parahippocampus

Rostral middle frontal
Insula
Inferior temporal lobe
Fusiform

Voxel-Based Analysis of Diffusion Metrics in the Whole Brain. The diffusion maps
(ICVF, ODI and FA) were co-registered to the MNI152 T1 template (1mm) brain template.
This was done through the following steps:
1. The structural T1 image of each subjected was flirted and then fnirted to
MNI152 T1 template
2. Brain-extracted b0 was flirted to the structural T1 images
3. The combination of these two transformations were applied to each diffusion
map to become in the MNI 152 1mm standard space
After transformation, a 3-diemnsional Gaussian smoothing with full width at half
maximum of 6 mm was performed for each diffusion map in SPM12. Voxel-wise
comparisons of whole brain ICVF, ODI and FA maps between HC and PD groups were
performed using two-sample t-tests in SPM12, while controlling for the effects of age. The
statistical parametric maps (p values) are presented superimposed on a T1 image from
a single subject to permit informative anatomical reference. The results were accepted as
significant where p<0.001, uncorrected for multiple-comparisons. Correlations between
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whole brain ICVF, ODI and FA values and neuropsychological measures, were performed
using one-sample t-test in SPM12.
Statistical Analysis. Mean ICVF, FA and ODI extracted from each ROI were
compared between groups using an analysis of covariance (ANCOVA), accounting for
effects of age. p-value <0.05 was considered to be significant. No corrections for multiple
comparisons were applied.
4.5 Results
4.5.1 Sample Characteristics
Table 6 presents demographic and clinical characteristics of the PD and HC groups.
Healthy controls (n = 8) and PD patients (n = 18) were closely matched in age (69 ± 9 vs.
63 ± 5.8, p = 0.08) gender (p = 0.4) and race (p=0.6). The performance on tests of overall
cognition and processing speed significantly differed between groups. PD patients scored
significantly lower (p=0.048) on the MOCA overall cognitive test (21±4.9) compared to
the HC (25±3.6). Similarly, PD patients had a significantly (p=0.02) lower score on the
SDM, processing speed test (34.6±3.6) compared to the HC (46.7±4.4).
The mean disease duration was 7.3±4.5 years, with an interquartile range of 6.75
years (Q1=3.75 and Q3=10.5 years). Disease severity ranged from mild to moderate
(median H&Y = 2), where H&Y=2 implies bilateral disease symptoms without impairments
of balance (Figure 3A). The total score of the UPDRS-part III ranges from 0 to 108. The
PD group had a mean 28±9 total score on the UPDRS-III (Figure 3B). The daily L-dopa
equivalent dose (LEDD) was calculated to be 780.5±119.7 mg.
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Table 6. Demographic and Clinical Characteristics of PD Subjects and
Healthy Controls
Participant
PD
HC
P-value
N
18
8
Gender (F:M)
4 F:14 M
3 F, 5 M
0.4
Race (AA:C)
7 AA:11 C
4 AA, 4C
0.6
Age (years)
69±9
63±5.8
0.08
Disease
7.3±4.5
duration
(years)
Onset Side
6:12
(R:L)
UPDRS III
28±9
total
UPDRS SubScore
0.004
Ipsilateral side
10.6±4.2
Contralateral
7.4±3.3
side
H & Y Median
2.0
LEDDTOTAL
780.5±119.7
(mg)
MOCA [range]
21±4.9
25±3.6
0.048
SDMT raw
34.6±3.6
46.7±4.4
0.02
score
Hallucination
6
0
(N)
Legend:
N: Number of Subjects; F: Female; M: Male; AA: African American; C: Caucasian; MOCA =
Montreal Cognitive Assessment test; SDMT: Symbol Digit Modality Test; UPDRS -III = Unified
Parkinson’s Disease Rating Scale part III; H&Y = Hoehn and Yahr stage; LEDD = Levodopa
Equivalent Daily Dose. Difference is statistically significant (*p<0.05) (mean ± SD)
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Figure 8. Histograms of Disease Duration and UPDRS-III score in PD group
A

B

Motor Asymmetry. The initial symptoms of PD had emerged on the right side of the
body in 6 patients and on the right side in 12 patients. The UPDRS-III was divided into
two sub-scores, one on the side of symptoms onset (ipsilateral) and the second on the
contralateral side. Motor asymmetry scores were significantly different between both
sides, where a higher score was found on the side of symptom onset (p = 0.004).
Clinical and Cognitive Status. PD patients had mild to moderate disease severity
and a mean disease duration of approximately seven years. This cohort of PD patients
was, overall, still in an early disease stage, with mild cognitive impairment (Figure 9A).
Language and delayed recall subsets contributed the most to poor scores on the MoCA
in the PD group (Figure 9B), where patients scored only 53% and 33% of the maximum
score on these domains, respectively.
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Figure 9. Summary of Performance on MoCA and SDMT in PD group
A

B

4.5.2 Cortical Microstructural Changes Corresponding to Braak Stage 4
Mean values ± SEM of cortical thickness (mm), ICVF, ODI and FA for each cortical
ROI involved in Braak stage 4 are summarized by participant group in Table 7. Statistical
comparisons accounting for age are displayed next to the results of Unadjusted
comparisons.
Cortical thickness did not differ between PD and HC groups for any of the studied
ROIs. There were significant FA reductions in the entorhinal cortex (p=0.035),
parahippocampus (p=0.041) in the PD group compared to the HC. Changes in FA were
not accompanied by significant differences in ICVF or ODI in both regions of interest. For
the cingulate cortex, ICVF was significantly lower in the PD compared to healthy controls.
In the caudal anterior cingulate, ICVF was significantly lower in the PD group (p=0.033)
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and with a trend toward lower ICVF in the posterior cingulate ROI (p = .055). Finally, there
was no evidence for a difference in ODI between groups, despite evidence of reduced
ICVF in the cingulate cortex and lower FA in the paralimbic regions (Entorhinal cortex and
parahippocampus).
Table 7. Comparison of Diffusion Metrics in PD and HC Groups in Cortical
Areas Identified in Braak Stage 4
Region of
Structural
HC
PD
p-val
p-val
interest
metric
Mean±SEM Mean±SEM (Unadj.) (Adj.
age)
Entorhinal
Cortical
3.17±0.13
3.15±0.07
0.879
0.408
thickness
(mm)
ICVF
0.50±0.015 0.51±0.015
0.809
0.362
ODI
0.51±0.016 0.53±0.009
0.377
0.390
FA
0.19±0.008 0.17±0.003
0.081
0.035
Parahippocampus Cortical
2.45±0.1
2.58±0.07
0.331
0.137
thickness
(mm)
ICVF
0.51±0.13 0.51±0.008
0.938
0.357
ODI
0.50±0.024 0.52±0.008
0.453
0.225
FA
0.20±0.014 0.18±0.004
0.161
0.041
Rostral Anterior
Cortical
2.68±0.07
2.67±0.08
0.948
0.504
Cingulate
thickness
(mm)
ICVF
0.45±0.01 0.43±0.006
0.155
0.078
ODI
0.48±0.008 0.49±0.007
0.248
0.546
FA
0.21±0.008 0.18±0.006
0.037
0.141
Caudal Anterior
Cortical
2.53±0.07
2.44±0.06
0.371
0.766
Cingulate
thickness
(mm)
ICVF
0.47±0.008 0.44±0.006
0.033
0.102
ODI
0.45±0.007 0.45±0.01
0.695
0.907
FA
0.24±0.01 0.22±0.007
0.198
0.406
Posterior
Cortical
2.3±0.036
2.2±0.058
0.343
0.948
Cingulate
thickness
(mm)
ICVF
0.46±0.008 0.44±0.006
0.055
0.144
ODI
0.49±0.01 0.47±0.007
0.30
0.582
FA
0.22±0.01 0.21±0.006
0.447
0.408
p-val (Unadj.): p-value unadjusted; Student’s-t test
p-val (Adj. age): p-value adjusted for age; ANCOVA
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4.5.3 Cortical Microstructural Changes Corresponding to Braak Stage 5
Table 8 displays the mean cortical thickness, ICVF, ODI and FA values adjusted for
age in each ROI between healthy controls and PD participants. Following adjustment for
age, ICVF was still significantly lower in the PD patients compared to controls in the
inferior temporal lobe (p=0.0098). However, cortical thickness and ODI did not differ
between groups in the inferior temporal lobe. The insula was characterized by reduced
FA in the PD group compared to the HC (p=0.047). The rostral and caudal middle frontal
regions did not show any between-group significant differences in ICVF, FA or ODI.
Table 8. Diffusion Metrics in PD and HC Groups in Cortical Areas Identified
in Braak Stage 5
Region of
Structural
HC
PD
p-val
p-val
interest
metric
(Unadj.) (Adj.
age)
Inferior
Cortical
2.64±0.06
2.6±0.04
0.546
0.862
Temporal
thickness
Lobe
(mm)
ICVF
0.44±0.005 0.42±0.005 0.0081
0.01
ODI
0.51±0.02 0.51±0.009
0.949
0.656
FA
0.19±0.02 0.16±0.003
0.213
0.056
Insula
Cortical
2.46±0.05 2.38±0.06
0.809
0.497
thickness
(mm)
ICVF
0.46±0.02 0.45±0.007
0.763
0.189
ODI
0.47±0.02 0.49±0.005
0.465
0.251
FA
0.21±0.02 0.18±0.004
0.182
0.047
Rostral Middle Cortical
2.35±0.06 2.28±0.04
0.825
0.404
Frontal
thickness
(mm)
ICVF
0.42±0.004 0.41±0.009
0.208
0.568
ODI
0.52±0.01 0.51±0.008
0.642
0.981
FA
0.17±0.01 0.15±0.005
0.176
0.14
Caudal Middle Cortical
2.46±0.05 2.36±0.04
0.192
0.346
Frontal
thickness
(mm)
ICVF
0.44±0.004 0.42±0.009
0.249
0.403
ODI
0.51±0.009 0.51±0.007
0.688
0.986
FA
0.17±0.004 0.16±0.006
0.158
0.308
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p-val (Unadj.): p-value unadjusted, Student’s-t test
p-val (Adj. age): p-value adjusted for age; ANCOVA
Regional Diffusion Analysis of Cortical Areas Reported to Undergo Atrophy in
PD. Comparisons between PD patients and healthy controls of mean ICVF, ODI and FA
adjusted for age, for each region of interest are displayed in Table 9. In the PD group,
ICVF was significantly lower in the superior parietal lobe (p=0.033) and fusiform
(p=0.049). The reduction in ICVF was accompanied by reduced FA only in the fusiform
(p=0.024). ODI in the studied ROIs was not significantly different between groups,
although a trend toward a lower ODI was reported in the superior parietal lobe in the PD
groups (p=0.057).

Table 9. Diffusion Metrics in PD and HC Groups in Cortical Areas
Susceptible to Atrophy
Region of
Structural
HC
PD
p-val
p-val
interest
metric
(Unadj.) (Adj.
age)
Superior
Cortical
2.16±0.05 2.11±0.03
0.362
0.615
Parietal Lobe
thickness(mm)
ICVF
0.43±0.007 0.42±0.006
0.14
0.033
ODI
0.5±0.008 0.48±0.007
0.057
0.262
FA
0.17±0.004 0.17±0.006
0.640
0.574
Inferior
Cortical
2.38±0.04 2.22±0.04
0.029
0.1
Parietal Lobe
thickness
(mm)
ICVF
0.42±0.006 0.40±0.007
0.056
0.085
ODI
0.51±0.01 0.50±0.008
0.222
0.634
FA
0.17±0.007 0.15±0.005
0.159
0.099
Fusiform
Cortical
2.6±0.07
2.48±0.07
0.241
0.743
thickness
(mm)
ICVF
0.46±0.01 0.45±0.007
0.181
0.049
ODI
0.52±0.02 0.54±0.007
0.362
0.214
FA
0.18±0.02 0.16±0.003
0.143
0.024
p-val (Unadj.): p-value unadjusted, Student’s-t test
p-val (Adj. age): p-value adjusted for age; ANCOVA
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4.5.4 Correlation between cortical microstructural alterations in PD and
clinical symptoms
Association of mean ICVF and ODI for each ROI with MoCA and SDMT scores was
analyzed separately for the PD group (Table 10). In the PD group, no associations were
observed between performance on MoCA and SDMT task with ICVF and ODI of the
cortical regions.
Table 10. Association Between Regional Diffusion Metrics and
Cognition in the PD group (n=18)
Region of
Structural
Association
Association
interest
metric
with MoCA
with SDMT
rho (p-val)
(rho, p-val)
Entorhinal Cortex ICVF
(-0.314) 0.203
(-0.424) 0.079
ODI
-0.476 (0.962)
(-0.053) 0.835
FA
0.107(0.696)
0.03 (0.917)
Parahippocampus ICVF
(-0.377) 0.123
(-0.359) 0.144
ODI
(0.017) 0.947
0.412 (0.207)
FA
0.07 (0.802)
-0.207 (0.442)
Superior Parietal
ICVF
0.04 (0.875)
-0.26 (0.297)
Lobe
ODI
0.05 (0.838)
0.19 (0.444)
FA
0.268 (0.316)
0.122 (0.653)
Insula
ICVF
-0.46 (0.055)
-0.46 (0.053)
ODI
-0.2 (0.427)
-0.05 (0.834)
FA
0.426(0.100)
0.181(0.503)
Fusiform
ICVF
-0.23 (0.362)
-0.14 (0.575)
ODI
0.27 (0.275)
0.25 (0.315)
FA
0.26 (0.331)
-0.044 (0.871)
Caudal Anterior
ICVF
0.025 (0.921)
0.24 (0.329)
Cingulate
ODI
0.21 (0.408)
-0.05 (0.831)
FA
-0.069 (0.802)
0.156 (0.565)
Inferior Temporal ICVF
0.07 (0.774)
0.09 (0.718)
Lobe
ODI
0.2 (0.435)
0.21 (0.402)
FA
0.269 (0.314)
0.036 (0.893)
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The correlation analysis was repeated separately for the HC group and no significant
associations were found between the scores on cognitive tests and diffusion metrics in
the studied ROIs (Table 1, Appendix).
4.5.5 Whole Brain Diffusion Analysis of NODDI Metrics Between Groups
Whole brain analysis of the diffusion maps was conducted using GLM model while
accounting for age (Figure 10 and Table 11). After controlling for age, significantly lower
ICVF was detected in two clusters with peak voxels in the right (X=6, Y=26, Z=18) and
left anterior cingulate cortex (X=-32, Y=36, Z=28) (p-uncorrected, k>50). Within the left
anterior cingulate, ODI was significantly higher in the PD group compared to the HC
(p<0.001).
Whole brain FA analysis, also revealed significant changes. The right anterior
cingulate (X=2, Y=32, Z=12) displayed lower FA values in the PD group compared to the
HC (p<0.001). Additional areas with reduced FA, involved the right middle temporal gyrus
(X=66, Y=-34, Z=-2) and the right cerebellum exterior (X=28, Y=-60, Z=-26).
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A. FA

PD<HC

t-value

B. ICVF

C. ODI

PD>HC

p<0.001 uncorrected
Figure 10. Voxel-based analysis showing areas of significant difference between the PD and
control groups the NODDI and DTI parameters superimposed on a T1-weighted template (A)
Fractional anisotropy (FA), (B) intracellular volume fraction (ICVF), and (C) orientation dispersion
index (ODI). The results are shown using a statistical significance of uncorrected p<0.001 and
threshold of 50 voxels. The color bar indicates the t value of the between-group analysis.
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Table 11. Regions of Significant Differences in Diffusion Imaging Parameters
Between PD and Controls group
Anatomical
MNI
t-value
Cluster size
Puncorrected
region
coordinates (x,
y, z)
FA (PD<HC)
Right anterior
2, 32, 12
4.59
196
<0.001
cingulate
Right middle
66, -34, -2
4.10
307
<0.001
temporal gyrus
Right
28, -60, -26
4.83
51
<0.001
cerebellum
exterior
ICVF (PD<HC)
Right anterior
6,26,18
4.74
295
<0.001
cingulate
Left anterior
-32, 36, 28
4.4
295
<0.001
cingulate
ODI (PD>HC)
Left anterior
0, 28, 16
3.95
60
<0.001
cingulate
We studied associations between the diffusion metrics (ICVF, ODI and FA) in the
whole brain and the cognitive scores on the MoCA and SDMT assessments within the
PD group (Figure 11). FA measured in the left precuneus, right and left cerebral white
matter, was negatively correlated with MoCA scores in the PD group (Figure 11A). No
significant correlations were found between FA and SDMT scores.
Using whole brain analysis of NODDI parameters, both ICVF and ODI showed
significant correlation with performance on the SDMT. ICVF in the left middle temporal
lobe correlated negatively with SDMT score, such that poorer performance was
associated with lower ICVF values (Figure 11B). The correlation between ODI and
cognitive performance varied in the white and gray matter areas. In the right and left
cerebral white matter, ODI correlated negatively with both MoCA (Figure 11E) and SDMT
scores (Figure 11F), whereas ODI in the right superior parietal lobe correlated positively
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with performance on the cognitive tests (Figure 11C, D). Further areas where ODI
correlated positively with SDMT scores were detected within the left lingual and
supramarginal regions (Figure 11C) and with MoCA score in left posterior cingulate cortex
(Figure 11D).
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Figure 11. Correlations between diffusion metrics (ICVF, ODI and FA) and cognitive performance
in the Parkinson disease group. The results are shown using a statistical significance of
uncorrected p<0.001 and threshold of 50 voxels. The color bar indicates the t value of the
significant differences.
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4.6 Discussion
We used two diffusion MRI models, NODDI and DTI, and surface-based cortical
thickness analysis to examine the microstructural abnormalities in the cerebral cortex of
PD patients compared to healthy participants. We analyzed our data using two main
approaches, either ROI analysis based on a priori cortical region known to be involved in
PD or voxel-based analysis of the whole brain. For the ROI-based analysis, we selected
cortical ROIS’s that are expected to show Lewy Pathology in Braak’s stages 4 and 5 and
compared diffusion MRI measures between groups. Our findings of reduced FA, ICVF
and increased ODI in the cingulate and temporal cortices of PD patients support the
hypothesis that Lewy pathology might be associated with cortical microstructural
alterations.
The major findings in this study using NODDI in PD relate, first, to significant reduction
of ICVF in the cingulate and temporal cortical regions in the PD group, suggesting loss of
axonal density or reduction in axonal volume in these regions. Second, the increase of
ODI within the cingulate cortex and the correlation of ODI and ICVF with overall cognition
and processing speed, suggests a relationship between cortical microstructural
abnormalities and the severity of cognitive decline as PD progresses. Finally, our results
were consistent with our DTI findings, where FA was also reduced in the cingulate and
temporal cortical areas of PD patients, in addition to major paralimbic areas (entorhinal
cortex and insula). In contrast, no gray matter abnormalities were detected with surfacebased cortical thickness analyses suggesting that, DTI and NODDI diffusion models offer
greater sensitivity to detect cortical microstructural abnormalities associated with PD
pathology. This conclusion is further strengthened by the whole-brain correlation analysis,

90
which revealed significant relationships between FA, ICVF and ODI metrics in significant
clusters with SDMT and MoCA scores, reflecting severity of cognitive decline. Our in vivo
findings in DTI and NODDI were clinically meaningful and support the potential utility of
NODDI metrics as sensitive biomarkers of cortical microstructure in PD. NODDI metrics
helped provide a better interpretation of the microstructural changes underlying PD
pathology in the cerebral cortex, by separating the changes in neurite density from
orientation dispersion.
Surface-based cortical thickness (CTh) analysis revealed no cortical thinning in our
PD cohort compared to HC. This negative finding was consistent whether using a priori
cortical ROIs and accounting for age or with vertex-wise analysis of CTh differences in
FreeSurfer. In this context, previous neuroimaging assessing cortical thinning in PD have
yielded inconsistent results. Previous studies reporting no between-group differences in
cortical thinning in PD patients without cognitive impairment (Mak et al., 2015) or with
cognitive impairment (Uribe et al., 2016). On the other hand, other studies reported that
mild cognitive impairments in PD is associated with cortical atrophy in temporo-parietal
regions (Mak et al., 2015 and Pagonabarraga et al., 2013). Mak et al. (2015) revelated
three different patterns of cortical thinning in a sample of 88 nondemented PD patients,
(1) parietal-temporal atrophy with worse cognitive performance, (2) frontal-occipital
atrophy and (3) a non-atrophic pattern. These different patterns might suggest the
existence of PD subtypes with varied cortical atrophy profiles. On the other hand, it might
reflect the limited sensitivity of conventional MRI analysis techniques to pronounced
tissue damage, as opposed to subtle reductions in tissue integrity below the detection
threshold of cortical thickness assessment.
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The ROI-based analysis of NODDI metrics revealed significant differences between
groups. In ROIs associated with early Lewy pathology in Braak stage 4, only FA
reductions were identified in the entorhinal cortex and parahippocampus. These results
are in line with the early involvement of paralimbic regions in Lewy pathology. Later Braak
stages are associated with wider spread of Lewy pathology to the neocortex, including
temporal areas, insula and prefrontal regions (Braak stage 5).
We detected reduced ICVF only in the inferior temporal lobe (p=0.01) without aberrant
ODI (p=0.656) or cortical atrophy. Other ROIs known to harbor Lewy pathology and
associate with cognitive decline, were also studied and included the fusiform, superior
and inferior parietal lobes. Reduced ICVF was reported in both the fusiform (p=0.049)
and the superior parietal lobe (p=0.033). Regarding the consistent decrease in ICVF
detected in the caudal anterior cingulate, inferior temporal lobe, fusiform and superior
parietal lobe, we interpret these changes as reflective of the reduced signal contribution
from the cortical neuropil. Whether this reduction is caused by reduced dendritic
complexity and possibly density, remains unknown. Histological validations of NODDI
metrics in humans are still inadequate (Grussu et al., 2017) findings from this study are
interpreted cautiously. Thus, whether changes in NODDI metrics reflect cortical neuropil
regression associated with Lewy pathology requires histological validation linked to PD.
Using whole brain analysis of NODDI metrics, we detected reduced ICVF in the right
and left anterior cingulate of the PD group and increased ODI in the anterior cingulate.
Both ROI and voxel-based analysis revealed reduced ICVF in the cingulate cortex, in
conjunction with previous and growing evidence supporting a predominant involvement
of limbic structures such as the anterior cingulate in PD. The anterior cingulate gyrus
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(ACG) plays a role in higher-level functions, such as decision making, motivation and
goal-directed behaviors and internal emotional responses. In PD, the ACG is affected
early and severely, where regional Lewy body density in the ACG associates with clinical
dementia rating scale (Kovari et al., 2003 and Braak et al., 2003). The increased ODI in
conjunction with reduced ICVF in the ACG, can be explained by the loss of dendrites in
random directions. This loss of dendrites randomly and subsequent loss of dendritic
complexity, might have influenced water diffusion in the extracellular space and possibly
translated to higher orientation dispersion.
Functionally, ODI correlated with cognitive decline differently when in white versus
gray matter, which is an expected finding. In fact, ODI is higher in gray matter compared
to white matter, due to the greater variability in dendritic orientation compared to axons.
ODI decreases with higher alignment along the mean direction in the voxel and is lowest
in the corpus callosum (Zhang et al., 2012). In our PD cohort, ODI in the right and left
cerebral white matter, correlated negatively with performance on the MoCA and SDMT.
This translates to worse overall cognition and processing speed with higher ODI values
in the cerebral white matter. In white matter area, this may reflect that axons with
increased orientation variability are associated with worse cognitive performance.
On the other hand, ODI in gray matter areas (posterior cingulate, superior parietal
lobe, lingual and supramarginal gyri) was associated positively with performance on the
SDMT and MoCA. Higher orientation dispersion in gray matter may imply the increased
complexity of dendritic arborizations. On the other hand, reduced orientation dispersion,
possibly reflecting reduced dendritic branching, is associated with worse cognitive status
(Figure 2C, D).
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A direct comparison of the NODDI and FA whole-brain and ROI-based findings in our
study shows that FA detected larger areas of cortical changes associated with PD than
ODI or ICVF. FA was significantly lower in the entorhinal cortex, parahippocampus, rostral
anterior cingulate, insula and fusiform. Whole-brain analysis, revealed lower FA in the
anterior cingulate, in addition to the middle temporal lobe in the PD group. Finally, a
significant negative correlation was detected between FA in the precuneus and cerebral
white matter, and MoCA score, where worse cognition is associated with lower FA. These
findings might reflect that FA have a higher sensitivity than NODDI metrics for detecting
PD-related cortical microstructure.
Our findings of reduced FA, ICVF and increased ODI in the cingulate and temporal
cortices of PD patients support the hypothesis that Lewy pathology might be associated
with cortical microstructural alterations. Indeed, ROI-based and whole-brain analysis of
the diffusion metrics showed consistent abnormalities in the cingulate and parts of the
inferior and middle temporal lobes. Other areas known to be involved early in Lewy
pathology such as the entorhinal cortex and parahippocampus, showed only reductions
in the FA without changes in the ICVF or ODI. Although highly speculative, these
combined findings suggest differential sensitivity of NODDI and DTI metrics to different
pathological processes occurring in PD. In addition, 77% of our PD patients had PD for
less than 10 years, which means that they could be at different stages of the Lewy
pathology and we cannot assign patients to specific Braak stages.
NODDI model, like all biophysical models, requires a number of assumptions of tissue
properties (Zhang et al., 2012). NODDI assumes the value of intrinsic diffusivity is fixed
over the whole brain, in both gray and white matter and for all subjects (old and young,
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healthy and with brain disorders). If these assumptions are not valid for the tissue being
studied or subjects’ demographics and clinical status, then the NODDI metrics might be
misleading and biased. It is plausible that this assumption does not fully represent all
pathological processes occurring in a brain disorder, such as potential regions alterations
in intrinsic diffusivity or variations in neurite permeability. Future studies will be required
to evaluate these assumptions in different tissue characteristics and under pathological
and developmental conditions.
Longitudinal studies on larger cohorts of PD patients will be essential to confirm our
results and to follow accurately the cortical microstructural changes due to PD
progression. Another crucial investigation would be to study the effects of potential
disease-modifying treatments, to assess whether diffusion metrics changes in the cortical
regions being targeted by medications.

95
CHAPTER 5 SUBCORTICAL VOLUMETRIC AND DIFFUSION ALTERATIONS
ASSOCIATED WITH PD
5.1 Summary
We investigated volumetric and diffusion abnormalities within subcortical areas
involving the basal ganglia in a group of PD participants (n=18) compared to age- and
gender matched healthy controls (n=8). Fractional anisotropy (FA), intracellular volume
fraction (ICVF) and orientation dispersion index (ODI) maps were derived from diffusionweighted images. For each hemisphere, we derived the subcortical volumes of the
subcortical structures, including the striatum, and extracted the FA, ICVF and ODI
metrics. Paired t-tests were used to examine any potential asymmetry in the studied
parameters in the PD group, followed by an Analysis of covariance (ANCOVA) to
compared PD patients and HC participants. Finally, we tested for correlations between
diffusion indices and clinical measures.
There were no significant differences in subcortical volumes between groups.
Reduced ODI was detected in the caudate of PD group compared to HC (p=0.033) with
no changes at the level of FA or ICVF. Within the PD group, diffusion microstructural
asymmetries were pronounced and significant. FA was significantly lower in the caudate
(mean difference= -0.014) and putamen (mean difference= -0.013), in the side
contralateral to symptoms onset (p=0.012 and p=0.029, respectively). The contralateral
caudate was also characterized by increased ODI (mean difference= 0.007, p=0.051)
with no significant asymmetries recorded in the ICVF (p=0.119). Across all PD patients,
ODI within the contralateral caudate and putamen correlated negatively with disease
stage. ODI in the caudate also correlated with measures of processing speed were both
the ipsilateral and contralateral ODI values showed a positive correlation with SDMT
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scores. We conclude that diffusion measures of microstructure (ODI and FA) appear to
be more sensitive for the detection of PD-related pathological changes compared to
conventional volumetric measures.
5.2 Introduction
PD is characterized by dysfunction of the dopaminergic nigrostriatal pathway and
resultant motor dysfunction. The pathological events start with the degeneration of
dopaminergic projections from the SNpc to the medium spiny neurons (MSNs) in the
neostriatum. The loss of dopamine (DA) innervation is region-specific and follows a
topographic subregional pattern (Kish, 1988).
Previous postmortem studies of histopathologically confirmed PD patients have
shown that the greatest depletion of DA occurs in the putamen, particularly in the caudal
portions, whereas there is less 1% of DA remaining (Kish, 1988). Dysfunction of the
putamen secondary to DA denervation can disrupt the basal ganglia motor loop and
contribute to the cardinal motor deficits in PD. Within the caudate nucleus, DA loss is
milder and is greatest in the most rostral portion with only 4.3% of DA left (Kish et al.,
1988). The caudate has a key role in executive function with heavy connections coming
from dorsolateral frontal areas. In this extent, cognitive decline in PD has been associated
with DA loss within the caudate (Lewis et al., 2003). Therefore, valid in vivo methods to
evaluate the structure and morphology of the dorsal striatum is highly crucial for
monitoring the clinical progression of PD.
Current knowledge of morphological changes in MSNs following dopamine
denervation comes from postmortem studies. In late stage PD, neostriatal MSNs are
characterized by marked loss of dopaminergic neurons, dendritic atrophy and loss of
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dendritic spines (Zaja-Milatovic et al., 2005). Dendritic length of the MSNs was reduced
uniformly in the putamen and caudate of PD patients compared to controls. However,
reductions in spine density showed a topographic gradient that roughly matches that of
dopaminergic denervation. From this perspective, no significant spine loss was observed
in the caudate or rostral putamen, however, severe loss in dendritic spine density was
reported in the caudal putamen. While these Dendritic morphological abnormalities have
only been reported in postmortem studies, in vivo MR measures sensitive to tissue
characteristics such as structural atrophy and microstructural damage could have a great
potential for exploring pathological changes.
A number of MRI-based techniques have been utilized to examine the pathology of
subcortical structures and provide non-invasive biomarkers of structural tissue integrity in
PD. Subcortical volumetric changes in PD have been studied using either voxel-based
morphometry (VBM) or automatic volume segmentation. Surprisingly, MRI volumetric
studies of the dorsal striatum, a region that is known to be depleted with dopamine and
mediate the cardinal motor symptoms, have yielded contradictory results. Some reported
caudate and putamen atrophy using regions of interest analysis in advanced-stage
patients, but not in de novo or early stage PD groups (Hopes et al., 2016). Other studies
using voxel-based morphometry showed no significant regions of gray matter changes
(Lee et al., 2014 and Pelizzari et al., 2019), but did reveal significant reductions (corrected
p< 0.05) in the adjusted volumes of the putamen, nucleus accumebens and hippocampus
in early stage PD patients (Lee et al., 2014). The ICICLE-PD study (Mak et al., 2015), a
longitudinal study over 18 months in 108 well-characterized PD subjects, have shown
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that patients with mild cognitive impairment had greater atrophy in the left caudate (2.5%±8.8%) from baseline volume compared to healthy controls (1±4.9%).
Also, DTI measures such as FA and MD have been proposed to detect in vivo
structural changes in the subcortical areas of PD patients.

In this framework, the

Parkinson's progression marker initiative (PPMI) have reported a higher rate of FA
reduction in the SN of PD patients (3.6±1.4% from baseline) compared to HC, which
correlated with increasing dopaminergic deficits (Zhang et al., 2016). Other DTI studies
(Kamagata et al., 2016 and Kamagata et al., 2017) have reported no significant
differences in diffusion parameters measured in the putamen, caudate and pallidum, but
did find reductions in FA in the contralateral SNpc (p=0.00049). Opposite results were
also found, where FA was observed to increase in the substantia nigra and posterior
putamen in PD patients (n=46) over a period of 6 years (Chan et al., 2016). Deep gray
matter structures such as the globus pallidus and putamen are vulnerable to iron
accumulation with age, and studies in PD have showed increased iron deposition in the
basal ganglia of PD patients (Ulla et al., 2013), and mainly in the caudal putamen. This
iron deposition in the SN and basal ganglia of PD patients may in turn influence DTI
metrics and partly explain the discrepancies in FA findings.
With the several limitations of DTI in modelling the diffusion signal and difficulty in
interpreting the alteration in the diffusion metrics, more advanced modeling of the
diffusion signal is needed to investigate subcortical changes secondary to PD pathology.
Neurite orientation dispersion and density imaging (NODDI) is a promising technique for
studying disease-specific microstructural alterations that occur in PD. For this purpose,
we will use NODDI to study specific tissue alterations in the subcortical regions of PD
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patients. NODDI derived metrics provides proxy measures for the fraction and orientation
of neurites (axons and dendrites) by assuming that the diffusion signal in each voxel
belongs to three compartments (intracellular, extracellular, and cerebrospinal fluid).
5.3 Aims
The main objectives of the present study were to (i) measure NODDI markers of tissue
microstructure in the subcortical regions of PD patients compared to HC, (ii) assess the
association between NODDI parameters and measures of disease severity and cognitive
decline (iii) and finally study conventional MRI markers of tissue atrophy such as volume
and DTI makers. Given the that striatum is the central structure affected with dopamine
deprivation, we hypothesized that we would find significant reduction in the ICVF in the
caudate and putamen, as well as potential ODI changes, possibly reflecting dendritic
regression in the neuropil. We also hypothesized that NODDI metrics in the caudate will
correlated with cognitive decline in the PD group.
5.4 Methods
Subcortical Volume Segmentation.

FreeSurfer (v.6.1.0) was used to estimate

subcortical volumetric measures and generate masks of these structures for further
extraction of diffusion metrics. The technical aspects of subcortical segmentation from
T1-weighted images have been described elsewhere (Fischl and Dale, 2002). The
following subcortical gray matter structures were used for analysis in the study: amygdala,
caudate, hippocampus, pallidum, putamen, nucleus accumbens and thalamus. Global
brain measures were also estimated including total intracranial volume (TIV). Masks for
the studied subcortical regions were created using fslmaths applied the aseg file and
finally were binarized to generate the final region of interest (ROI).
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Total Intracranial Volume Estimation. The FreeSurfer pipeline was used to estimate
the total intracranial volume (TIV) depending on an atlas-based spatial normalization
process. In summary, each subject is registered to an atlas template (MNI305 space).
The determinant of the transformation matrix used to align the image with the atlas is
used to generates TIV. Differences in the TIV associated with PD diagnosis were
examined by modelling TIV as a dependent variable while controlling for age using
ANCOVA.
Statistical Analysis
A. Subcortical Volumes
To account for potential effects of disease-related asymmetry, we compared the
volume of subcortical structures between the sides ipsilateral and contralateral to
symptoms onset. For this purpose, a paired-t test was used to compared the contralateral
and ipsilateral subcortical volumes within the PD group. This analysis revealed no
asymmetry; thus, striatal volumes were averaged bilaterally for each subject and the
mean volume was used in subsequent analyses. The average volume for each
subcortical structure was compared between groups using ANCOVA while controlling for
age. All tests were 2-tailed. A p-value of <0.05 was considered significant and uncorrected
for the number of subcortical structures. All statistical analysis was done using R version
3.6.1 (2019-07-05) on a x86_64-apple-darwin15.6.0 (64-bit).
B. Extraction of Diffusion Parameters from Subcortical Volumes
For the measurement of subcortical nuclei NODDI parameters, we aligned the NODDI
maps from diffusion space into the standard space of the subcortical nuclei masks
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obtained from T1 segmentation. The following pipeline summarizes the necessary steps
of co-registration (Figure 12):
1. A binary brain mask was obtained from the mean b0 volume using brain extraction
tool
2. The brain mask was applied to the NODDI parameter maps using fslmaths
3. The skull-striped T1 image in MNI space (T1_brain) was segmented using FSL
FAST to generate the partial volume maps
4. The brain-extracted b0 (b0_brain) image was aligned to T1_brain using flirt
5. The boundaries from the white matter segmentation and the rigid body
transformation matrix from flirt were used as input for the Boundary-Based
Registration (BBR) between b0_brain and T1_brain
6. The ICVF, ODI and FA maps were then co-registered to T1_brain space by using
the registration matrix from the co-registeration of b0 in the BBR step
7. Finally, fslmeants was used to extract the mean diffusion metrics from each
subcortical volume.
Mean diffusion metrics for each subcortical ROI was analyzed separately between
groups. An Analysis of Covariance was done for between-group comparisons, accounting
for age. p<0.05 was considered to be significant.
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Figure 12. Preprocessing Pipeline for Extracting Subcortical Diffusion
Metrics
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C. Correlation Between Subcortical Diffusion Metrics and Clinical Severity
For the correlation analysis, only ROIs identified as having a significant between or
within group differences were tested. We studied the association between the diffusion
metrics and clinical variables, including disease duration, motor severity (UPDRS III) and
cognition (MOCA and SDMT raw scores). Where appropriate, correlations were
performed using either Pearson’s r or Spearman’s ρ coefficients. A p-value of 0.05 was
considered significant.
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5.5 Results
5.5.1 Subcortical Volume Analysis in PD group compared to HC
Within Subject Comparisons. To account for possible effects of disease-related
asymmetry, the subcortical of contralateral and ipsilateral structures were first compared
in PD patients using a paired-t test. This analysis revealed no asymmetry in volumes
between the sides of disease onset in the caudate (p=0.394), putamen (p=0.876), globus
pallidus (p=0.121) and thalamus (p=0.807). Thus, normalized striatal volumes were
averaged bilaterally for each subject and the mean volume was used in subsequent
analyses.
Between Subjects Comparisons. Group comparisons of subcortical volumes (ml)
were performed by analysis of covariance with adjustment for age. No significant
differences volume atrophy was found in the caudate (p=0.364), putamen (0.193), globus
pallidus (0.771) thalamus (0.729), Globus pallidus (p=0.261), Amygdala (p=0.95),
Nucleus Accumbens (p=0.52) and Hippocampus (p=0.29).
5.5.2 Subcortical Microstructural Abnormalities in PD Compared to HC
Between Subjects Comparisons. Group comparisons of subcortical diffusion
metrics were performed by analysis of covariance with adjustment for age (Table 12). The
average FA, ODI and ICVF for both the right and left hemispheres for each subject was
calculate and compared between groups. Our analysis revealed no significant differences
in FA, in the caudate (p=0.326), putamen (0.319), globus pallidus (0.575) or thalamus
(0.314). Similarly, both groups did not differ significantly between groups in ICVF of the
caudate (p=0.805), putamen (0.954), globus pallidus (0.611) and thalamus (0.348).
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Finally, significant reduction in ODI was observed in the caudate pf PD patients compared
to HC (p=0.033).
Table 12. Comparisons of Averaged Diffusion metrics among
hemispheres between PD and HC groups
Variable
PD
Controls
Significance
fpη2
Mean±SEM
Mean±SEM
value value
FA
Caudate
1.009 0.326
0.042
0.23±0.008
0.21±0.007
Putamen
1.04 0.319
0.043
0.28±0.007
0.26±0.006
Globus Pallidus
0.323 0.575
0.014
0.37±0.01
0.38±0.01
Thalamus
1.06
0.314
0.044
0.33±0.004
0.33±0.007
ICVF
Caudate
0.062 0.805
0.003
0.55±0.02
0.54±0.02
Putamen
0.003
0.954
0.00015
0.62±0.02
0.61±0.02
Globus Pallidus
0.266 0.611
0.011
0.83±0.02
0.85±0.02
Thalamus
0.917 0.348
0.038
0.62±0.02
0.59±0.01
ODI
Caudate
2.749 0.033
0.113
0.44±0.009
0.47±0.008
Putamen
0.871 0.36
0.036
0.46±0.007
0.47±0.005
Globus Pallidus
0.578
0.455
0.025
0.45±0.009
0.45±0.007
Thalamus
0.01 0.921 0.00044
0.36±0.006
0.37±0.006
ANCOVA; p-value adjusted for age
5.5.3 Microstructural Asymmetry Within PD Group in the Dorsal Striatum
Within Subject Comparisons. There was a significant within-subject effect of
hemisphere side on diffusion metrics in the PD subjects (Table 13). FA was significantly
lower in the Caudate, contralateral to symptoms onset (0.22±0.008, p=0.012) compared
to the ipsilateral side (0.24±0.009). This decrease in FA was also accompanied by an
increased ODI in the caudate contralateral to symptoms onset (0.44±0.01, p=0.051)
compared to the other side (0.43±0.009). As for ICVF, none of the studied regions were
significantly different between hemispheres, except for the putamen, which showed a
trend in lower ICVF in the side contralateral to symptoms onset (p=0.059).
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Table 13. Comparisons of Diffusion Metrics Between Hemispheres within the PD
Group
Variable
Ipsilateral Contralateral
Significance
tp95% CI
Mean of
Mean±SEM Mean±SEM
value value
difference
FA
Caudate
-2.83 0.012 [-0.025, -0.014
0.24±0.009
0.22±0.008
0.004]
Putamen 0.29±0.008
-2.39 0.029 [-0.024, -0.013
0.27±0.007
0.002]
Globus
-1.18 0.255
[-0.04,
-0.014
0.38±0.01
0.37±0.01
Pallidus
0.01
-1.73 0.102
[-0.015,
-0.007
0.33±0.005
0.33±0.005
Thalamus
0.001]
ICVF
Caudate
-1.644 0.119
[-0.032,
-0.014
0.57±0.02
0.54±0.02
0.004]
Putamen
-2.02 0.059
[-0.038,
-0.018
0.63±0.02
0.61±0.02
0.0008]
Globus
-1.03 0.211
[-0.025,
-0.0096
0.84±0.02
0.83±0.02
Pallidus
0.006]
0.222 0.827
[-0.015,
0.0018
0.62±0.02
0.62±0.02
Thalamus
0.019]
ODI
Caudate
[-4.6,
0.0066
0.43±0.009
0.44±0.009 2.0953 0.051
0.00133]
Putamen 0.46±0.008
0.221
0.828
[-0.01,
0.0012
0.46±0.008
0.013]
Globus
0.421 0.679
[-0.02,
0.005
0.45±0.01
0.45±0.01
Pallidus
0.03]
1.776 0.094
[-0.001,
0.005
0.36±0.007
0.36±0.006
Thalamus
0.011]
Paired t-test
Between Subject Comparisons. Knowing that we found significant hemispheric
asymmetry in the ODI and FA of the PD group, we wanted to analyze each hemisphere
separately and compare it with the average diffusion metrics from the HC group while
accounting for age (Table 2, Appendix). Our analysis revealed no significant differences
between groups in FA when comparing each side of the symptoms separately for any of
the studied subcortical regions. ODI was marginally reduced in the caudate of the PD
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group (p=0.086) compared to the HC. Removing age as a covariate, renders the reduction
in ODI to be highly significant (p=0.007, t=2.3 and 95% CI 0.01 to 0.06).
5.5.4 Correlation Between Subcortical Diffusion Abnormalities and Clinical
Measures
Within Subject. Correlation coefficients between diffusion metrics in subcortical
structures and disease duration and the main cognitive tests scores are shown in Table
14. ODI in the contralateral to symptoms onset was significantly correlated with disease
duration (r = −0.48, p = 0.043) such that longer disease duration was associated with
lower ODI. This was the case also for the Putamen contralateral to symptoms onset,
where ODI was negatively corelated with disease duration (r=-0.47, p=0.051). As for the
performance on cognitive measures, ODI in the contralateral and ipsilateral caudate
showed a positive correlation with SDMT score (r=0.49, p=0.038; r=0.51, p=0.032), where
better performance on the SDMT was associated with higher ODI in the caudate. As for
the UPDRS motor score, it was not shown to correlate with either ICVF or ODI in the
putamen and caudate.
We also inspected whether the hemispheric asymmetry in FA show any correlation
with the clinical measures. Finally, no significant associations were found between FA in
the striatum and any of the cognitive measures and disease duration.
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Table 14. Pearson Partial Correlation (r) between diffusion metrics and
Clinical Severity Symptoms in PD Group
VariableDisease duration
MOCA score
SDMT z-score
Hemisphere
(years)
r
p
95% CI
r
p
95%
r
p
95%
CI
CI
ODI
Contralateral
-0.48 0.043
[-0.77,
0.33 0.177 [-0.16,
0.49 0.038
[0.03,
Caudate
Putamen

-0.47

0.051

Ipsilateral
Caudate

-0.43

0.076

Putamen

-0.39

0.109

FA
Contralateral
Caudate

0.42

0.086

Putamen

0.08

0.739

FA
Ipsilateral
Caudate

0.34

0.164

Putamen

0.14

0.568

0.018]
[-0.8,
0.0003]

0.21

0.406

[-0.75,
0.048]
[-0.73,
0.09]

0.31

0.216

0.14

0.570

[-0.06,
0.74]
[-0.4,
0.53]

0.34

0.164

0.05

0.836

[-0.15,
0.7]
[-0.35,
0.57]

-0.1

0.7

0.19

0.440

0.69]
[-0.29,
0.62]

0.44

0.068

[-0.19,
0.68]
[-0.35,
0.57]

0.51

0.032

0.42

0.082

[-0.7,
0.15]
[-0.51,
0.42]

-0.21

0.405

0.12

0.649

[-0.54,
0.39]
[-0.3,
0.61]

0.03

0.906

0.14

0.592

0.78]
[-0.03,
0.75]
[0.05,
0.79]
[-0.06,
0.74]

[-0.62,
0.29]
[-0.37,
0.55]

[-0.49,
0.44]
[-0.35,
0.57]

5.6 Discussion
We used DTI and NODDI to study tissue microstructural abnormalities in the caudate,
putamen, globus pallidus and thalamus of PD patients, in addition to assessing potential
striatal volumetric atrophy. The first novel finding was that PD pathology was associated
with lower ODI in the caudate, with no significant changes in the ICVF or FA. Within group
analysis of PD patients, revealed that caudate ODI was significantly higher in the
hemisphere contralateral to symptoms onset (p=0.051) and correlated with disease
duration (p=0.043) and processing speed (p=0.038). Furthermore, our results
demonstrate that FA is reduced in both the caudate and putamen, also in the side
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contralateral to symptoms onset. Interestingly, FA did not correlate with duration of illness
and cognitive decline. Our findings highlight the potential role of diffusion MRI in
characterizing microstructural changes in the caudate and putamen associated with PD
pathology in the absence of volumetric atrophy.
The dorsal striatum (caudate and putamen) composes the main input structures of the
basal ganglia and receives direct dopaminergic projections from the substantia nigra. In
PD, nigrostriatal denervation can cause structural alterations in the neuropil of the
striatum, such reduced dendritic length and spine loss in the medium spiny neurons of
the striatum (Zaja-Milatovic et al., 2005) and loss of neurons (Bugiani et al., 1980). Such
changes may contribute to a volume reduction in these areas. Our study revealed no
significant volume change in the putamen and caudate between groups. While little
attention has been given to understanding the pathological mechanisms preceding a
detectable volume reduction, we attempted to study more subtle microstructure indices
such as FA, ICVF and ODI.
We hypothesized that we would find reductions in ICVF of the caudate and putamen
in PD patients but we did not detect it. However, ODI was significantly lower in the PD
group, probably reflecting reduced dendritic complexity with no significant loss in the
dendrites. This might have been translated as reduced ODI but with no changes at the
level of ICVF. A previous NODDI study by Kamagata et al., 2016 have reported significant
reductions in ICVF and ODI in the putamen of PD subjects (n=58) compared to controls
(n=38). In this study, the subcortical ROIs were delineated manually and an unpaired ttest was used to compare between group differences in regions divided as ipsilateral,
contralateral or averaged without controlling for age. The deviation of our results from this
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study might be related to a number of technical reasons, such as the sample size,
patients’ clinical characteristics, method of subcortical segmentation and statistical
analysis.
Other explanations for our negative findings also exist. First, we extracted each
diffusion measure from the entire subcortical structures and no subregional segmentation
was done for further analysis. We know from previous PET and postmortem studies that
there is a subregional heterogeneity in the areas affected across the striatum. The caudal
extent of the putamen is the first and the most dopamine depleted striatal subregion,
mediating the cardinal motor symptoms and signaling PD diagnosis (Kish et al., 1988).
Thus, when averaging the diffusion measures across all the subregions of the putamen,
we might me washing out the differentially affected subregions with other that are not
affected.
The second explanation is that other pathological processes could be occurring
concomitantly and affecting the diffusion signal, such that any possible change in the
diffusion metrics from dendritic loss might be compensated by another process. It is well
established that PD is associated with microglial activation in nigrostriatal and limbic
areas from postmortem (Imamura et al., 2003) and PET imaging of [11C] (R)-PK11195.
While we did not assess microglial activation in our PD cohort, we cannot disregard
that this process might be occurring. With the presence of microglia in the extracellular
space, undergoing substantial changes in both morphology and density throughout the
stages of neuroinflammation, these changes are expected to significantly influence water
hinderance in the extracellular space. In fact, a rodent study (Barnett et al., 2019) found
that microglial density associated positively with ODI, such that microglial-mediated
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neuroinflammation can have a potential effect on the degree of hindered diffusion in the
extracellular space. Therefore, if microglial activation is occurring in our PD cohort, and
the density of microglia is increasing in parallel with the dendritic regression in the medium
spiny neurons, we might not be able to detect ICVF changes at the levels of the dendrites
and spines.
More support of this explanation comes from the within group comparisons of the
diffusion metrics. We were able to detect increases in the ODI of the caudate contralateral
to symptoms onset (p=0.051, mean difference= 0.0066) with concomitant reductions in
FA (p=0.012, mean difference= -0.014). We cautiously interpret the increase in ODI as
being related to potential microglial activation in the striatum, which alters water diffusivity
in the extracellular compartment and indirectly affects the estimation of ODI. The
reductions in FA also corroborate our ODI findings, where a decrease in anisotropy can
be caused by an increase in the dispersion of the orientation distribution.
Within the PD group, we found a significant negative correlation between the ODI in
the caudate and putamen with disease duration. This is an important finding highlighting
their potential to serve as progression biomarkers of PD. In addition, a significant positive
correlation was found between caudate ODI and SDMT score of processing speed,
emphasizing the function of the caudate in cognition. While we found no correlation
between ODI in the striatum and motor severity, it should be noted that our patients were
on dopaminergic medication during their motor assessment. The dopaminergic
medication can mask the real level of motor severity. Further studies in a larger sample
of PD patients OFF-medication are required to corroborate a relationship between
microstructural indices and clinical status.
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Our study has several limitations. The small sample size of both our PD patients and
healthy controls restricted our power to achieve statistical significance when comparing
NODDI metrics. Larger sample studies with longitudinal follow ups can provide the
necessary statistical power to either confirm or refute the sensitivity of NODDI to
differentiate between groups. Also, our subjects were on their dopaminergic treatment
when their motor abilities were assessed for the UPDRS.
In conclusion, our findings confirm the crucial role of the caudate and putamen in PD,
at the level of both reduction in indices of dendritic complexity and microstructural
asymmetry. Since dopamine denervation is not homogeneous in the striatum,
subregional segmentation of this structure is warranted in the future to test the sensitivity
of NODDI in detecting microstructural alterations due to PD pathology. s
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CHAPTER 6 WHITE MATTER MICROSTRUCTURAL ABNORMALITIES
ASSOCIATED WITH PD
6.1 Summary
Parkinson’s disease (PD) is characterized neuropathologically by the loss of
dopaminergic neurons in the substantia nigra pars compacta (SNpc). The loss of these
neurons is thought to affect the nigrostriatal pathway (NSP) and the basal ganglia−motor
cortex circuits, resulting in the cardinal motor symptoms. On the other hand, cognitive
deterioration in PD has been linked to microstructural changes in the corpus callosum
(CC). In this study, we aimed to reconstruct the NSP and segment the corpus callosum
into ten subregions in our PD (n=18) and HC (n=8) participants. We used NODDI in
parallel with DTI, to test whether the diffusion metrics in these two white atter tracts are
altered and if they associate with motor disability and cognitive dysfunction. The NSP
tractography revealed no significant differences in FA, ICVF or ODI values between
groups. The subregional CC analysis revealed significant reductions in the ICVF and FA
of the genu-2 subregion, accompanied by an increased ODI. Our findings of abnormal
microstructural integrities of the CC genu-2 subregion in PD demonstrated that NODDI is
potentially sensitive for PD-related pathological changes in major white matter tracts.
6.2 Introduction
A key neuropathological feature of Parkinson disease (PD) is the degeneration of
dopaminergic neurons in the substantia nigra pars compacta (SNpc). Dopaminergic
neurons from the SNpc project their unmyelinated axons via the medial forebrain bundle
to the striatum, which is known as the nigrostriatal pathway (NSP). The loss of these the
nigrostriatal fibers and thus dopaminergic innervation, results in the dysfunction of the
basal ganglia−motor cortex circuits which underlies the cardinal motor symptoms in PD.
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Postmortem studies have shown that at time of motor symptoms onset, there is about
31% loss of SN dopaminergic in PD patients, after adjusting for age (Fearnley and Lees,
1991, and Greffard et al., 2006). Greffard and colleagues (2006) also found that the
UPDRS-motor score is linearly linked to neuronal density in the SN (r=−0.83, p<.001).
Attempts to trace the nigrostriatal fibers and their course have been conducted in
Rhesus monkeys (Carpenteer and Peter, 1972). Efferent projections of the SN traverse
the internal capsule and the globus pallidus to enter the putamen and part of the caudate.
This study has shown that nigrostriatal fibers are topographically organized. The lateral
region of the caudal two-thirds of the SN project predominantly to the dorsal putamen,
compared to the medial region that is related primarily to the ventral portions of the
putamen. Fiber entering the putamen are very fine, long and radiate in many directions.
In addition, the caudal two-thirds of the SN have projections primarily to the suprathalamic
parts of the caudate nucleus, compared to the rostral SN that projects to the head of the
caudate nucleus. This is highly relevant in the context of dopamine loss in the neostriatum
of PD patient.
Postmortem studies have shown that dopamine loss in the putamen is more severe
compared to the caudate. Specifically, the dorsal putamen being more depleted of
dopamine than the rostral part and the dorsorostral part of the caudate head with lowest
levels of dopamine compared to the caudal extent (Kish et al., 1988). Therefore,
identifying the microstructural changes in the NSP is essential to the assessment of PD
severity.
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Figure 13. Schematic Image of the nigrostriatal projections in Rhesus
Monkeys (Carpenteer and Peter, 1972)

Characterizing the NSP in humans in vivo is not straightforward, as nigrostriatal fibers
are mainly unmyelinated, thin and follow a curved trajectory (Pritzel et al.,1983). Previous
studies have used fiber tractography to reconstruct the nigrostriatal pathway in PD
patients (Andica et al., 2018, Tan et al., 2015 and Guo et al., 2020). The Fiber
tractography is a useful technique to reconstruct white matter fiber tracts in vivo in the
human brain (Basser et al., 2000). The reconstructed fiber pathways are indicative of the
underlying pathways, rather than the actual tract. A key assumption of many tractography
algorithms, is that the principal diffusion direction (the major eigenvector) can be used to
approximate the tissue fiber orientation at the same location. Deterministic tractography
algorithm follows the major eigenvector direction of the diffusion tensor to propagate the
tract in small and discrete steps and is frequently used in scientific and clinical setting
(Basser, 1998). After a tract is generated, diffusion-related metrics can be extracted and
used to assess tissue microstructures and possible neurodegeneration.
Tan et al. (2015) isolated the NSP using deterministic tractography and by placing two
spherical ROIs, one in the ventral SN to serve as a seed and the other in the globus
pallidus as a target. Tracing studies have demonstrated that nigrostriatal projections
traverse the globus pallidus to synapse in the neostriatum. In this study, advanced stage

115
PD patients had a significantly lower average FA in the NSP compared to healthy controls
(p=0.002). Other studies have failed to find any nigrostriatal FA changes in PD patients
(Andica et al., 2018 and Guo et al., 2020).
In addition to DTI metrics, other studies have utilized Neurite density and dispersion
imaging to assess microstructural changes in the NSP of PD patients (Andica et al.,
2018). The NSP was constructed via deterministic tractography by placing regions of
interest in the ventral SN and the globus pallidum. This study found reduced intracellular
volume fraction (ICVF) in the NSP, contralateral to symptoms onset, in the PD group
compared with healthy controls. These results are consistent with the greater
dopaminergic loss on the contralateral side to motor symptoms onset. The most recent
tractography study in PD (Guo et al., 2020) utilized probabilistic tractography to isolate
the NSP. Probabilistic tractography algorithms generate the probability density function
of fiber orientation within each voxel, as well an estimate of the uncertainty of these
orientations. The SN and putamen were used as a seed and target, respectively. while
no significant changes were found in ICVF between PD and HC groups, the average ODI
was significantly lower in the PD group.
In addition to the NSP, other studies have explored whole brain white matter tracts in
PD. A longitudinal study of de novo PD patients (n=71) showed an increased FA at
baseline in the anterior corona radiata, anterior corpus callosum and inferior-occipital
longitudinal fasciculus WM compared to healthy controls (Taylor et al., 2018). After one
year follow up, there was a faster FA decline in PD subjects compared to the healthy
participants (n=45) in the left optic radiation and anterior and middle corpus callosum and
significant increase in the MD of the left optic radiation and anterior and middle corpus
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callosum, which were significantly associated with the changes in the total unified
Parkinson disease related score (UPDRS). To study if alterations in myelin content occur
in PD, myelin water imaging (MWI) has been used in a cross-sectional study utilizing
multi-component driven equilibrium single pulse observation of T1 and T2 (mcDEPSOT).
PD patents with normal cognition (n=28) displayed increased myelin water fraction
(MWF), a surrogate for myelin content. This increase in myelin content was reported in
the thalamic radiations and posterior limb of the internal capsule, superior longitudinal
fasciculus, genu and body of CC (Dean et al., 2016). Such changes of myelin content
might be consistent with increases in FA reported in the study by Taylor. It has been
postulated that areas of WM can undergo compensatory changes in early PD, as reflected
by the increased FA and myelin content.
In a tract-based spatial statistics study (Li et al., 2017) to study WM alterations and
overcome the limitations of ROI analysis, an extensive reduction in FA was found in the
genu, body and splenium of the CC in the early PD group. These findings are in line with
the study by Kamagata et al. that found baseline significant FA reductions in the genu of
the CC and prefrontal WM in PD patients with dementia (0.49 ± 0.04) compared with PD
group with normal cognition (0.52 ± 0.03) and HC (0.52 ± 0.03), and correlated
significantly with cognition score on the mini-mental state examination. These findings
support the hypothesis that the genu of the CC which contain fibers projecting to the
prefrontal cortex might be involved in the pathological process mediating dementia in PD.
Indeed, the CC is involved in the both, the regulation of limb movement and cognition.
Other studies reported different results regarding the extent and location of WM changes.
No changes in WM FA were found in cognitively normal PD patients versus healthy
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subjects in a cross-sectional study by Hattori et al., but significant FA reductions were
found in the PD group with mild cognitions impairment and dementia in parietal white
matter like the superior longitudinal fasciculus and the CC, where FA values were
correlated with MMSE score. PD patients with dementia were found to have FA
reductions mainly in the body of the CC, corona radiata and cingulum compared to
cognitively normal PD (Chondrogiorgi et al., 2019). The cingulum has a role in episodic
memory and visuospatial processing and it connects the hippocampus to the posterior
cingulate and prefrontal cortex. While reductions in FA are thought to reflect loss of WM
microstructure due to demyelination, axonal damage or increased orientation dispersion,
the exact microstructural element responsible for the change in FA remains unknown.
Axonal pathology has been observed in postmortem PD studies (Galvin et al., 1999).
Dystrophic presynaptic terminals in the dentate of the Hippocampys, Hilus and CA2/3
regions were reported in a postmortem study of 5 PD patients. The axon terminals also
showed accumulations of the synaptic proteins, synapsin, synaptophysin, and
synaptobrevin and a 3-fold increase in the vesicular content. This presynaptic axon
terminal pathology might interfere with synaptic trafficking and neurotransmitters release
and ultimately result in synaptic dysfunction. In a transgenic rat model overexpressing
mutant A53T α-syn, axonal pathology in terms of dystrophic and bulging axons, altered
synaptic and axonal transport protein and dramatic changes in cytoskeletal proteins
preceded α-synuclein-mediated neuronal loss (Chung et al., 2009). Multimodal imaging
techniques sensitive to white matter (WM) microstructure like axonal packing density,
myelin content, fractional anisotropy, tissue complexity and other markers of fiber
architecture are needed to detect early and late microstructural changes in PD WM areas.
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6.3 Aim
First, we aimed to utilize probabilistic fiber tractography to construct the NSP in our
PD and HC sample. Second, we aimed to estimate DTI and NODDI diffusion metrics
within the NSP and corpus callosum to assess tissue microstructure and potentially
capture nigrostriatal degeneration
Given prior studies of CC and nigrostriatal tract involvement in PD, we hypothesized
that: (1) PD pathology would be associated with a decrease in ICVF of the nigrostriatal
tract reflecting PD-related losses in neuritic projections from the SN; (2) Decrease in ICVF
in the genu of the CC; (3) ODI in WM tracts would increase with PD, reflecting greater
dispersion of axons; and (4) PD-associated changes in WM microstructure of the CC and
nigrostriatal tract would be associated with executive function and motor disability,
respectively.
6.4 Methods
Since PD patients overwhelmingly (95%) presented asymmetric onsets of motor
symptoms, we replaced the left and right brain hemisphere labels with contralateral and
ipsilateral labels, according to each patient’s clinically predominated side of Parkinsonian
symptoms onset (i.e. contralateral denotes the brain side opposite to the body side of
symptoms; ipsilateral denotes the same brain side as the body side of symptoms).
Tractography of Nigrostriatal Tract. Diffusion data in the subject’s native space was
used to reconstruct the NSP. Diffusion images were brain extracted, corrected for Gibbs
ringing effects and denoised in Mrtrix, and corrected for motion, eddy-current and
susceptibility-induced distortions. For each subject, automatic mapping of the nigrostriatal
white matter tract was conducted in the native diffusion space. Probabilistic tractography

119
of the nigrostriatal and was performed using tckgen function from Mrtrix3 according to the
following parameters (Figure 14):
1. We estimated response functions from the preprocessed diffusion-weighted
images using dwi2response with the “dhollander” algorithm for multi-shell data
(Dhollander et al., 2016)
2. The response functions were then used to estimate fiber orientation distributions
(FOD) based on 8th order constrained spherical deconvolution (CSD)
using dwi2fod (Tournier et al., 2004). We used the msmt_csd algorithm (Jeurissen
et al., 2014), which computes three separate FODs for WM, GM and CSF from the
multi-shell data (b=711, 2000 and 2855 s/mm2).
3. For fiber tracking, we then used tckgen with the iFOD2 (improved 2nd order
integration over fiber orientation distributions) algorithm.
4. For all subjects, each voxel within the defined seed regions was seeded with 5000
streamlines that migrated according to local probability density functions.
5. Streamlines seeded from the Substania Nigra (SN) which contacted the Caudate
(CAU), were retained as estimates of the nigrostriatal pathway.
6. Exclusion ROIs in the cerebral cortex adjacent to the CAU were placed to
terminate the tract beyond the target ROI.
The SN was drawn manually on 3 slices of the FLAIR image and included both, pars
compacta and pars reticulata because they were not resolvable on the FLAIR images.
The Caudate was drawn on the T1 image on 10 consecutive slices to cover the entire
rostro-caudal extent of the caudate. ROIs were drawn on right and left hemisphere
separately. In the case where inter-hemispheric volumes differed by > 10% for SN and
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> 20% for Caudate, they were inspected and redrawn. Following ROI delineation, FLAIR
and T1 were transformed into native DTI space and the transformation matrix was applied
to the SN and CAU masks.
The following additional tckgen settings and inputs were used: default step size of
0.8 mm, max. angle between successive steps = 10o, max. length = 160 mm, min. length
value set the min. length 8 mm, cutoff FA value = 0.1, b-vectors and b-values from the
diffusion-weighted gradient scheme in the FSL format, maximum number of fibers =5000,
and unidirectional tracking.
Tract-specific measures of diffusion metrics (Mean FA, ODI, and ICVF) were derived
from the generated nigrostriatal tract and labelled as ipsilateral or contralateral to initial
motor symptoms in PD patients or as an average across hemispheres.
Figure 14. Probabilistic Tractography of the Nigrostriatal Tract

Substantia Nigra

Caudate

Caudate
Substantia Nigra

Generated Tract

Corpus Callosum Region of Interest Analysis. The corpus callosum segmentation
was performed in standard space according to the partitioning method by Aboitiz et al.
(1992), whereby the CC was divided along its length into ten segments: genu (GG1, GG2,
GG3), body (BB1, BB2, BB3), isthmus (ISTH) and splenium (SS1, SS2, SS3).
In order to map the CC subregions from standard space to the subject’s native space,
the following steps were done (Figure 15):
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1. T1 structural images of each subject was registered to MNI152 2mm space
through two steps:
a. FLIRT T1 structural image to MNI 2mm space and generate the affine
transformation matrix
b. FNIRT T1 structural image to MNI 2mm space by applying the affine transform
matrix first and generate thing coefficients that determine the warp-field
c. Apply warp field generates to structural T1 image to co-register to MNI 1mm
space
2. B0 non-diffusion weighted image of each subject was registered to MNI1152 1mm
space
a. FLIRT B0 image to T1 structural image and generate the affine transformation
matrix
b. Apply warp field from step 1c to B0 to co-register to MNI 1 mm space
c. Generate the inverse matrix of the affine transformation matrix (2a) and warp
field (1c)
3. Segment T1 structural image in standard space of each subject using FSL FAST
tool and generate white, grey and CSF partial volume maps (PVE)
a. Apply a threshold (0.95) to the PVE of white matter, such that we retrieve only
pixels that are 95% or more white matter
b. Multiple the corpus callosum masks with the thresholded white matter PVE map
4. Apply the inverse warps generated in step 2c to the thresholded corpus callosum
masks
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5. Use FSLMEANTS to extract the FA, ICVF and ODI by applying the masks of the
corpus callosum subregions in subject’s native space.
Figure 15. Processing Steps for Extraction of Diffusion Metrics from
Callosal Subregions
Step 1: T1 in MNI space (1mm)

Step 2: B0 in MNI space (1 mm)

Step 3: Segment T1 using FAST

Step 4: Apply inverse matrices to CC
masks

6.5 Results
6.5.1 Diffusion Microstructural Metrics in the Nigrostriatal Tract
In Figure 16, tract-specific values for each of the diffusion parameters (FA, ICVF and
ODI) are displayed as scatterplots with mean and standard error of the mean by group
(HC and PD) and hemisphere (Right and Left). Group differences in the Nigrostriatal
diffusion values were evaluated by a repeated measure ANOVA (RM-ANOVA) where
diagnosis (PD or HC) was the between-subject factor and the right/left side was a withinsubject factor. We hypothesized that the PD group will have a significantly reduced ICVF
and FA in the nigrostriatal pathway compared to the HC group due to the loss of the
dopaminergic projections connecting the SN and the Caudate. The results of the RM-
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ANOVA did not reveal any significant effect for the group (p=0.58) or hemisphere (p=0.38)
on the nigrostriatal ICVF. In addition, no significant interaction was found between the
group and hemisphere (p=0.93). Although no significant effect for the group was found,
we re-analyzed the data using a simple ANOVA test, comparing each hemisphere
separately between the groups while accounting for age. The mean±SEM ICVF was
0.76±0.018 in the right nigrostriatal pathway of the PD group compared to 0.78±0.017 in
the HC group (CI=[-0.04-0.07], p=0.32). Similarly, the left nigrostriatal ICVF was not
significantly different (CI=[-0.05-0.07], p=0.3) between the groups (HC: 0.79±0.05 and
PD: 0.78±0.08). As for the ODI, it was similar between the groups, where the mean±SEM
of the right nigrostriatal pathway was 0.25±0.008 in the PD group versus 0.25±0.006 in
the HC group (CI=[-0.02-0.02], p=0.99). This was also the case for the ODI in the left
hemisphere, where the means (PD: 0.26±0.007 and HC: 0.26±0.005) did not differ
between groups (CI=[-0.02-0.02], p=0.97). With the negative findings in the NODDI
parameters, we opted to investigate whether we will detect any changes in the FA. The
same procedure of analysis was followed as before with extracting the mean FA from the
constructed tract and comparing the means between the two groups. The two groups
displayed similar mean FA values in the right (PD:0.55±0.01 and HC 0.56±0.01, p=0.54),
and left nigrostriatal pathways (PD:0.55±0.01 and HC:0.56±0.01, p=0.7).
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Figure 16. Diffusion Metrics Extracted from the Nigrostriatal Tract in PD and HC
groups

6.5.2 Diffusion Microstructural Abnormalities in the Corpus Callosum
Subregions
We found significant microstructural changes within the genu of the corpus callosum
in patients with PD (Figure 17). We observed a pattern of reduced ICVF and higher ODI
in the second subregion of the genu (GG2) in the PD group compared to the healthy.
Intracellular volume fraction was significantly lower in the GG2 (p=0.004) of the PD group
(0.63±0.009) compared to the HC (0.58±0.01), while orientation dispersion index was
significantly higher (p=0.026) in GG2 of the PD group (0.17±0.009) compared to HC
(0.13±0.004). At the level of fractional anisotropy, we found significant reductions in the
genu-2 (p=0.047) and splenium-1 subregions (p=0.021) in the PD group compared to the
HC. Detailed analysis of all the subregions is provided in the Appendix, Table 3.
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Figure 17. Comparison of Diffusion Metrics Profile Across the Callosal
Subregions Between Groups
A. ICVF displayed as function of group
and CC segments, showing significantly
lower ICVF in the genu-2 subregions of PD
group compared to the HC (p=0.004)
✻✻

B. ODI displayed as function of group and
CC segments, showing significantly higher
ODI in the genu-2 subregion of PD group
compared to the HC (p=0.026)
✻

✻

C. FA displayed as function of group and
CC segments, showing significantly lower
FA in the PD group compared to the HC in
the genu-2 (p=0.047) and splenium-1
(p=0.021) subregions.

✻

ANCOVA; Adjusted for age
None of the diffusion indices in the genu 2 subregion of CC correlated with PD disease
duration, overall cognition and processing speed (Table 15).
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Table 15. Relationship between Callosal Diffusion Metrics and Clinical
Severity
Region of
Structural
Association
Association
Association
interest
metric
with MoCA
with SDMT
with disease
score rho (pscore rho (pduration
val)
val)
Genu 2
ICVF
0.21 (0.395)
0.28 (0.255)
0.28 (0.258)
ODI
-0.1 (0.679)
-0.17 (0.500) -0.004 (0.987)
FA
0.09 (0.715)
0.17 (0.488)
0.22 (0.375)

6.6 Discussion
In this study, we investigated two diffusion-based MRI model, DTI and NODDI, and
their sensitivity to microstructural changes within two white matter tracts relevant to PD,
the nigrostriatal pathway (NSP) and corpus callosum (CC). Our principal aim was to test
the hypothesis that the loss of dopaminergic neurons in SN will be associated with a
decreased ICVF and increased ODI in the NSP, along with a decrease in FA. Our second
aim, was to characterize the microstructural changes within the subregions of the corpus
callosum associated with PD pathology. We hypothesized that axonal abnormalities will
be detected within the genu of the CC, as reduced ICVF and increased ODI, along with
reductions in the FA. We found that the ICVF, ODI and FA were sensitive to group specific
differences in the genu of the corpus callosum, known to be prone to PD pathology. The
reconstructed NSP remained unchanged between groups for the diffusion metrics
studied. In summary, our results indicate that ICVF and ODI might disentangle early
microstructural changes associated with PD in specific subregion of the CC, that might
explain the reduction observed in fractional anisotropy.
Tractography of the nigrostriatal pathway in humans has been demonstrated in few
studies (Lehericy et al., 2004 and Tan et al., 2015). Striatomesencephalic fibers consist
of both striatonigral fibers and nigrostriatal dopaminergic fibers (Lehericy et al., 2004).

127
The nigrostriatal fibers were isolated using a seeding mask in the dorsal extent of the SN
and a target mask in the posterior putamen. The generated NSP coursed through the
subthalamic nucleus and ascended laterally to the globus pallidus and terminated in the
posterior putamen (Lehericy et al., 2004). Another recent study utilized the globus pallidus
(GP) as the target mask, where the generated NSP traversed the GP to synapse in the
striatum (Tan et al., 2015). The difficulty in reliably identifying the NSP and scant human
histological characterization of this pathway, limited the studies analyzing the NSP in PD
patients. Having that in mind, we attempted to explore the NSP microstructure in our PD
cohort with caution.
Our study utilized probabilistic tractography in 17 PD patients and 7 HCs to evaluate
the NSP diffusion parameters using as a seed, the SN and the Caudate as a target. The
ROIs were delineated manually and included the whole structure. Our regression analysis
did not reveal any significant differences in the diffusion metrics (ICVF, ODI and FA)
between groups. Also, when comparing the NSP between sides ipsilateral and
contralateral to symptoms onset within the PD group, there were no significant
differences. Our negative results can be explained by a number of reasons. First, we
chose the caudate instead of putamen for the feasibility in tracing this structure and its
visualization. Thus, the fibers originating from the SN and targeting the caudate might not
be as severely affected in PD as the tract terminating in the putamen. This is very
plausible, as there is human histological evidence showing that putamen is more affected
with dopaminergic denervation compared to the caudate in PD (Kish et al., 1988).
Second, we extracted the diffusion parameter averaged through the whole NSP tract.
By averaging the diffusion metrics along the entire tract, it might have masked regional
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structural changes localized to specific parts of the tract. Thus, it would be inadequate to
compare our results with published data on NSP tractography in PD patients, given the
methodological differences in the location and size of the ROIs, differences in the target
study population and the way of extracting the diffusion metrics. Still, the existing NSP
tractography studies in PD have yielded heterogenous results, where some found FA
increased (Hikishima et al., 2015), decreased (Tan et al., 2015) or unchanged (Andica et
al., 2018) in the PD group compared to the HC. Finally, diffusion tractography cannot
differentiate the directionality of fiber tracts and thus the reconstructed NSP tract, can
include both nigrostriatal and striatonigral tracts, including other tracts that might be
traversing the same pathways into other targets. The degree to which striatonigral tract
is affected in PD is unknown and thus, we cannot rule out any possible effects on our
diffusion results.
The corpus callosum is a major white matter tract for interhemispheric connectivity
and plays important roles in high-level cognition and sensory integration. Microstructural
changes within the corpus callosum have previously explored using conventional DTIderived metrics in PD patients with mild cognitive impairments (PD-MCI) and dementia
(PDD). DTI findings of the CC have been controversial with some studies finding changes
particularly pronounced in the genu and splenium subregions in PDD patients (Bledose
et al., 2010 and Hattori et al., 2012) and other failing to find any tensor-derived alterations
in CC and cingulum of PD-MCI patients (Witlshire et al., 2010). Notably, a consistent
finding in PDD have been the reduced FA in the genu of the CC, which correlates with
cognitive dysfunction (Kamagata et al., 2013). The same study also found significant FA
reductions in the prefrontal white matter, which is an important finding considering the
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projections of the genu fibers to the prefrontal area (Witelson et al., 1989). Although DTI
studies have shown that microstructural alterations are robust mainly in advanced stages
of PD, other diffusion models can provide more insight. NODDI can facilitate the
interpretation or the lack thereof FA changes associated with PD pathology in the CC.
Aboitiz et al. (1992) defined ten subregions of the corpus callosum according to their
regional fiber composition. The Genu is divided into 3 subregions, GG1, GG2 and GG3.
These subregions are characterized by a high density of thin (0.2-1µm) and unmyelinated
(16% of total axons) to lightly myelinated axons. These regions project to prefrontal areas
and higher-order association cortices. In our PD cohort, the diffusion abnormalities were
found only in the GG2 subregions, with reductions in ICVF and increased ODI.
Meanwhile, none of the diffusion metrics in the GG2 correlated with cognitive dysfunction,
possibly due to the effect of the dopaminergic medication on their cognitive performance
or the relatively early stage PD cohort. FA reductions further involved the splenium-1
subregion in addition to the genu-2. This might indicate that FA measure might be more
sensitive to pathological changes in the CC compared to ICVF or ODI.
Our results of decreased ICVF can be indicative of axonal thinning, which in turn can
affect the ODI. Axonal thinning and the subsequent reduction in the intracellular volume
fraction, may imply that water diffusion in the extracellular space can become freer and
move in more directions. Furthermore, this may contribute to the decreased alignment of
water diffusion along the main diffusion direction within the voxel, and hence a greater
dispersion. We acknowledge that the true biological interpretation of increased ODI and
reduced ICVF is currently vague, but it fits well with the current understanding of the CC
involvement in PD. By examining the subregions of the CC using Aboitz (1992)
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segmentation, we did not only confirm the involvement of the CC genu in PD, but more
specifically the second subregion of the genu (GG2).
This finding is potentially important for evaluating and tracking the cognitive decline
associate with PD progression. We conclude that NODDI provides evidence compatible
with microstructural abnormalities in the corpus callosum and reveals new insight into the
possible axonal pathology in PD, namely thinning and increased axonal dispersion. Our
study was cross-sectional and was conducted on a small sample size, thus future
longitudinal studies with larger PD cohorts are required to validate our results and
importantly, to examine the trajectory of alterations in the NODDI-derived metrics along
the disease progression.

131
CHAPTER 7 SIGNIFICANCE OF INTRACELLULAR VOLUME FRACTION ACROSS
THE CORPUS CALLOSUM SUBREGIONS
7.1 Summary
In the following section, we will describe the profile of diffusion microstructural metrics
across the corpus callosum, and interpret the biological significance of their alterations in
Parkinson disease (PD). This study made use of the healthy controls group (n=8) to study
the corpus callosum as a white matter model to interpret the intracellular volume fraction
(ICVF) and orientation dispersion index (ODI). Across the CC, ICVF was lowest in the
genu (0.63±0.01), increased in the body (0.68±0.03) and recorded the highest values in
the splenium 0.76±0.02. With caution, we interpret this pattern of increased ICVF as an
indicator of larger axonal diameter as we go from the genu to the splenium. In the case
of PD, we observed a decrease in ICVF in the genu-2 subregion of the CC, possibly
reflecting reduction in axonal size, rather than axonal loss. ODI profile was smooth across
the ten subregions of the CC, with a trend toward lower dispersion in the splenium. ODI
increase in the genu-2 subregion of the PD group can be due to a freer diffusion in the
extracellular space due to decreased axonal volume.
7.2 Introduction
The corpus callosum (CC) is the most prominent axonal pathway for interhemispheric
communication. The CC has been well studied in humans (Aboitiz et al., 1992 and Aboitiz
et al., 1996) and non-human primates (LaMantia and Rakic, 1990) in terms of the density,
diameter and myelination of its constituent axons. Well-documented histological
characterization of the human CC makes it an appropriate white matter model for studying
the significance of NODDI metrics alterations, the intracellular volume fraction (ICVF) and
orientation dispersion index (ODI).
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The regional fiber composition of the CC in humans (Aboitiz et al.,1992) and
macaques (LaMantia and Rakic, 1990) is characterized by a decreased axonal density
and increased axonal diameter along the CC, from the genu to the splenium. Aboitiz et
al. (1992) showed that the density of fibers with a diameter > 0.4µm (total fiber count) is
highest in the genu and tend to decrease toward the posterior midbody (BB3). Fiber
density then increases when entering the splenium and tend to decrease in the most
posterior splenial region (SS3). As we go from the anterior genu (GG1) to the posterior
midbody (BB3), there is a 25% reduction in the overall fiber density, from approximately
400,000 in GG1 to 300,000 fibers/mm2 in BB3. The reason for this overall decrease in
fiber density in the midbody was attributed to the increase in interfiber distance between
the axons which results from the oligodendrocytes proliferation usually associated with
large diameter fibers to accommodate the requirement of myelin.
Thin fibers are mostly dense in the genu and mid splenium (SS2), where 72% of the
total fiber population in the genu have a diameter between 0.2-1µm. As we progress
toward the mid and posterior body, fibers diameter gets larger and then decreases when
entering the splenium and peaks again in SS3. Thus, the density of large diameter fibers
(>3 µm and 5 µm) is highest in the posterior midbody (BB3) and posterior splenium (SS3).
The most common axon diameter increased steadily from 0.6/µm in the genu to 1 ~µm in
the splenium (LaMantia and Rakic 1990). While axons in the body and splenium are
myelinated, unmyelinated fibers comprise about 16% of the total fibers in the genu and
their diameter ranges between 0.1-1µm. Thin axons in the genu and SS2 connect
prefrontal areas and higher-order sensory areas of the temporal and parietal lobes,
respectively, where processing time can be long enough to permit cascade processing
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and interhemispheric transfer of information. Large diameter fibers concentrated in the
body and posterior splenium (SS3) connect primary and secondary auditory and visual
areas, respectively.
The density of axons stabilizes in the early postnatal period (LaMantia and Rakic
1990) and develops with increasing age, by virtue of increasing axon size and
myelination. A human postmortem studies (n=20) have shown that with advancing age
(25-68 years), there is an increase in axonal diameter, mainly in the genu and splenium
of the corpus callosum (Aboitiz et al., 1996). A possible explanation for this observation
is that with age, callosal fibers grow in size and myelin sheath thickness, which results in
an increase in the number of large diameter axons at the expense of small diameter axons
(Aboitiz et al., 1996). This trend in age-related changes in callosal fiber composition have
been supported by diffusion magnetic resonance imaging (MRI) techniques. In a sample
of 36 healthy adults (aged 22–72), a significant increase in axons diameter was observed
in the genu (r = 0.48, p = 0.01), coupled by a reduction in the packing density in the genu
(r = -0.57, p < 0.001) and splenium (r = -0.57, p < 0.001) (Fen et al., 2019).
The profiles across the CC for intracellular volume fraction (ICVF) and orientation
dispersion index (ODI) was investigated in a pediatric population (Genc et al., 2017). In
this study, a high-low-high trend was observed for ICVF across the ten CC segments,
with a minimum value in the isthmus and maximum in the splenium. ODI followed a low–
high–low pattern from the genu to the isthmus, peaking at the body-1 subregion and
reaching the minimum at splenium-2 before rising again at splenium-3. The high ODI in
the body of the CC has been also observed in a human postmortem study utilizing both
diffusion MRI and histology (Mollink et al., 2017), which showed a strong correlation

134
between ODI and dispersion derived from histology (r=0.79) and revealed that fibers
intertwine and diverge at the midline of the CC.
7.3 Aims
These established variations in axon composition in the corpus callosum subregions
and relationship with age, render it possible to investigate the relationship between
NODDI metrics and underlying white matter microstructure. Our healthy controls sample
(n=8) is limited by size and demographics, and thus it cannot be used to draw a
statistically meaningful relationship between NODDI metrics and established fiber
compositions of the CC subregions. For this purpose, we will describe qualitatively the
observed pattern of NODDI metrics variations along the CC and postulate the significance
of each metric in terms of fiber composition, using previously established histological
profile of the CC composition.
7.4 Methods
NODDI Metrics Extraction from the Corpus Callosum. The segmentation and
extraction of diffusion parameters have been described in Chapter 6, Methods section. In
brief, the corpus callosum was segmented into ten subregions according to Aboitiz et al.
(1992): genu (G1, G2, G3), body (B1, B2, B3), isthmus (ISTH) and splenium (S1, S2, S3).
The segmentation is represented as a color-coded map on the T1-image in Figure 18.
Partial volume effects were minimized by multiplying the CC masks with a thresholded
white matter map, so that there is a 0.95 probability that each voxel belongs to white
matter. The masks of the CC subregions were transformed into subject diffusion space
for DTI and NODDI quantification. The resulting registration was inspected in all subjects.
Only the healthy controls (n=8) data was used for this section. The mean±SEM of NODDI

135
metric for each of the ten subregions was plotted on a graph for visualization and
qualitative assessment of the variation pattern.
Figure 18. Corpus callosum parcellation. The NODDI metrics and FA were sampled across
the CC from ten separate ROIs obtained from the CC manual segmentation. G1 (Genu-1), G2
(Genu-2), G3 (Genu-3), B1 (Body-1), B2 (Body-2), B3 (Body 3), ISTH (Isthmus), S1 (Splenium1), S2 (Splenium-2), S3 (Splenium-3).
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7.5 Results
NODDI-derived metrics showed a unique profile in the subregions of the corpus
callosum (Table 16). ICVF was lowest in the genu (0.63±0.01) and increased as we enter
the body (0.68±0.03) and recorded the highest values in the splenium 0.76±0.02. This
steady increase in ICVF was paralleled by an increased fractional anisotropy along the
CC. the genu FA was 0.60±0.02, increased to 0.64±0.04 in the body and finally reached
0.70±0.02 in the splenium. On the other hand, variations in the ODI along the CC were in
the opposite direction and smoother compared to the FA and ICVF. ODI decreased from
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0.14±0.006 in the genu, to 0.13±0.01 in the body and reaching a minimum in the splenium
(0.12±0.01).

Table 16. Diffusion Metrics Across the Callosal Subregions in
the Healthy Group (n=8)
ROI
ICVF
ODI
FA
Genu 1
0.61±0.01
0.14±0.004
0.60±0.01
Genu 2
0.63±0.009
0.13±0.004
0.61±0.02
Genu 3
0.64±0.02
0.15±0.009
0.60±0.02
AVERAGE
0.63±0.01
0.14±0.006
0.60±0.02
Body 1
0.67±0.03
0.14±0.01
0.63±0.04
Body 2
0.67±0.03
0.13±0.01
0.65±0.03
Body 3
0.70±0.03
0.12±0.01
0.65±0.04
AVERAGE
0.68±0.03
0.13±0.01
0.64±0.04
Isthmus
0.70±0.03
0.13±0.02
0.60±0.04
Splenium 1
0.73±0.02
0.13±0.02
0.67±0.03
Splenium 2
0.75±0.02
0.12±0.009
0.72±0.02
Splenium 3
0.80±0.02
0.13±0.01
0.72±0.02
AVERAGE
0.76±0.02
0.12±0.01
0.70±0.02

7.6 Discussion
Across the corpus callosum, we observed a pattern of increasing ICVF from the genu
to body and finally splenium (Figure 19). The ODI profile was smooth and did not differ
drastically along the CC. The pattern of increased ICVF observed along the CC deviates
from the high-low-high axonal density profile established histologically, but agrees with
the profile of increased axonal diameter from the genu to the splenium (Aboitiz et al.,
1992). We believe that ICVF may provide information regarding the axonal size, rather
than the axonal density. Moreover, ICVF might be biased toward estimating large
diameter axons compared to smaller caliber fibers.
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Figure 19. Variation of NODDI Metrics Across the Callosal
Subregions in the healthy group

NODDI is a biophysical model that decodes the diffusion signal into three different
compartments, intracellular, extracellular and isotropic. The intracellular volume fraction
(ICVF) and isotropic volume fraction (Viso) are relative signal fractions from the diffusion
signal and do not represent the absolute water volume fractions (Novikov et al., 2016).
This is because myelin water fraction is not included by the NODDI model. The
contribution of the water fraction trapped within the myelin sheath is typically neglected in
diffusion MRI sequences, with echo times (TE) exceeding 50ms. The transverse
relaxation (T2) time-constant for myelin water is very short and ranges between 10–20
ms (MacKay et al 1994). This causes the signal coming from myelin compartment to
decay rapidly during the long TE employed, thus making the diffusion MRI signal
insensitive to myelin water. Within this context, the fraction of each compartment included
in the NODDI model, corresponds to “measurable water” fractions and not to the absolute
volume fraction of the voxel (Jelescu et al., 2016)
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The NODDI-derived metric, ICVF, is modelled as the volume fraction of the acquired
signal from the intra-neurite space (axons and dendrites). It is considered as a proxy for
the axonal and dendritic density and is expressed as “neurite density” in the model name
(Zhang et al., 2012). We studied the significance of ICVF alterations using the corpus
callosum as a white matter model. In the CC, there is a consistent regional variation in
fiber composition along anterior-posterior axis, as reflected in axon density, myelination
and diameter (Aboitiz et al., 1992). Axonal density tends to decrease from the genu to the
body, and to increase again when entering the splenium. According to Aboitiz et al., the
decrease in fiber density results from the increased interfiber distance to accommodate
oligodendrocytes proliferation in the body of the CC. Axonal diameter increases steadily
as one moves from the genu to the splenium, where the median axon diameter increases
from 0.6/µm in the genu to 1 ~µm in the splenium. The variation in median diameter
across the antero-posterior axis of the CC may partly explain the increased ICVF from
genu to splenium.
In our study, we observed a regional variation in ICVF, being lowest in the genu and
increasing as one goes to the body, reaching he maximum in the splenium. This steady
increase in ICVF may be attributed to the increased axonal caliber when entering the
body and splenium. The highest axon density is found in the genu and is mainly
composed of small diameter axons. Yet, the contribution of high density of small axons
to the diffusion signal might be smaller compared to that from larger diameter and less
dense axons in the body and splenium. Axons with large diameters contain more water
and can accommodate larger internal displacements, and so, contribute more to the
diffusion signal compared to smaller diameter axons (Alexander et al., 2010). This is
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reflected by the increased ICVF profile from the genu to splenium. Indeed, our results
agree with studies showing that the splenium have the highest intra-axonal water fraction
(Jelescu et al., 2016) and highest ICVF values (Genc et al., 2017 and Kunz et al., 2014).
This observation also indicates that the NODDI approach might be sensitive mainly to
large diameter axons at the expense of smaller diameter fibers, which causes ICVF to
underestimate the volume fraction of the fibers with small diameters. Thus, a pathology
affecting mainly small diameter axons might be undetected by ICVF measures. These
observations demonstrate a limitation in interpreting ICVF. A decrease in ICVF, like the
one observed in the G2 subregion of the PD group, might be indicative of either a reduced
axonal diameter or loss of fiber with a relatively large diameter. Whether such pathological
changes at the level of fiber density and diameter in the microstructure of the genu occur
in PD, remain to be determined through histological studies.
NODDI models the fiber orientations by a Watson distribution, which is characterized
by a concentration parameter κ that characterizes the dispersion of the fibers around a
mean orientation μ. Small κ values correspond to large fiber dispersion and thus a higher
ODI. In regards to fiber dispersion, we observed a relatively comparable ODI profile
across the CC subregions with a trend toward lower levels in the splenium. The CC is a
uniformly coherent white matter bundle where axons run parallel to each other and are
most coherent in the splenium subregion (Jelescu et al., 2016). In the study by Genc et
al. (2017), ODI was highest in B1, and followed a downward trajectory reaching the
minimum at the splenium. The ODI peak in the body of the CC might be related to the
fiber connections to heterotopic areas (Mollink et al., 2017). In our healthy cohort, ODI
was lowest in the splenium, consistent with previous studies, however, we did not observe
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a peak ODI in the body. In the G2 subregion, a higher ODI was detected in the PD group
compared to the HC, along with a decrease in ICVF. In Alzheimer’s disease, a similar
increase in ODI was observed in the CC as a whole, which also correlated with the tauburden (R2 = 0.96 and p = 0.003) (Colgan et al., 2016). Moreover, in subject with mild
cognitive impairment, higher ODI was observed in the cingulum, thalamic radiation, and
forceps major (Wen et al., 2019). Changes in ODI can be due to altered organization of
fiber bundles, or variations in extracellular water diffusion due to microstructural
properties like axon diameter or extracellular volume fraction (Mollink et al., 2017). As
axons get thinner and the extracellular space increase, water diffuse in more random
directions becomes less restricted. As such water diffusion around the fiber bundle
become more dispersed (κ becomes smaller), leading to higher ODI.
While the NODDI model provides diffusion metrics that decode the intracellular and
extracellular microstructural properties, it assumes fixed intrinsic and extracellular
diffusivities. This problematic assumption may be an oversimplification of the actual
diffusivities and lead to a bias in the estimated parameters. Indeed, a certain degree of
biological variability is expected in both the intracellular and extracellular diffusivities,
depending on the tissue type (gray or white matter), stage of development and presence
of pathology. A NODDI study in cortical gray matter tissue optimized the intrinsic diffusivity
specifically for gray matter to be 1.1 μm2/ms (Fukotomi et al., 2018). Indeed, the intrinsic
parallel diffusivity (dII) set to 1.7 μm2/ms in the NODDI model was regarded suboptimal in
the gray matter and infant brains but appropriate for adult brain white matter (Guerrero et
al., 2019). Additionally, changing the intrinsic diffusivity lead to significant changes in the
estimated NODDI metrics. Our intrinsic diffusivity analysis did point out to an improvement
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in the characterization of the ODI profile in white matter tracts, where a clear divergence
in ODI was formed between the genu and splenium of the CC after increasing the intrinsic
diffusivity beyond 1.7 μm2/ms (Figure 2, Appendix).
Since there is still no consensus yet as to whether the intrinsic diffusivity varies from
the assumed values in NODDI model, we opted to use the original value assumed in the
original publication (1.7 μm2/ms). We acknowledge that the NODDI assumption on fixed
diffusivities may be invalid and it is possible that the intrinsic diffusivity varies with
pathology. However, we do not expect that our results will change drastically when
changing the intrinsic diffusivities. We still expect to find reduced intracellular volume
fraction and increased dispersion associated with PD pathology in the corpus callosum.
In addition to NODDI metrics of intracellular volume fraction and fiber dispersion, noninvasive techniques to infer axonal diameter and myelin fraction would be an invaluable
addition for understanding the effects of PD pathology on each microstructural parameter
separately.
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CHAPTER 8 DISCUSSION AND FUTURE DIRECTIONS
8.1 Summary of findings
This thesis examined the utility of NODDI to detect tissue microstructural
abnormalities in white and gray matter regions known to be involved in PD pathology.
NODDI is a biophysical diffusion model that enables in vivo characterization of neurites
density and morphology, through the derived metrics, intracellular volume fraction (ICVF)
and orientation dispersion imaging (ODI), respectively.
The first study examined NODDI-derived metrics in cortical regions that are expected
to show Lewy Pathology according to the Braak’s staging model. By extracting metrics
related to neurite density and morphology, namely intracellular volume fraction (ICVF)
and orientation dispersion imaging (ODI), we attempted to characterize the in vivo cortical
microstructural changes related to PD. First, using an ROI analysis comprised cortical
regions involved in Braak stages 4 and 5, we found that PD is associated with reductions
in ICVF in the temporal lobe and fusiform, in the absence of cortical thinning. Second,
using whole brain analysis of NODDI-derived microstructural metrics, we were able to
confirm the involvement of the cingulate cortex with reduced ICVF and concomitant
increase in ODI.
In the subsequent studies, we assessed the ability of NODDI to detect tissue
microstructural changes in subcortical areas and white matter tracts known to be severely
affected in PD. The second study assessed the ability of ICVF and ODI to detect neuronal
damage in the dorsal striatum, known to be affected in PD as a result of dopamine
denervation. Using an ROI analysis, we were able to find evidence of reduced dendritic
complexity despite in the caudate in the absence of volumetric atrophy in our PD cohort.
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In addition, FA and ODI were sensitive to PD-pathological changes in the caudate and
putamen, contralateral to disease onset. This is consistent with nigrostriatal dopamine
loss on the side contralateral to symptoms onset.
The third study aimed at identifying the microstructural changes in major white matter
tracts known to be involved in PD. We studied first the nigrostriatal pathway, which was
reconstructed between the substantia nigra and caudate using probabilistic tractography.
In addition, we examined another white matter tract known to be involved in PD, which is
the corpus callosum (CC). We segmented the CC into ten subregions starting from the
genu, passing by the body and ending with the splenium. NODDI was able to highlight
significant alterations in axonal microstructure of the CC, where reductions in ICVF and
FA, paralleled by increased ODI were apparent in the genu-2 subregion PD group
compared to the HC.
Lastly, our fifth study aimed at exploring the significance of the in vivo microstructural
abnormalities identified in the PD group, in the light of a well-characterized white matter
model. For this purpose, we used the CC to investigate the variations of ICVF and ODI
across the ten subregions, which differ in axonal density, size and myelin content. We
found that ICVF might be sensitive to density of large axons, as it was increasing from
the genu to the splenium, consistent with the increase in the density of large diameter
axons.
In the context of Braak’s staging of Lewy pathology, we have confirmed the
involvement of the cerebral cortex in PD, and more specifically, identified alteration in
diffusion indices of tissue microstructure in the fusiform and inferior temporal lobe,
irrespective of cortical atrophy. These results highlight the prominent and early role of
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microstructural changes, preceding cortical thinning in cortical regions susceptible to PD
pathology. Moreover, we were able to detect microstructural changes in the caudate, in
line with previous histological evidence of MSNs dendritic regression.
8.2 Discussion
Conventional MRI techniques are commonly employed in PD for investigating cortical
changes due to Lewy pathology. Structural imaging evidence have identified cortical
abnormalities in PD such as cortical thinning and volumetric atrophy, with association to
cognitive decline. However, the rate and pattern of these structural changes vary greatly
among PD patients. Variations in findings might reflect the low sensitivity of conventional
MRI structural methods to subtle microstructural changes occurring at an earlier stage
before neuronal loss. Conversely, recent developments in diffusion MRI resulted in new
biophysical models of brain tissues to examine axonal and dendritic microstructure.
NODDI is one such model that offers a new opportunity to study neurodegenerative
processes in PD, in brain regions known to be affected with Lewy pathology. NODDI
provides quantitative measures of neurite density and dispersion and might be better
suited to detect the earliest stages of neuronal tissue damage associated with PD.
Our research presented here had three main objectives. First, we wanted to
characterize PD-related microstructural changes in neurite density and dispersion within
selected regions of the cerebral cortex known to be involved with Lewy pathology in a
cohort of PD subjects compared to healthy controls. In accord with Braak stages 4 and 5,
we hypothesized that PD would be associated with a decrease in ODI and ICVF in limbic
and prefrontal cortical areas, respectively, given potential PD-related losses in neurite
complexity. Second, we studied the ability of ICVF and ODI to detect dendritic regression
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in the medium-spiny neurons of the putamen and caudate, which are highly relevant for
the development of motor impairments in PD. We hypothesized that NODDI-derived
indices of neurite density and dispersion, would exhibit significant reductions in the dorsal
striatum of PD patients compared to healthy controls. Third, we used probabilistic
tractography to map the nigrostriatal pathway between the caudate and the substantia
nigra and performed subcortical segmentation of the corpus callosum. Within these tracts,
we studied white matter microstructural changes using NODDI metrics and expected to
find reduced ICVF and increased ODI, indicating loss of axons or reductions in axonal
size and increased fiber dispersion.
PD is a neurodegenerative disorder characterized by the loss of dopaminergic
projection neurons from the substantia nigra (SN) to the striatum (putamen and caudate
nucleus), and is associated with the presence of intra-neuronal protein inclusions in cell
bodies (Lewy bodies) and dendrites (Lewy neurites). Striatal dopamine denervation in
response to neurodegeneration in the SN, severely affect the nigrostriatal pathway and
results in the emergence of the cardinal motor impairments in PD (tremor, rigidity, and
bradykinesia). Accordingly, diffusion MRI studies have evaluated FA in the NSP and
reported mixed results, with either marked FA reductions (Yoshikawa et al., 2004, Tan et
al., 2015 and Zhang et al., 2015), or no changes (Andica et al., 2018 and Schuff et al.,
2015). Knowing that FA reductions can result from several pathogenic process such as
demyelination, cell swelling, axonal loss or increased dispersion, utilizing a biophysical
diffusion model like NODDI might help characterize the microstructural changes in the
NSP as related either to axonal loss or axonal dispersion. As such, PD patients were
expected to show a robust decrease in ICVF in the NSP tract, which reflects selective
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loss of dopaminergic projections. Our study did not find any significant group effect in the
reconstructed NSP using either NODDI or DTI metrics. The NSP in our study was
reconstructed between the SN and the caudate. In PD, the caudate is minimally affected
with Lewy pathology and dopaminergic denervation compared to the putamen. Thus, the
choice of the target region (caudate), might explain the difficulty in detecting significant
microstructural abnormalities in the reconstructed NSP. Other tractography studies have
used the Globus pallidus (Andica et al., 2018) or putamen (Tan et al., 2015) as target
regions. To our knowledge, no diffusion MRI study have explored the NSP tract
connecting the SN with caudate in PD. Further in vivo diffusion MRI studies focusing on
the NSP are warranted to study the microstructural abnormalities associated with
dopaminergic denervation, as it holds a promising clinical utility to predict the trajectory
of motor impairment in PD.
Within the same context, several postmortem studies have provided an evidence for
the involvement of striatal microstructural abnormalities in PD. Specifically, it has been
shown in the caudate and putamen, substantial reductions in the spine density and the
extent of dendritic arbor of the medium spiny neurons (Stephens et al. 2005). Moreover,
dopamine transporters and tyrosine hydroxylase (TH) optical density are significantly
lower in the dorsal putamen of human PD postmortem tissue, and are morphologically,
characterized by thick and enlarged varicosities suggesting degeneration (Kordowe et al.,
2013). Reductions in striatal dopamine markers can be due to either neuronal
degeneration or dopaminergic dysfunction that can results from a prominent loss of
dopaminergic phenotype (Kordowe et al., 2013). These findings motivated tissue

147
microstructural analysis in our study using NODDI and DTI metrics, specific to the
caudate and putamen.
Significant ODI reduction were observed in the caudate of the PD group, with no
changes in ICVF or FA. We were able to detect microstructural asymmetries within the
PD, where FA reductions were more pronounced in the caudate and putamen of the
hemisphere contralateral to symptoms onset. Similarly, ODI was significantly higher only
in the caudate. The reductions in FA observe in our PD group might be thus due to
geometric reorganization of the dendritic tree, as evident by increased orientation
dispersion. Notably, increased dendritic branching and thickening have been observed in
TH-positive neurons as evidence for compensatory sprouting in the striatum of MPTPtreated monkeys (Song et al., 2000). The formation of new branches or sprouting, has
been hypothesized as a compensatory response to dopaminergic depletion (Song et al.,
2000).
In summary, our results of reduced FA and increased ODI lends support to previous
findings of morphological changes in striatal neurons, rather than degeneration, in
response to dopaminergic denervation. Moreover, increased ODI can be indicative of the
increased dendritic branching as a compensatory mechanism. The absence of ICVF
changes in the PD group also strengthens the hypothesis of a dopaminergic dysfunction
in the striatum, rather than a degenerative process. While this study has observed these
compensatory microstructural changes after a month from MPTP injections, it is unclear
whether they persist as PD progresses with time. Answering this fundamental question
requires longitudinal diffusion MRI studies to track the variations in microstructural metrics
as the PD progresses.
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Lewy pathology extends beyond the SN, and is hypothesized to spread in along a
caudal-rostral path, from the lower brainstem to the cerebral cortex, in a manner that fits
remarkably with the clinical motor and non-motor dysfunction. According to Braak’s
neuropathological staging system, Lewy pathology first starts in the olfactory bulb and
medulla oblongata (stage 1). From the medulla oblongata, Lewy pathology spreads to the
pons and midbrain (stages 2 and 3) and eventually gains access to the cerebral cortex,
to involve the anterior cingulate, association temporal mesocortex and neocortex (Stages
4–5). Finally, primary sensory and motor areas also develop Lewy pathology (stage 6).
The staging system is supported by predictable clinical changes including premotor,
motor and non-motor disease manifestations. Premotor symptoms of hyposmia,
constipation and sleep disorder fits remarkably with Lewy pathology in the olfactory bulb,
enteric nervous system and brainstem reticular formation. The spread of Lewy pathology
to the midbrain is associated with the classic characteristic motor symptoms of PD. As
PD progresses beyond the first decade of diagnosis, dementia can affect nearly 50% of
patients (Williams-Gray et al., 2013). Within this context, cognitive decline and dementia
in PD, could be related to the spread of Lewy pathology to limbic and neocortical such as
anteromedial temporal mesocortex (Stage 4), insula (Stage 5) and anterior cingulate
(Stage 5) (Kovari et al., 2003, Hurtig et al., 2000, Mattila et al., 1999 and Mattila et al.,
2000).
The histological evidence supporting an association between cortical Lewy pathology
and dementia in PD, motivated the investigation of the cortical microstructure in PD
patients compared to HC, using diffusion MRI in predefined regions of interest. In the
absence of major cortical atrophy, our study found significant abnormalities in diffusion
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MRI metrics of tissue microstructure. ICVF was significantly lower in the anterior cingulate
cortex and inferior temporal lobe, which correspond to Braak stages 4 and 5. Despite
these prominent findings, we expected ICVF reductions to span limbic cortical regions
belonging to Braak stage 4 and are known to have a role in memory impairments
(Entorhinal cortex and parahippocampus). On the other hand, FA reductions in the PD
group were far more extensive and involved additional cortical regions beyond those
detected by ICVF variations. For instance, the entorhinal cortex, parahippocamus and
insula were shown to have lower FA in the PD group, with no apparent changes in
NODDI-derived metrics. This is counterintuitive, as we would have expected the
reductions in the FA to be matched with lower neurite density (ICVF) or increased
dispersion (ODI). In this case, FA might be considered more sensitive to the underlying
microstructural changes in response to PD pathology or DTI and NODDI- metrics might
be sensitive to different pathological processes.
The limited number of histological studies validating NODDI metrics in gray and white
matter speaks to the complications in interpreting the observed/absent NODDI
alterations. On the other hand, we were able to detect decreases in ICVF in the absence
of any significant FA changes in the inferior temporal lobe. These conflicting results are
interesting in the light of the different microstructural alterations that could be affecting
each metrics uniquely. For instance, a decrease in ICVF alone might be associated with
an expected decrease in FA (as we showed in gray matter). However, the existence of
both, geometric (increased dispersion) and biological microstructural alterations
(decreased axonal density) in the same location (as we showed in the genu of the CC),
might not be translated as a variation in FA. Therefore, microstructural indices measured
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using DTI and NODDI should be considered complimentary techniques to allow a wider
sampling of possible microstructural changes associated with a pathology.
8.3 Conclusion
Our study has shown that diffusion MRI techniques, namely DTI and NODDI, are
sensitive to microstructural pathology associated with PD in the cerebral cortex through
measures of FA, ICVF and ODI. It is noteworthy to put our results into the context of Lewy
pathology staging system as proposed by Braak et al. (2003). Our findings of abnormal
microstructural integrities in limbic areas known to involved in PD Lewy pathology using
DTI-derived metrics is potentially insightful for examining the cortical microstructure in
vivo. Reductions in ICVF associated with PD have been more localized and restricted to
the fusiform and inferior temporal lobe. This can possibly reflect the sensitivity of this ICVF
to early pathological changes associated with PD. If validated histologically, NODDIderived metrics might be clinically useful to monitor the progression of PD pathologies at
the microstructural level. We were also able to provide in-vivo evidence of reduced
microstructural organization in the caudate of PD patient, potentially reflecting reduced
dendritic complexity. Finally, white matter involvement has been confirmed and was
characterized in the corpus callosum subregions. We highlight the genu as the region
being most implicated in PD, with both reduced fraction of axons and spatial organization.
8.4 Limitations and future directions
The present findings must be interpreted by taking into account a number of
limitations. Our PD group was cognitively heterogeneous, with subjects ranging from
being cognitively intact to demented. This may suggest that the severity of Lewy
pathology burden in the cerebral cortex is significantly different between subjects. In
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future studies, we plan to divide the PD group into PD-MCI (mild cognitive impairment)
and PD-NC (normal cognition) groups, to determine the specificity of the NODDI and DTI
metrics to different pathological changes present during the two stages of the disease.
Clinical cognitive data was acquired during the “on” medication state in some patients.
Thus, the anti-Parkinson medication might have amplified the variability in symptoms
across patients and their performance on cognitive testing, thus reduced sensitivity to
detect correlations between diffusion metrics and clinical changes. The LEDD and years
with PD diagnosis were not used as regressors due to the small sample size. Future work
will aim for a larger sample size of participants, to be incorporate the potential confounding
factors, correct for multiple comparisons and to assess the reproducibility of results. We
aim to extend our study by following up the PD and HC subjects after one-years from
baseline visit. This longitudinal design will allow us to elucidate the trajectory of
microstructural abnormalities in PD subjects and examine its potential involvement in
progression to PD dementia.
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APPENDIX
Chapter 3
Table 1. Association Between Regional Diffusion Metrics and
Cognition in Healthy group (n=8)
Region of
Structural
Association
Association
interest
metric
with MoCA
with SDMT
score rho (pscore (rho,
val)
p-val)
Superior Parietal
ICVF
0.12 (0.799)
-0.44 (0.328)
Lobe
ODI
-0.04 (0.928) -0.20 (0.667)
FA
0.28 (0.316)
0.12 (0.653)
Inferior Parietal
ICVF
-0.56 (0.187) -0.61 (0.146)
Lobe
ODI
-0.21 (0.658) -0.21 (0.646)
FA
0.40 (0.12)
0.21 (0.446)
Fusiform
ICVF
0.11 (0.809)
-0.31 (0.493)
ODI
0.55 (0.205)
-0.06 (0.897)
FA
0.26 (0.331)
-0.04 (0.871)
Caudal Anterior
ICVF
-0.32 (0.477) -0.54 (0.215)
Cingulate
ODI
0.60 (0.153)
0.15 (0.752)
FA
-0.07 (0.802)
0.16 (0.565)
Inferior Temporal ICVF
-0.1 (0.833)
0.16 (0.735)
Lobe
ODI
0.39 (0.394)
-0.06 (0.891)
FA
0.27 (0.314)
0.04 (0.893)
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Table 2. Comparisons of FA and ODI for each hemisphere in PD Group with Average Metrics in HC group
Variable

FA
Caudate
Putamen
Globus
Pallidus
Thalamus
ODI
Caudate
Putamen
Globus
Pallidus
Thalamus

PD

Controls

Ipsilateral
Mean±SE
M

Mean±SE
M

fvalue

pvalue

0.24±0.00
9
0.29±0.00
8
0.38±0.01

0.21±0.00
7
0.26±0.00
6
0.38±0.01

1.715

0.203

1.666

0.33±0.00
5
0.43±0.00
9
0.46±0.00
8
0.45±0.01
0.36±0.00
7

Significance

PD

Controls

Contralater
al
Mean±SEM

Mean±SE
M

fvalue

pvalu
e

η2

0.069

0.22±0.008

0.336

0.21

0.068

0.27±0.007

0.694

0.413

0.029

0.37±0.01

0.21±0.00
7
0.26±0.00
6
0.38±0.01

0.33±0.00
7

1.701

0.205

0.069

0.33±0.005

0.33±0.00
7

0.386

0.56
8
0.57
8
0.87
4
0.54

0.01
4
0.01
4
0.00
1
0.01
7

0.47±0.00
8
0.47±0.00
5
0.45±0.00
7
0.37±0.00
6

3.22

0.086

0.123

0.44±0.009

2.549

0.38

0.034

0.46±0.008

0.12
4
0.4

0.1

0.8
0.909

0.35

0.038

0.45±0.01

0.037

0.849

0.002

0.36±0.006

0.47±0.00
8
0.47±0.00
5
0.45±0.00
7
0.37±0.00
6

η2

Significance

0.318
0.026

0.736
0.087
0.000
1

Chapter 4
Figure 1. Comparison of raw average volume of the caudate and putamen
between HC and PD groups

p=0.364

p=0.193

0.77
1
0.99
3

0.03
1
0.00
4
3.e06

154
Chapter 7
Table 3. Group Comparison of DTI and NODDI Metrics Across the Callosal Subregions
ROI
ICVF
ODI
FA
PD
HC
p-val
PD
HC
p-val PD
Genu 1
0.365
0.59±0.01 0.61±0.01
0.17±0.007 0.14±0.004 0.11
0.55±0.01
Genu 2
0.58±0.01 0.63±0.009 0.0044 0.17±0.009 0.13±0.004 0.026 0.55±0.02
Genu 3
0.144
0.61±0.01 0.64±0.02
0.18±0.008 0.15±0.009 0.103 0.54±0.02
Body 1
0.157
0.104 0.58±0.02
0.63±0.01 0.67±0.03
0.17±0.009 0.14±0.01
Body 2
0.316
0.073 0.60±0.02
0.65±0.01 0.67±0.03
0.16±0.009 0.13±0.01
Body 3
0.574
0.076 0.61±0.02
0.68±0.01 0.70±0.03
0.15±0.007 0.12±0.01
Isthmus
0.96
0.146 0.56±0.02
0.70±0.02 0.70±0.03
0.17±0.01
0.13±0.02
Splenium 1
0.739
0.144 0.57±0.03
0.71±0.02 0.73±0.02
0.18±0.01
0.13±0.02
Splenium 2
0.695
0.74±0.02 0.75±0.02
0.14±0.008 0.12±0.009 0.213 0.65±0.02
Splenium 3
0.724
0.985 0.71±0.02
0.80±0.02 0.80±0.02
0.13±0.007 0.13±0.01

HC
0.60±0.01
0.61±0.02
0.60±0.02
0.63±0.04
0.65±0.03
0.65±0.04
0.60±0.04
0.67±0.03
0.72±0.02
0.72±0.02

p-val
0.103
0.047
0.255
0.304
0.288
0.299
0.337
0.021
0.351
0.628

Intrinsic diffusivity. The optimal diffusivity recommended in the original NODDI paper
is dII = 1.7 μm2/ms. Other plausible values were considered from 0.6 to 3.0 μm2/ms in
increments of 0.1 μm2/ms. For each of the 25 values, the NODDI model was fitted to the
measured dMRI signal voxel by voxel using Accelerated Microstructure Imaging via
Convex Optimization (AMICO) (Daducci et al., 2015). For one healthy control, one slice
covering GM, WM, and CSF was chose for fitting to reduce time of processing
(compared to fitting the whole brain). After fitting the date, we extracted the NODDI
parameters from seven different ROIs comprising white matter (genu and splenium of
CC and optic radiation), cortical gray matter (visual, sensory and motor cortex) and
subcortical gray matter (thalamus). Due to the low number of healthy subjects, we were
not able to run a proper analysis and estimate the optimal value of the intrinsic
diffusivity. We will show our results and describe them qualitatively.
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Figure 2. Graphs showing the relationship between ICVF, ODI and Viso) with different intrinsic diffusivity values (from
0.6-3mm2/s)).
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Parkinson disease (PD) is a neurodegenerative disorder characterized histologically
by the loss of dopaminergic neurons in the substantia nigra (SN), and clinically by motor
symptoms. PD pathology extends beyond the SN, and involves the presence of
intraneuronal inclusions in neuronal bodies (Lewy bodies) and dendrites (Lewy
dendrites). A staging system for Lewy pathology has been proposed, where it is
hypothesized that the disease initiates in the peripheral nerves system and spreads along
a caudal-rostral pathway to the brain stem and the cerebral cortex. Histological and
imaging studies highlight a role for cortical Lewy pathology and atrophy, respectively, in
mediating the cognitive decline with disease progression. In this regard, little is known
about the cortical microstructural effects preceding cortical atrophy. Neurite orientation
dispersion and density imaging (NODDI) is a diffusion model that characterizes tissue
microstructures through three main indices, intracellular volume fraction (ICVF),
orientation dispersion index (ODI) and isotropic volume fraction. Our study utilized two
diffusion MRI models, diffusion tensor imaging and NODDI, in combination with cortical
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thickness assessment to study the microstructural changes in the cerebral cortex of a PD
cohort (n=18) compared to healthy controls (n=8). We demonstrated that PD pathology
is associated with reduced cortical tissue organization as reflected by significant
reductions in ICVF and fractional anisotropy in the cingulate, fusiform and temporal
regions, indicating reduced dendritic complexity in these regions. Moreover, decreased
ODI in the caudate was associated with PD-pathology, possible reflecting dendritic
regression as a result of dopaminergic denervation. White matter (WM) microstructural
abnormalities were also characterized in the corpus callosum, and significant FA and
ICVF reductions, in parallel with increased ODI were consistently found in the genu
subregion. These results might indicate that PD pathology is associated with WM axonal
loss and morphological changes. In summary, we believe that the detected pattern of
abnormalities in diffusion metrics in gray and white matter regions highly relevant for PD
Lewy pathology and might be a future biomarker for tracking disease progression.
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AUTOBIOGRAPHICAL STATEMENT
“Knowledge is better than wealth: Knowledge protects you, whereas you have to
protect wealth. Wealth decreases with spending, whereas knowledge increases with it.
Knowledge is a faith to be followed. It helps you practice obedience to your lord in your
lifetime, and leaves a beautiful legacy of remembrance after your death; whereas the
benefits of wealth cease with its ceasing. And knowledge rules, while wealth is ruled over.
Those who hoard wealth are dead even as they live, whereas the learned remain as long
as the world remains – their persons may be lost, but their teachings live on in people’s
hearts”.
-Imam Ali Ibn Abi Talib (AS)

